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SUMMARY  
The extracellular calcium-sensing receptor (CaSR) is a G-protein coupled receptor 
central to systemic Ca2+ homeostasis in mammals. We have previously shown that CaSR 
is expressed in primary bovine aortic vascular smooth muscle cells (VSMCs). 
Furthermore, dominant-negative adenoviral knockdown of this receptor in bovine 
VSMCs in vitro causes enhanced calcification in the presence of culture conditions which 
mimic vascular calcification in vivo. Using mineralising conditions in vitro, we have also 
previously demonstrated that positive pharmacological allosteric activation of CaSR 
using the calcimimetic, R-568, significantly reduces calcification of bovine VSMCs. 
These findings now implicate the CaSR, not just in systemic Ca2+ homeostasis, but also 
in potential protection against vascular calcification; a condition associated with 
increased blood pressure, left ventricular hypertrophy, chronic kidney disease and 
cardiovascular morbidity. Using a specific targeted deletion strategy, we have developed 
CaSR-specific knockout in VSMCs driven by the SM22α promoter. Using in vitro, ex 
vivo and in vivo approaches, here, I have characterised the cardiovascular phenotype of 
this novel transgenic mouse model. In vivo data demonstrate that ablation of CaSR from 
VSMCs causes hyperkalaemia at 3 months of age and hypercalcaemia throughout life. 3 
month old CaSR-VSMC Knockout (KO) mice also exhibit reduced bone mineral 
integrity and increased heart weight at the age of 18 months. Ex vivo analysis implicates 
the VSMC-CaSR as a modulator of blood vessel tone. CaSR-VSMC KO mice exhibit 
reduced luminal diameters of the aorta and mesenteric arteries. CaSR-VSMC KO also 
reduces contractile tone in addition to evoking Ca2+-dependent relaxation only, compared 
to CaSR-wild-type (WT) mice which exhibit both Ca2+-dependent contraction and 
relaxation of the aorta. In vitro analyses confirm that CaSR expression and activation 
reduces Ca2+-dependent proliferation and mineralisation. In conclusion, the VSMC CaSR 
is a modulator of vascular tone ex vivo and of VSMC proliferation and calcification in 
vitro. 
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CHAPTER 1:  
GENERAL INTRODUCTION 
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1.1 The cardiovascular system: an anatomical perspective 
The cardiovascular system comprises an intricate network of large vessels, small vessels 
and capillaries (Burton, 1954). This delicate network serves as a transport mechanism, 
delivering crucial O2 throughout the body to cells and tissue. The familiar blood vessel 
observed in a myriad of higher organisms is easily distinguishable by its open luminal 
structure surrounded by a resilient and elastic wall (Conway et al., 2001). Blood vessels 
comprise of three distinct cell layers; each of which demonstrate significant and unique 
roles in maintaining vascular function (Figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Blood vessel morphology. A typical arteriole consisting of a tunica intima, tunica media and 
tunica adventitia. Modified from CardioSmart.org (CardioSmart, 2012). 
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1.1.1 Vascular endothelium 
As a single layer of endothelial cells and the internal elastic lamina (IEL) membrane 
(Gutterman, 1999), the vascular endothelium is a minority cell population in the 
vasculature, however this does not subtract from the major physiological role that these 
cells elicit in the cardiovascular system. The role of endothelial cells (ECs) in the 
vasculature has been extensively investigated over the years since pioneers Robert 
Furchgott and John Zawadzki first observed the crucial role of endothelial cells in 
acetylcholine-dependent dilation (Furchgott, 1984, Furchgott et al., 1984, Furchgott and 
Vanhoutte, 1989). Furchgott showed that dilation of the aorta through acetylcholine can 
only be achieved when an intact endothelium is present. Furthermore, enzymatic or 
physical removal of these endothelial cells consistently causes vessels to be devoid of an 
acetylcholine-dependent dilation (Furchgott, 1984, Furchgott et al., 1984, Furchgott and 
Vanhoutte, 1989). In fact, in other aortic preparations lacking the endothelium, Furchgott 
and Zawadzki demonstrated the opposite; a contractile role of acetylcholine (Furchgott 
and Vanhoutte, 1989). Prior to this notion, it was commonly believed that contraction 
and dilation was co-ordinated chiefly by the vascular smooth muscle cells themselves 
(VSMCs). We now know that indirect endothelial-dependent dilation of VSMCs can 
occur by signalling through ECs by a number of agents including adenosine diphosphate 
(ADP), adenosine triphosphate (ATP), bradykinin, thrombin, serotonin, histamine, 
acetylcholine, epoxyeicosatrienoic acids (EETs), prostacyclin (PGI2), a cyclooxygenase-
dependent metabolite of arachadonic acid (AA) and nitric oxide (NO)- a product of L-
arginine and the nitric oxide synthase (NOS) pathway (Cherry et al., 1982, Vanhoutte et 
al., 1986, Palmer et al., 1987, Vanhoutte, 1987, Furchgott and Vanhoutte, 1989, Bukoski 
et al., 1997, Wang and Bukoski, 1998, Edwards et al., 2008, Luksha et al., 2009).  
 
From these initial studies by Furchgott and Zawadzki it was clear that the endothelium is 
profoundly important in co-ordinating vascular tone. In fact, the discovery of an 
endothelium-derived relaxation factor (EDRF) has been investigated thoroughly over the 
past decades. It is now accepted that EDRF and NO are indistinguishable, although 
multiple dilation and hyperpolarising factors still exist (Palmer et al., 1987, Sandow et 
al., 2009, Chadha et al., 2011). Interestingly, this has posed questionable molecular 
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mechanisms by which the endothelium and tunica media signal to one another. Although 
NO diffuses easily to adjacent VSMCs, it was clear that in order for additional 
endothelium-derived hyperpolarizing factors (EDHFs) to evoke dilation in VSMCs, there 
must be a semi-permeable barrier at work to deliver these molecules (Lew et al., 1989, 
Sandow et al., 2009). It was first proposed that endothelial pockets that extend through 
the internal elastic lamina form connections with VSMCs allowing the transfer of 
diffusible molecules. This was first described in 1957 by Moore and Ruska who isolated 
small vessels from a dog heart and noted small invaginations and vesicles between ECs 
and VSMCs through the IEL (Moore and Ruska, 1957). Since then, they have been 
characterised as myoendothelial gap junctions (MEJs) and play a key role in transcellular 
and paracellular diffusion of small solutes and molecules (Moore and Ruska, 1957, 
Chaytor et al., 1998, Edwards et al., 2008, Heberlein et al., 2009). These small 0.5µm 
diameter MEJs exhibit an inversely proportionate abundance in increasingly smaller 
vessels, although the type of vessel is a major predictor of MEJ presence (Haas and 
Duling, 1997). This arguably has important functional ramifications in smaller resistance 
vessels which require acute and localised signalling (Michel et al., 1995). From a 
structural perspective, MEJs are composed of small connexin proteins, specifically, 
Connexin 37 and 40 (Cx37 and Cx40) in the vasculature and are typically found in larger 
vessels (Simon and McWhorter, 2002). Interestingly, Cx37 and Cx40 are the only 
connexin family members found in the mouse aorta where they function in a 
compensatory manner, although Cx43 has been reported in a heterogeneous manner in 
other vessels (Nicholson and Bruzzone, 1997). Knockout (KO) studies of these 
connexins specifically in mouse endothelial cells causes severe systemic cardiovascular 
abnormalities such as haematomas (Simon and McWhorter, 2002). There is also now 
evidence that endothelial cells extend through the IEL to make physical contact with 
vascular smooth muscle cells by myoendothelial projections (MPs) (Aaronson, 2012, 
Tran et al., 2012). Furthermore, these projections are proposed to house 
endoplasmic/sarcoplasmic reticula (ER/SR) which extend from the main cytosolic body 
of the cell into this outward cellular appendage (Kerr et al., 2012). In this way, Ca2+ is 
more readily and locally available for release from these internal stores through inositol 
triphosphate (IP3) receptors present on their surfaces, signalling adjacent vascular smooth 
muscle cells to contract or dilate accordingly (Kerr et al., 2012). This mechanism is 
described in Figure 2.  
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Figure 2. Myoendothelial gap junctions in arterial vessel walls. (A) Myoendothelial projections extend 
into the internal elastic lamina where they form connections by connexins to VSMCs. (B) The endothelial 
endo/sarcoplasmic reticulum (ER and SR respectively) is extended into the myoendothelial projection 
allowing for very localised Ca2+ signalling. Inositol trisphosphate receptors (IP3Rs) are activated by inositol 
trisphosphate (IP3) causing an increase in intracellular Ca2+. This is accompanied by hyperpolarisation of 
the endothelial cell by removal of K+ through intermediate conductance Ca2+-activated potassium channels 
(IKCa) (Busse et al., 2002). Ca2+i can stimulate the production of nitric oxide synthase and ultimately nitric 
oxide which translocates to adjacent VSMCs. This ultimately induces vasodilation of VSMCs. Figure 
adapted from Kerr et al and Tran et al (Kerr et al., 2012, Tran et al., 2012).  
A 
B 
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1.1.2 Vascular smooth muscle cells 
The tunica media cell layer is enriched with an abundance of vascular smooth muscle 
cells (VSMCs) which exhibit a characteristically elastic phenotype (Chamley-Campbell 
and Campbell, 1981). The number of VSMCs that comprise the tunica media is indeed 
incredibly variable. Layers of VSMCs in smaller vessels decrease with decreases in 
luminal diameter. It has been reported that vessels of >300µm comprise around 6-8 layers 
of VSMCs. Comparatively, smaller resistance vessels and arterioles with diameters of 
30-50µm can have just a single monolayer of VSMCs (Miller et al., 1987, Wagenseil et 
al., 2009, Wagenseil et al., 2010). Contractility and support is typically provided through 
the enriched ECM laid down in the form of collagen. Although collagens I, II, III, IV, V 
and VI have been reported in abundance in the tunica media, there is evidence that 
collagens I and III are predominantly responsible for giving strength to the vessel wall, 
particularly in the descending aorta (Wagenseil and Mecham, 2009). In addition to 
collagen, strength is provided by fenestrated sheets of elastin which provide much 
structural support (O'Connell et al., 2008). These ECM components are absolutely 
critical for a functional vessel and, interestingly, mice lacking the elastin (Eln) gene die 
soon after birth due to cardiovascular abnormalities including stiff arteries, high left 
ventricular pressure and low cardiac output (Wagenseil et al., 2010). Intriguingly, during 
this study investigators found that mice heterozygous for the Eln gene displayed a 
significant increase in layers of elastic lamina. Heterozygote mice developed, on average, 
11 elastic laminae compared to the normal 8 wild-type lamina sheets (Wagenseil et al., 
2010).  
 
Functionally, VSMCs play a crucial role in maintaining vascular tone (Furchgott and 
Vanhoutte, 1989, Dora, 2010, Garland and Weston, 2011) however, to carry out 
contractile responses and act as an integral structural component of the vessel wall, 
VSMC must adopt multiple phenotypes (Chamley-Campbell and Campbell, 1981). The 
two major phenotypes that VSMCs adopt have been designated synthetic and contractile. 
In the synthetic phenotype, VSMCs are more actively engaged in the synthesis of 
extracellular matrix (ECM) components, contain few myofilaments and may undergo 
proliferation. This is, unsurprisingly accompanied by an upregulation in intracellular free 
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ribosomes, endoplasmic reticulum and mitochondria to aid these functions (Thyberg et 
al., 1995, Yoshida et al., 2005). In the contractile state, the cytoplasm is rich in 
myofilments such as actin and smooth muscle actin 22 α (SM22α) (Han et al., 2009). 
Interestingly, some researchers have demonstrated the ability of SM22α and actin to co-
localise and bind to one another (Kobayashi et al., 1994, Fu et al., 2000). This phenotype 
switching is a principal determinant of healthy cardiovascular function.  
 
1.1.3 Vascular adventitia 
The outer tunica adventitia layer is composed of pavement endothelial cells and 
fibroblasts that act as a protective lining to the blood vessels (Burton, 1954). Furthermore, 
these outer cells house a plethora of fibrillar collagens, elastic fibres and elastic lamellae 
which are secreted by the VSMCs and heterogeneous myofibroblasts. These function to 
construct an elaborate ECM in the tunica adventitia (Gerrity and Cliff, 1972, Bendeck et 
al., 1994). Interestingly, microarray analysis for matrix protein expression such as Col1 
and elastin using specific gene oligonucleotides in neonatal mice has demonstrated that 
expression of these adventitial ECM proteins progressively increases from 7-14 days 
after birth, followed by a decrease in expression from approximately 2-3 months. These 
results are not only consistent in mice, but also in humans (Stenmark, 2006, Wagenseil 
and Mecham, 2009). In addition to these matrix proteins, numerous basement membrane 
constituents are also expressed including fibronectin and matrix metalloproteinases 
(MMPs) (Stenmark, 2006, Wagenseil and Mecham, 2009). These findings suggest that 
the vascular adventitia serves as an early structural scaffold of the vessel wall in which 
the endothelium and VSMCs will develop and mature within. 
 
Together, the three cell layers function to allow the passage of blood through a vast 
network of arteries, veins and capillaries throughout the body to deliver O2 to organs and 
tissues, as well as to remove CO2 from these regions, preventing the development of an 
anaerobic environment (Burton, 1954, Wagenseil and Mecham, 2009).  
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1.2 Ca2+ signalling in VSMC and phenotype switching 
As a secondary messenger within the cell, free ionised calcium (Ca2+o) can elicit 
numerous functional changes to vascular cells, more importantly, in ECs and VSMCs. In 
VSMCs, rises in intracellular Ca2+ (Ca2+i) causes contraction (Mulvany and Nyborg, 
1980, Mulvany and Aalkjaer, 1990). Contraction ensues when the intracellular calcium 
ion concentration ([Ca2+]i) in the VSMC increases. This way, Ca2+ is a direct facilitator 
of vasoconstriction. Changes in [Ca2+]i can come about in a variety of ways and are 
indeed co-ordinated through the actions of appropriate receptors sensitive to Ca2+o 
including the extracellular calcium-sensing receptor (CaSR) (Ward, 2004), Ca2+-
channels (Adams et al., 1989), sarcoplasmic reticulum receptors, α1-adrenergic receptors 
and muscarinic M3 receptors (Carafoli, 1987, Felder, 1995, Carafoli, 2002). 
 
1.2.1 Vasoconstriction of vascular smooth muscle cells 
Contraction of VSMCs is co-ordinated through the action of Ca2+i (Morgan and Morgan, 
1984a, Wray et al., 2005, Ledoux, 2006). The main source of Ca2+i is obtained from the 
extracellular environment. Ca2+ influx occurs when the plasma membrane is depolarised. 
Ca2+ influx can occur through voltage-gated Ca2+-channels (VGCCs). Of the ten 
members of the VGCC family, two are found in the cardiovascular system; CaV 1.2 and 
CaV 1.3 (Mangoni et al., 2003, Rhee et al., 2009). The first type, large “L-type” voltage-
gated Ca2+-channel (LCa) requires a strong depolarisation for activation and subsequently 
causes an influx of Ca2+ (Catterall et al., 2005). The second method of Ca2+ uptake is 
through T-type voltage-gated Ca2+-channels (TCa). These channels are activated by 
weaker polarisations (Benham et al., 1987, Smirnov and Aaronson, 1992, Catterall et al., 
2005). Together, these two channel types help maintain vascular tone through the actions 
of Ca2+ flowing in to VSMCs. During depolarisation, cations such as Ca2+ are transported 
into the cell through VGCCs, thus inducing a contractile response. During 
hyperpolarisation, as a consequence of an efflux of K+, VGCCs are closed, Ca2+i is 
sequestered to internal stores resulting in dilation. (Jaggar et al., 1998). The actions of 
Ca2+i as a vasoconstrictor, particularly within vascular smooth muscle, are well-
documented. When Ca2+i is elevated, it binds to CaM and consequently, CaM-dependent 
activation of myosin light-chain kinase (MLCK) occurs (Dillon et al., 1981). During 
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activation of myosin light chain (MLC) through MLCK, myosin ATPase is stimulated, 
causing the hydrolysis of ATP. Ultimately this leads to myosin chain bridging between 
actin and myosin filaments (Bárány, 1967, Hai and Murphy, 1989). Myosin chains can 
later be broken down to dilate VSMCs by the action of myosin light-chain phosphatase 
(MLCP) (Kitazawa et al., 2009). In this way MLCK and MLCP have antagonistic roles. 
 
Although Ca2+-channels play a significant role in Ca2+ entry into the cell, other 
mechanisms exist, often in combination to allow [Ca2+]i to increase and allow contraction 
(Morgan and Morgan, 1984b, Morgan and Morgan, 1984a). A rise in free cytosolic Ca2+ 
can be obtained from intracellular stores, often when G-protein coupled receptors 
(GPCRs) are activated (Minneman, 1988). A well-studied example of this is the α1-
adrenergic receptor (often termed adrenoceptors/α1-ARs) which responds to 
catecholamines such as dopamine, norepinephrine and the selective agonist 
phenylephrine (Minneman, 1988). When agonists bind to α1-ARs, G-protein signalling 
occurs through the Gq/11α subunit (Gosau et al., 2002). Heterotrimeric Gq activates PLC 
which in turn hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and 
diacylglycerol (DAG). Increased IP3 induces IP3 receptor activation and subsequentl 
release of Ca2+ from internal stores (Berridge, 1984, Berridge and Irvine, 1984, 
Minneman, 1988). The elevation in Ca2+i is then free to bind to CaM as previously 
described and elicit a MLC-mediated contraction of the VSMC (Itoh et al., 1989, Wray 
et al., 2005, House et al., 2008). Mechanisms of Ca2+-mediated vasodilation and 
vasoconstriction can be observed in Figure 3. 
 
1.2.2 Vasodilation of vascular smooth muscle cells 
In order for endothelial cells to elicit a dilatory response, an intracellular signalling 
pathway is initiated. In the case of the well-characterised endothelium vasodilator 
acetylcholine, this binds to the muscarinic acetylcholine M3 metabotropic, G-protein 
coupled receptor (GPCR) at the plasma membrane (Boulanger et al., 1994, Andersson, 
2002). Activation of M3 receptors then activates the Gq pathway (Kunkel and Peralta, 
1993). This leads to activation of phospholipase C (PLC) and production of inositol 
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triphosphate (IP3) which acts on IP3 receptors on the endoplasmic reticulum (Berridge, 
1993). Consequently, Ca2+ is liberated from internal stores into the cytosol thereby 
increasing [Ca2+]i. Additionally, store depletion initiates Ca2+ entry into the endothelial 
cell via the store operated Ca2+ entry channel (SOCE) (Edwards et al., 2008). This Ca2+i 
binds to CaM which activates endothelial nitric oxide synthase (eNOS) (Morris and 
Billiar, 1994). Since eNOS is Ca2+ and calmodulin-dependent, it is largely active when 
[Ca2+]i is high despite being constitutively expressed (Palmer et al., 1988, Bredt and 
Snyder, 1990, Knowles and Moncada, 1994). In its active state, eNOS catalyses the 
conversion of L-arginine into L-citrulline and NO; the diffusible EDRF which is largely 
accepted to be translocated through MEJs to adjacent VSMCs (Walford and Loscalzo, 
2003). In VSMCs, NO exerts its dilatory role by binding to the soluble heme-containing 
enzyme, guanylyl cyclase (GC). The activation of this leads to accumulation of cyclic 
guanosine monophosphate (cGMP). cGMP directly inhibits Ca2+ influx by inhibiting 
voltage-gated Ca2+-channels (Bolotina et al., 1994) and can also activate protein kinase 
G (PKG), specifically  PKG-1. These actions of NO, cGMP and PKG collectively serve 
to activate the sarcoplasmic reticulum Ca2+- ATPase (SERCA) and sequester [Ca2+]i 
(Simmerman and Jones, 1998, Massberg et al., 1999, Walford and Loscalzo, 2003, 
Kitazawa et al., 2009). Interestingly, PKG-1 carries out two actions as a potent regulator 
of vasodilation. In addition to activating SERCA, PKG-1 also phosphorylates the large 
conductance Ca2+-activated K+ channels (BKCa). By phosphorylating BKCa channels, 
they become open and cause membrane hyperpolarization. Downstream of this, voltage-
dependent Ca2+-channels are closed preventing Ca2+ influx and further dilation (Kitazawa 
et al., 2009).  
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Figure 3. Mechanisms of Ca2+-mediated vasodilation and vasoconstriction. (i) Vasodilators such as 
acetylcholine bind to muscarinic M3 GPCRs on endothelial cells. Binding induces signal transduction, 
resulting in activation of IP3Rs on the ER/SR. Ca2+i is increased as Ca2+ is released from internal stores 
causing endothelial Ca2+-dependent activation of eNOS. NO generated from the enzymatic actions of 
eNOS is diffused in a paracellular manner. NO is small enough to diffuse in the absence of myoendothelial 
junctions. Here, NO inhibits Ca2+ influx from BKCa channels, activation of IP3Rs and lastly 
vasoconstriction. (ii) Activation of α1-adrenergic receptors by agonists such as phenylephrine or 
epinephrine causes activation of VSMC IP3Rs. Ca2+ is liberated from internal stores and results in myosin 
bridging in VSMCs and vasoconstriction. 
  
(i) 
(ii) 
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1.3 Vascular calcification; an introduction to soft tissue mineralisation 
Vascular calcification is often a consequence of an unhealthy lifestyle, and a 
pathophysiological state that will affect every adult as they progressively enter their 
senior years of life (Demer and Tintut, 2008). Statistical data from a study carried out in 
2004 indicate that, by the age of approximately 60, most men and women have some 
Ca2+ deposits in the distal aorta (Allison, 2004). Vascular calcification promotes heart 
failure and hypertrophy by interfering with normal vessel compliance and elasticity 
(Demer and Tintut, 2008). Until the early 1990’s VC was considered to be the passive 
and cell-independent mineralisation within blood vessels, driving elastic smooth-muscle 
cells in vessel walls towards something biologically more reminiscent of bone. It was 
widely believed that, over time, Ca2+o and inorganic phosphate (Pi) in extracellular fluids 
may coalesce into inorganic minerals such as hydroxyapatite (HA) and whitlockite; 
minerals which are insoluble under normal physiological conditions (O'Neill, 2008, 
O'Neill and Koba, 2010). In 1994, Linda Demer and colleagues challenged this theory 
declaring for the first time in a seminal study that calcification at atherosclerotic lesions 
may be co-ordinated through transdifferentiation of VSMCs in human and bovine aortae 
(Demer and Watson, 1994). This controversial claim indicated that the complexities of a 
metabolically active biological system may somehow interfere with fundamental 
physicochemical processes that one might observe in a simple chemical reaction in vitro. 
For the first time the group showed that osteogenic markers, such as bone morphogenetic 
protein 2 (BMP-2), were upregulated in calcified atherosclerotic lesions in vivo. The 
consequences of this finding ushered in a new theory of soft tissue mineralisation, which 
supersedes the previous notion that cells in the vascular wall have an unchanging 
phenotype. Since this pioneering research, the theory of vascular cell transdifferentiation 
has introduced a new niche for cardiovascular research (Boström et al., 1993, Demer and 
Watson, 1994). 
 
In recent years, numerous research groups have attempted to define where this 
transdifferentiation phenomenon may occur, and, if it is the sole determinant of 
atherosclerotic and vascular calcification. Vascular smooth muscle cells are present in 
the tunica media of blood vessels and have shown to be key players in this phenotype 
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switching (Luo et al., 1997, Davies, 2003, Shao et al., 2005, Shao, 2006, Shen et al., 
2011), most likely due to their overwhelming presence in the arterial wall (Burton, 1954). 
The tunica media is comparatively large in comparison with the intima, which consists 
of just one layer of endothelial cells, suggesting that VSMCs play a major role in 
determining the vessel phenotype overall. VSMCs are characteristically contractile, for 
example, by α1-AR stimulation (Hoffman and Lefkowitz, 1982, Minneman, 1988, 
Heusch, 2011). Similarly, they can also elicit dilation indirectly through activation of 
muscarinic M3 receptors on endothelial cells (Felder, 1995, Andersson, 2002). In this 
regard, VSMCs are largely the major physical modulators of vascular tone and during 
calcification vascular tone is often significantly impaired. This evidence indicates that 
these VSMCs exhibit significant plasticity, and so may be susceptible to 
transdifferentiation. 
 
It has been extensively documented that vascular calcification is associated with a loss 
of the ability of vascular smooth muscle cells to contract, indicating that a change occurs 
in this region of the vessel wall. Consequently, much research into VC in recent years 
has been investigated in VSMCs and, encouragingly, many research groups have 
demonstrated the ability of primary mouse VSMCs in culture to undergo 
transdifferentiation at the molecular level when pro-mineralising conditions are present 
(Luo et al., 1997, Davies, 2003, Shao et al., 2005, Shao, 2006, Shen et al., 2011). This 
has been shown in isolated VSMCs from rats (Ciceri et al., 2011, Ciceri et al., 2012), 
cows (Shioi et al., 1995, Shalhoub et al., 2006, Alam et al., 2008, Kircelli et al., 2012) 
and humans (Proudfoot et al., 2000, Reynolds, 2004, Reynolds, 2005, Olesen et al., 2006, 
Shalhoub et al., 2010). Typically, these researchers note the presence of visual nodules 
in in vitro cell cultures as well as the gain of expression of numerous osteogenic markers 
including the master osteoblastic transdifferentiation factor Runx2 (often termed cbfa1), 
osteocalcin (OC), alkaline phosphatase (ALP) and collagen type-I (Col1). 
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1.4 Classification of vascular calcification 
Calcification is a condition that can affect many cell types and blood vessels. To date, 
numerous types have been classified including atherosclerotic calcification of the tunica 
intima, medial calcification of the tunica media, aortic valve calcification and 
calciphylaxis (Freeman and Otto, 2005, Thom et al., 2006). It has been predicted that the 
often co-localisation of intimal and medial calcification indicates that these calcifications 
are one unified process. However, a study by Duhn et al has produced evidence 
suggesting that the two are distinctively separate processes. The group demonstrated this 
by examining breast arterial calcification (BAC) in patients with chronic kidney disease 
(CKD). A study of the breast tissue of 16 patients all showed signs of calcification 
exclusively in the tunica media. The group concluded that BAC could be an important 
indicator and marker of medial calcification (Drüeke and Massy, 2011, Duhn et al., 
2011). The key distinctions between intimal and medial calcification have been covered 
extensively in a number of review articles (London, 2003, Kapustin and Shanahan, 2009, 
London, 2011). Differences widely accepted across the field are that intimal calcification 
is a consequence of inflammation consistent with the development of plaques and 
occlusive lesions, whereas medial calcification is typically a condition of conductance 
vessels such as the femoral artery and aorta and is tightly-linked to Ca2+o/Pi dysregulation 
often present in CKD patients (London, 2003, Shroff and Shanahan, 2007, Kapustin and 
Shanahan, 2009, London, 2011). 
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1.4.1 Intimal atherosclerotic calcification 
Atherosclerosis is an inflammatory disease of the cardiovascular system which is 
significantly accelerated by high serum cholesterol (Demer, 2001), smoking (Witteman 
et al., 1993, Howard et al., 1998), hypertension (Ross, 1993, Ross, 1999), lipoproteins 
(Ghiselli et al., 1981, Williams et al., 2010), high blood sugar (Jongstra-Bilen et al., 
2006), dead smooth muscle cells and macrophages (Jongstra-Bilen et al., 2006). 
Atherosclerosis begins in younger years in humans and extends into adulthood where 
such conditions are present that exacerbate it (Allison, 2004). Typically, bifurcations of 
blood vessels are susceptible target areas for the development of atherosclerotic 
calcification where turbulent blood flow can cause shear stress to the vascular 
endothelium (Daugherty et al., 1997, Fayad and Fuster, 2001). At these sites, lipoproteins 
can deposit and small plaques can begin to develop, extending outward into the lumen 
(Ivanovski et al., 2009). Additionally, plaque growth is positively correlated with 
calcification of the intima where lipids, macrophages, lymphocytes, fibroblasts and dead 
VSMCs can coagulate with Ca2+o and Pi products such as HA (Amento et al., 1991, 
Clarke et al., 2006). Interestingly, the stability of plaques in calcified regions is 
determined chiefly by ECM components, specifically collagen. When the fibrous cap of 
the plaque is poor in ECM proteins this can be an indicator that rupture and subsequent 
thrombosis is likely to follow. Surprisingly, although thrombosis is a major consequence 
of plaque rupture, 90% of ruptures are asymptomatic and can be effectively repaired at 
the vessel wall (Budoff and Gul, 2008), however, repeated cycles of rupture and repair 
can occur as seen in Figure 4. Plaque rupture is a crucial event in cardiovascular 
morbidity. At rupture, plaque contents are released into the lumen of the affected artery 
inducing blood adhesion and coagulation (Williams et al., 2010). Plaque instability can 
be induced by a number of factors including inflammatory cytokines such as interferon-
γ (IFN-γ) present in the vasculature (Binder, 2004). These can act to potentiate instability 
by inhibiting the synthesis of the crucial structural collagens (type I and III) laid down 
by surrounding VSMCs. Ultimately, this reduces the robustness of the fibrous cap 
increasing the risk of rupture (Amento et al., 1991). Plaque stability can be further 
increased when the lipid pool within the plaque is high, in addition to a significantly 
reduced amount of macrophages and lymphocytes which normally evoke mechanical 
stress on the fibrous cap in greater abundances (Libby, 2002). Additionally, lowered 
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blood pressure and oxidative stress can help maintain plaque stability (Libby and 
Aikawa, 2002).  
 
 
 
 
    
 
 
 
 
 
Figure 4. Recurrent atherosclerotic plaque rupture in the brachiocephalic artery of an 
apolipoprotein E deficient (apoE-/-) / transglutaminase 2 deficient (TG2-/-) double-knockout mouse. 
Red arrowheads indicate numerous previous fibrous caps. (A) Five successive plaque ruptures and repairs. 
(B) One fibrous cap with a dense lipid pool. Figure taken from Williams et al (Williams et al., 2010). 
A 
B 
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1.4.2 Medial vascular calcification 
 The principal type of calcification in this investigation relates to the calcification of the 
tunica media. Accumulation of Ca2+o and Pi minerals, particularly HA (Ca10(PO4)6(OH)2) 
in the VSMC layer is a well-documented characteristic of medial vascular calcification 
(Nitta et al., 2004, Johnson, 2005, Johnson et al., 2006, Shroff and Shanahan, 2007, Nitta, 
2011). Medial or “Mönckeberg” calcification was first described in 1903 by Johann 
Georg Mönckeberg (Mönckeberg, 1903) and is often detected in uremic and diabetic 
patients, suggesting that medial vascular calcification is at least in part a consequence of 
failure to excrete Pi (Giachelli, 1999). This is indeed observable in patients suffering with 
hyperphosphataemia, typically  brought on by CKD (Jono et al., 2000). Until recently, 
authors have disagreed that medial calcification is exclusively a condition of the tunica 
media and not just an addition to the internal elastic lamina (Micheletti et al., 2008). Both 
in vivo and in vitro models have shown that VSMCs demonstrate significant plasticity 
enabling them to transdifferentiate (Olesen et al., 2006, Hruska, 2009, Speer et al., 2009). 
The current transdifferentiation hypothesis, which is supported by much experimental 
data, suggests that VSMCs may begin to calcify when exposed to a number of conditions 
including a reduction in protective factors, and an increase in pro-calcific factors 
(Johnson et al., 2006). These factors cause VSMCs to excrete matrix vesicles (MVs); 
extracellular lipid bilayer-enclosed microstructures. It is likely that cells do this in order 
to off-load an excess of mineral components from internal stores, for example, from the 
ER (Anderson et al., 2005, Kapustin et al., 2011). Unfortunately, evidence suggests that 
these MVs which firstly act as a ‘rescue mechanism’ for the cells, actually provide an 
extracellular nidus for calcification and coagulation of factors including HA (Chen et al., 
2010a). In these conditions VSMCs adopt a more osteoblastic phenotype. They begin to 
express a number of osteoblast gene markers including ALP, osterix (OSX), 
osteoprotegrin (OPG), OC and the osteoblast transcriptional regulator, Runx2 (Shroff 
and Shanahan, 2007, Neven et al., 2010). Calcification is often an asymptomatic 
consequence of this mineral accumulation in the tunica media (Abedin, 2004). 
Interference with elastic lamina and healthy extracellular matrix components can 
increase turgidity and stiffness of major vessels such as the aorta, femoral and 
brachiocephalic arteries (Guérin et al., 2000). Consequently, individuals suffer from 
blood pressure increases and reductions in blood flow. This is often attributed to the 
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decreased contractility, vessel compliance and increased aortic stiffness. In excess, 
medial calcification can usher in a compensatory mechanism by the heart to normalise 
this effect, and so patients with medial calcification are prone to the development of left 
ventricular hypertrophy (Davies and Hruska, 2001, Nitta et al., 2004, Nitta, 2011). A 
diseased human femoral vessel artery can be seen in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Medial arterial calcification in a human femoral artery. Mineralisation in the VSMC layer 
is confirmed with alizarin red staining (red arrowheads). Medial calcification can be observed in lesions 
indicated with red arrows. Tearing of the vessel wall can be seen in these heavily calcified regions. Image 
courtesy of Dr. Alexander at Manchester University.  
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1.4.3 Aortic valve calcification 
Aortic valve calcification is the third most common cause of adult heart disease (Thom 
et al., 2006). The condition becomes more severe in ageing individuals. This is best 
observed in individuals over the age of 80 where 1 in 25 will have some degree of aortic 
valve calcification (Lindroos et al., 1993). The molecular mechanisms promoting this 
disease state are currently unknown, although research data support the idea that VSMCs 
transdifferentiate in the aortic valve into osteoblast-like cells (Nigam and Srivastava, 
2009, Wen et al., 2012). This has been demonstrated in mice where the Notch1 gene has 
been knocked out. Nigam and Srivastava showed that Notch1 has a repressive effect on 
osteogenic marker expression. The group showed this by looking at mRNA and protein 
levels of BMP-2 which was significantly upregulated in Notch1-KO mice fed high-fat 
diets (Figure 6). More importantly, Notch1-KO was associated with calcification of the 
aortic valve (Nigam and Srivastava, 2009).  
 
 
 
 
 
 
 
 
 
Figure 6. Aortic valve calcification in Notch1-knockout mice. (A and C) low- and high-powered 
magnification of von Kossa-stained aortic valves in WT mice fed on a normal diet. (B and D) low- and 
high-powered magnification of von Kossa-stained aortic valves in Notch1-KO mice fed on a high-fat diet 
(20% anhydrous milkfat / 1% corn oil / 0.2% cholesterol). In panel D mineral deposits can be seen as 
confirmed by the presence of black von Kossa nodules. Figure adapted from Nigam and Srivastava (Nigam 
and Srivastava, 2009). 
WT Mice Notch1-KO 
Mice 
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1.4.4 Calciphylaxis / calciphic uremic arteriolopathy 
Calciphylaxis, often termed calciphic uremic arteriolopathy (CUA), is a condition often 
associated with CKD and diabetes (Hayden and Goldsmith, 2010). CUA is a visible 
manifestation of dysregulated Ca2+o and Pi metabolism and often presents itself in 
patients with CKD or end-stage renal disease (ESRD). Patients suffer from small eschars 
on the skin on the lower body. Interestingly, such eschars are rarely seen on higher body 
extremities (Rogers et al., 2007). Reports suggest that these darkened patches of skin 
contain subcutaneous Ca2+ deposits. Furthermore, these deposits are co-localised with 
adipose tissue suffering from hypoxia as a direct result of calcification (Wilmer and 
Magro, 2002). CUA is particularly dangerous since these small calcifications can result 
in larger-scale necrosis (Wilmer and Magro, 2002). Researchers have also reported an 
upregulation of osteogenic markers in smooth muscle cells in these calcified lesions 
(Ahmed et al., 2001). CUA visible lesions can be observed in Figure 7. 
 
 
 
 
 
 
 
 
  
Figure 7. Skin lesions of calciphylaxis patients. (Left) Calcific ulcers present on a male Caucasian patient 
with diabetes on dialysis. (Right) Medial left thigh calcified lesions on an obese, diabetic caucasian female 
with diabetes on dialysis. Figure adapted from Wilmer and Magro (Wilmer and Magro, 2002).  
♂ ♀ 
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1.5 Vascular calcification: epidemiology and associated diseases 
Interestingly, despite well-documented health problems in western societies in recent 
years, VC is not a new pathological development. Unearthing of the mummified remains 
of a 5,300 year old “ice-man” discovered in the Tyrolean Alps in 1991 confirmed VC in 
ancient civilisations. Murphy et al conducted conventional radiography on the remains 
in 2003 and computed tomography (CT) revealed that the male of approximately 45 years 
old exhibited degenerative arthritis and vascular calcification of the aorta and carotid 
arteries (Murphy et al., 2003). Vascular calcification is abundantly widespread, affecting 
humans of all ethnic groups with varying degrees of severity (Roger et al., 2011). 
Calcification and related cardiovascular disease (CVD), including stroke and heart 
attacks, is most prevalent in white and black populations with lower incidence in Asian 
populations (Table 1). It often correlates with hypertension, type II diabetes and most 
exuberantly demonstrable in patients suffering with CKD (Johnson et al., 2006, 
Prosdocimo et al., 2010). Moreover, VC is at its most pathological (and effectively 
irreversible) manifestation in patients with ESRD. ESRD is reached after substantial, 
prolonged and severe CKD. The kidney function in ESRD patients is so drastically 
diminished that healthy Pi metabolism and 1,25(OH)2D3 synthesis are severely 
compromised. Because of this, the likelihood and relative intensity of VC is inversely 
and proportionately exaggerated during ESRD, which is often a key predictor of 
cardiovascular mortality (Witteman et al., 1986, Mizobuchi et al., 2009).  
 
Additional predictors of cardiovascular disease include high blood cholesterol and type 
II diabetes. In fact, the American Heart Association released stroke and CVD statistics 
based on a 2008 analysis and showed that 33.6 million Americans over the age of 20 
have inappropriate serum cholesterol levels of over 240mg/dL. Furthermore, a staggering 
18.3 million Americans (~8% of the population) suffer from diabetes mellitus. Updates 
to the statistics were also made in 2012, revealing that adults over the age of 20 who are 
overweight or suffer from obesity in America amount to 149.3 million; an alarming 
67.3% of the total US population. In addition to these striking statistics, the study also 
showed that 1 in 3 deaths in 2008 were related to CVD complications in people below 
the age of 75. This was below the life expectancy of 77.9 in the US (Thom et al., 2006, 
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Rosamond et al., 2007, Rosamond et al., 2008, Lloyd-Jones et al., 2009, Lloyd-Jones et 
al., 2010a, Lloyd-Jones et al., 2010b, Roger et al., 2011, Roger et al., 2012). Taken 
together, these statistics (based on the 2008 analyses) reveal that 82.6 million Americans 
(36.2% of the population) suffer from CVDs, of which VC is also a predominant 
contributor. 811,900 of these individuals later died from CVD mortality (Thom et al., 
2006, Rosamond et al., 2007, Rosamond et al., 2008, Lloyd-Jones et al., 2009, Lloyd-
Jones et al., 2010a, Lloyd-Jones et al., 2010b, Roger et al., 2011, Roger et al., 2012). 
These concerning statistics are best visualised in Figure 8, detailing overall annual costs 
resulting from these CVD health complications.  
 
It should also be noted that, in the UK, statistics released by the British Heart Foundation 
and European Heart Network state that the cost of prescription medication for 
hypertension, heart disease and heart failure therapies have actually dropped between 
2010 and 2011 (Nichols et al., 2012). Costs have dropped from approximately £400 
million to £330 million per year. Although this appears to be in stark contrast to US 
statistics, it is reported that this is due to cheaper therapies put in place. However, 
estimates of the cost of CVD to the UK economy as a whole are approximately £19 
billion per year, consuming some ~6% of the health care annual budget (Nichols et al., 
2012).  
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Table 1. Heart disease prevalence within different ethnic groups. Statistics were derived from the 
American Heart Association compilation from the National Health Interview Survey (NHIS) and National 
Centre for Health Statistics (NCHS) in 2009. Data relate to different ethnic groups residing within the 
United States suffering from heart disease (HD) over the age of 18 (Roger et al., 2011). 
  
ETHNIC GROUP % HD PREVALENCE 
American Whites 11.9% 
American Blacks 11.2% 
Hispanic / Latinos 8.5% 
American Indian/Alaskan Natives 8.0% 
Asian 6.3% 
Indian 9.0% 
Korean  4.0% 
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Figure 8. Cardiovascular disease costs in the United States over 5 years. Data released by the American 
Heart Association detail direct and indirect annual costs to the US through cardiovascular disease. Costs 
relate to health expenditures, cost of physicians and professionals, hospital services, home health care, and 
prescribed medications in addition to lost productivity resulting from CVD mortality. 2006, $403.1 billion; 
2007, $431.8 billion; 2008, $448.5; 2009, $475.3 billion; 2010, $503.2 billion (Thom et al., 2006, 
Rosamond et al., 2007, Rosamond et al., 2008, Lloyd-Jones et al., 2009, Lloyd-Jones et al., 2010b). 
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1.6 Factors which exacerbate vascular calcification 
Despite vascular calcification being largely multi-factorial, there are some key features 
which persist in all cases in humans. Regardless of ethnic background (or even species), 
we consistently see these familiar contributors across all areas of research. 
 
1.6.1 Chronic kidney disease and dysregulated Pi metabolism 
As a key player in Pi metabolism, the kidney has crucial role in the onset of calcification. 
During CKD, kidney function is diminished and has severe repercussions on Pi 
metabolism. The progression of CKD is a key predictor of VC (Bellasi et al., 2009). In 
many cases, early stages of CKD induce vascular calcification, but the most dangerous 
manifestations are most observable in patients which develop full blown ESRD 
(Mizobuchi et al., 2009, Shanahan et al., 2011). In fact, patients with ESRD have 
extensive aortic and coronary calcification and ~50% of these patients have valvular 
calcification (Hujairi et al., 2004). This is attributable largely to the diminished Pi 
excretion consequential of kidney dysfunction. This accumulation of Pi is a key feature 
of uremic patients and is termed hyperphosphataemia. Hyperphosphataemia has proved 
to be helpful predictor of vascular calcification.  
 
1.6.2 Associations between Ca2+o, Pi, Ca x Pi, PTH and CKD 
This association between Ca2+o, Pi, PTH, CKD and cardiovascular disease has been 
described in detail by Geoff Block and colleagues (Block et al., 1998). Over the past few 
decades an association between secondary hyperparathyroidism and a decline in renal 
function has been documented (Slatopolsky et al., 1972, Slatopolsky et al., 1984). In a 
1998 study, Block compiled data from patients of two groups. The first group were from 
the Case Mix Adequacy Study (1990) and the second group were from the Dialysis 
Morbidity and Mortality Study Wave 1 (1993). After normalising CKD patients in each 
group to account for differences in sex, age of onset, diabetes and smoking, Block and 
colleagues were able to associate patients with high serum Pi (>6.5mg/dL), and patients 
with high serum Ca2+ x Pi product (>40mg/dL) with premature death (Block et al., 1998). 
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The correlation was a clear indication that high Pi brought on by CKD and calcification 
were strongly intertwined in patients of all backgrounds. Work by Block et al has been 
particularly crucial in intimately linking actions of the parathyroid, the CaSR, Pi, Ca2+o 
homeostasis, CKD and heart disease. With large amounts of clinical data on patients with 
CKD, diabetes and heart disease, it has become easier to carry out epidemiological 
studies in these areas. 
 
1.7 Mechanisms of vascular calcification 
Vascular calcification is a multifaceted and multifactorial state which can be either 
symptomatic or asymptomatic (Abedin, 2004). As a result, attributing a specific pathway 
or single hypothesis which underlines how VC starts, progresses and develops is 
challenging. When looking at pathways for disease, one must consider the vast variety 
of genes, proteins and cell-types involved in regulating healthy and compliant vascular 
walls, albeit keeping in mind basic physicochemical processes which can coexist in 
biological systems. In 2004, Giachelli reviewed mechanisms that surround vascular 
calcification and attempted to envelop major aspects of pathogenesis in blood vessels and 
gather them into an intelligible and organised mechanism (Giachelli, 2004). Giachelli 
proposed that Ca2+o and Pi coalesce in the vasculature and precipitate to form crystals of 
hydroxyapatite and whitlockite. Indeed, this was found to be a good predictor of VC, 
particularly in CKD patients where serum Ca2+o and Pi levels are elevated (Goodman et 
al., 2000). Since calcification is a consequence of build-up of these minerals, this is a 
good place to start in developing a complete hypothesis. Secondly proposed, is the 
balance between calcification inhibitors and promoters discussed in the next section. 
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1.8 Inhibitors of vascular calcification (genetic factors) 
In order to determine whether a gene plays a role in disease it is often knocked out to 
generate a null-mouse, or a tissue-specific knockout mouse. These mice will either lack 
the gene in every cell type, or may have specific deletion of the gene driven by a tissue-
specific promoter. Reviewed in this section will be genetic determinants of vascular 
calcification, as demonstrated from in vivo studies. 
 
1.8.1 Fetuin A 
Fetuin A (α2-Heremans-Schmid glycoprotein) is a circulating endogenous inhibitor of 
mineralisation which has been shown to be taken up by VSMCs (Chen et al., 2010b). 
This glycoprotein has been shown to have a significant role in bone development and is 
highly correlated with CKD where progression of the disease is associated with decreased 
serum levels of fetuin A. It has also been shown that fetuin-A is a potent binder of apatite, 
and is therefore often considered an anti-mineralising factor (Jahnen-Dechent et al., 
2011). Typically, fetuin A is highly expressed in the developing fetus, where it might 
play a protective role against fetal ectopic mineralisation (Merx et al., 2005). This may 
be because embryonic Ca2+o is approximately 1.7mM; hypercalcaemic compared to 
adult. This embryonic relative hypercalcaemia is speculated to be for the purpose of 
optimal developmental regulation during organogenesis (1.0-1.3mM [Ca2+]o) (Kovacs 
and Kronenberg, 1997, Finney et al., 2008). Interestingly, CKD patients in dialysis with 
reduced fetuin A levels appear to have increased vascular calcification with greater CVD 
mortality rates (Reynolds, 2005). Fetuin A also acts as a protease inhibitor and in vitro 
studies have shown that it can regulate VSMC apoptosis and matrix vesicle calcification 
(Reynolds, 2005). The protective role of fetuin A is clearly observable in transgenic mice 
lacking the fetuin A gene. Merx et al demonstrate that, in fetuin A-deficient mice, ectopic 
and dystrophic calcification is extremely widespread. Paradoxically to our area of 
investigation, this knockout mouse demonstrates significant calcification in muscles, the 
heart, lungs, kidneys but, very surprisingly, not the aorta; a region which normally 
calcifies during CVD (Merx et al., 2005). Calcifications of the heart and myocardium are 
observed in Figure 9 where von Kossa staining confirms the presence of mineral. Since 
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aortic calcification was not observed, it is likely that the aorta has multiple protective 
mechanisms to prevent calcification, even in the absence fetuin A. 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Fetuin A knockout mice show spontaneous ectopic calcification of the heart. (A) WT mouse 
heart viewed by light microscopy. (B) KO mouse heart viewed by light microscopy. Small white calcified 
lesions can be observed (black arrows). (C) low-powered light microscopy of WT mouse myocardium 
tissue sections stained with von Kossa. (D) low-powered light microscopy of KO mouse myocardium 
tissue sections. KO tissue is speckled with small black nodules of mineral (von Kossa positive). (E) High-
powered light microscopy of WT mouse myocardium tissue sections stained with von Kossa. Tissue is 
devoid of ectopic mineral. (F) High-powered microscopy of KO myocardium tissue sections. Black 
mineral deposits are visible. Figure adapted from Merx et al (Merx et al., 2005). 
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1.8.2 MGP 
Initially discovered in bone, Matrix gla (γ-carboxyglutamic acid) protein (MGP), is a 
Ca2+o-binding protein abundant in serum (Price and Williamson, 1985). In addition to 
bone, MGP is normally expressed in cartilage, tooth, VSMCs, kidney, heart and the lung 
(Khoshniat et al., 2011). Post-translational modification of MGP is crucially important 
for it to elicit its protective role. The endoplasmic reticulum-bound γ-carboxylase enzyme 
is essential in converting immature MGP to a mature form containing Ca2+o-binding γ-
carboxyglutamic acid (Gla) residues, using vitamin K as a co-factor (Furie, 1990, Wallin 
et al., 2001). Crucially, it has been shown that MGP in its mature form can bind Ca2+o in 
addition to BMP-2; a potent promoter of calcification. Interestingly, Zebboudj et al have 
shown that MGP/BMP-2 complexes can form in vitro (Zebboudj et al., 2002). The group 
found that balance of these two proteins was crucial in determining the extent of 
calcification (Zebboudj et al., 2003). MGP is likely to co-ordinate its protective role in 
VSMCs chiefly by its synthesis and secretion by these cells, therefore making MGP 
readily and locally available as a protective agent (Proudfoot et al., 1998). MGP, 
however, can be tightly controlled by the actions of its inhibitor, warfarin. Studies have 
shown that in rat VSMCs in vitro, warfarin increases mineralisation in a dose-dependent 
manner (Beazley et al., 2012).  
 
Interestingly, in addition to fetuin A-KO mice demonstrating widespread ectopic 
calcification, MGP-deficient mice also develop a similar phenotype, reaffirming the 
protective roles of these factors. Luo et al developed a MGP-/- mouse, and in 1997 
reported severe calcification of all blood vessels in these mice. Calcification continued a 
few weeks into life until mice died of aortic rupture before adulthood. This further 
illustrates the essential role of MGP in the regulation of vascular calcification (Luo et al., 
1997). An important distinction between fetuin-A and MGP-KO mice is that MGP-KO 
mice develop calcification of the aorta. Ectopic mineralisation of the cardiovascular 
system is seen in MGP-KO mice in Figure 10. 
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Figure 10. Ectopic mineralisation of blood vessels in MGP knockout mice. 4-week old mice lacking 
MGP show significant calcification of all major blood vessels by alizarin red staining. Calcification can be 
seen in separate arteries indicated by black arrows. Figure adapted from Luo et al (Luo et al., 1997). 
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1.8.3 Pyrophosphate 
Inorganic pyrophosphate (PPi) is a potent inhibitor of medial calcification found all over 
the body. PPi is extensively produced in all cells undergoing DNA synthesis where PPi 
is a bi-product of the action of deoxynucleoside triphosphatases in the nucleus 
(Herdewijn and Marlière, 2012). Its levels are also tightly controlled by the actions of 
tissue non-specific alkaline phosphatases (TNAPs) anchored into the plasma membrane 
that act extracellularly (Schoppet and Shanahan, 2008, Villa-Bellosta et al., 2011). 
TNAPs play a crucial role in the catalytic hydrolysis of PPi into small Pi ions, therefore, 
can be considered as factors which exacerbate vascular calcification and 
hyperphosphataemia. PPi has been shown to be a direct inhibitor of hydroxyapatite 
formation, even at concentrations as low as 100nM (Francis et al., 1969). Extracellular 
PPi is generated by the actions of nucleotide pyrophosphatase/phosphodiesterase-1 
(NPP1) which hydrolyse ATP (Schoppet and Shanahan, 2008). Research by Villa-
Bellosta has shown this to be a tightly localised process, taking part within blood vessels. 
This was found when mRNA transcripts for NPP1 and TNAPs were located in mouse 
and rat aortae. Furthermore, the group showed that in NPP1 knockout mice, aortae did 
not synthesize PPi (Villa-Bellosta et al., 2011). The crucial role of PPi as a protector 
against vascular calcification is clear in children with generalized arterial calcification of 
infants (GACI). This disorder is caused by inactivating mutations in the NPP1 gene. 
Consequently, the sufferer cannot synthesize PPi and the result is large scale systemic 
calcification culminating in lethal aortic rupture (Rutsch et al., 2001, Rutsch et al., 2003, 
Prosdocimo et al., 2010).  
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1.8.4 BMP-7 
Bone morphogenetic proteins (BMPs) comprise a family of some 30 proteins typically 
involved in osteogenesis and organogenesis (Hruska, 2005). BMP-7 is a member of the 
transforming growth factor β (TGFβ) superfamily and acts as a crucial morphogen 
throughout development and adulthood (Hruska, 2005, Hruska, 2009). Normally, BMP-
7 is expressed widely in the kidney and functions to maintain the differentiated phenotype 
of tubular cells through paracrine and autocrine signalling. Their role in osteogenic and 
renal development is best seen in mice deficient in BMP-7. These mice die postnatally 
due to skeletal patterning defects, hypomineralisation of the ribcage and skull (as seen in 
Figure 11) and renal dysplasia (Hofmann et al., 1995). Interestingly, studies have shown 
that despite BMP-2 being so structurally similar to BMP-7, they both promote two very 
different mechanisms of actions in VSMCs. BMP-2 is typically an osteogenic marker 
and drives mineralisation- even in the vasculature (Lee et al., 2003). Conversely, BMP-
7 is a protective morphogen which maintains and promotes the VSMC phenotype (Dorai 
et al., 2000). Furthermore, its expression is reportedly diminished during vascular 
calcification. Its potent role as a cardiovascular protective agent is seen in low density 
lipoprotein receptor (LDLR)-deficient mice; a mouse model used to initiate and 
accelerate atherosclerosis. Atherosclerosis induction with high-fat diets in LDLR-/- 
appears to be rescued with BMP-7 treatment. During treatment, skeletal remodelling is 
resumed to the normal and hyperphosphataemia is significantly reduced (Davies, 2003). 
Although interestingly, one study suggests that BMP-7 may be deleterious, inducing 
thrombogenicity of atherosclerotic plaques (Sovershaev et al., 2010).  
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Figure 11. BMP-7 knockout mice demonstrate skeletal developmental defects of the skull, ribcage 
and right hindlimb. (Left panel) WT mice show normal skeletal growth of the ribcage (upper), skull 
(lower left) and right hundlimb (lower right). (Right panel) BMP-7 KO mice show abnormal ribcage 
development in size and shape (upper panel), presence of a cavity in the basosphenoid bone and fusion 
between the right alisphenoid bone and inner ear in the skull (lower left), and extra digits on right hindlimbs 
(lower right). Skeletons were stained with alcian blue (cartilage) and alizarin red (Ca2+ in bone). Figure 
adapted from Hofmann et al (Hofmann et al., 1995). 
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1.8.5 FGF23 
Fibroblast growth factor 23 (FGF23) is a major phosphaturic hormone produced in bone 
and upregulated during haemodialysis (Pai et al., 2011). FGF23 binds to the FGF receptor 
(FGFR) in the presence of its obligatory coreceptor Klotho, and plays a critical role in Pi 
metabolism, vitamin D regulation and overall renal function. When serum Pi levels 
become elevated, osteoclasts and osteoblasts begin to secrete FGF23 (Yamazaki et al., 
2010). Circulating FGF23 then acts to reduce serum Pi. This is done primarily by 
reducing the expression of the sodium/phosphate transporters in the kidney such as NaPi-
IIa and Pit-2 (Shimada et al., 2004). This way, excess plasma Pi is eliminated from 
extracellular fluids and excreted (Sage et al., 2009). Interestingly, two genetic disorders 
exist in humans which demonstrate substantial FGF23 dysregulation. These are 
autosomal dominant hypophosphataemic rickets (ADHR) and hyperphosphataemic 
familial tumoral calcinosis caused by activating and inactivating mutations of FGF23 
respectively. The latter can be recapitulated in mice where FGF23 is knocked out (Figure 
12). In these mice, severe ectopic calcification occurs with mineral deposition in the 
kidney and aorta. This has been confirmed experimentally by numerous groups including 
that of Stubbs et al, who showed calcification by alizarin red staining in mice at just 6 
weeks of age (Stubbs et al., 2007). Klotho-deficient mice also share many phenotypic 
characteristics of FGF23-deficient mice. In a 1997 publication detailing the phenotype 
of these mice, investigators noted premature arteriosclerosis, osteoporosis and medial 
calcification of the aorta (Figure 13) (Kuro-o et al., 1997). 
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Figure 12. FGF23-knockout mice show ectopic calcification in the aorta and kidney. Upper left: WT 
mouse aortae stained with von Kossa. Lower left: KO mouse aortae stained with von Kossa show 
mineralisation in the tunica intima and media. Right panel: WT and KO mouse kidneys stained with alizarin 
red. KO kidneys appear significantly smaller than WT and are abundant in Ca2+ as confirmed by alizarin 
red staining. Figure adapted from Stubbs et al (Stubbs et al., 2007). 
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Figure 13. Klotho deficient mice exhibit aortic calcification, osteoporosis and skin atrophy. (a) 
Calcification of the aorta in Klotho-/- mice. (b) Intimal thickening in muscular artery. (c) Calcification in 
kidney arteries. (d) Bone radiographs of femurs (left two) and tibiae (right two). (e) Skin sections of control 
mice. (f) Skin sections of Klotho-/- mice (Kuro-o et al., 1997). 
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1.8.6 Osteoprotegrin 
Osteoprotegrin (OPG) is a member of the tumour necrosis factor (TNF) receptor gene 
superfamily and is a soluble circulating ligand of receptor activator of nuclear factor 
kappa-B ligand (RANKL); a major promoter of mineralisation of bone (Kendrick and 
Chonchol, 2011). OPG is also highly expressed in vascular cells such as VSMCs and 
endothelial cells (Kendrick and Chonchol, 2011). Normally, OPG plays an important role 
in bone metabolism and is secreted to inhibit osteoclast function. In OPG-deficient mice 
there is a significantly reduced bone density and mass, however, a group who 
overexpressed OPG in the liver showed that mice gain bone density and mass (Bucay et 
al., 1998). Many studies including research by Dhore et al suggest a role for OPG as a 
protector against vascular calcification and atherosclerosis. Dhore et al showed that OPG 
is upregulated systemically during atherosclerosis (Dhore et al., 2001). This once again 
suggests that OPG is tightly regulated to reduce ectopic calcification and mineralisation. 
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1.9 Inhibitors and treatments of vascular calcification (non-genetic factors) 
In many cases it has been reported that non-genetic factors play significant roles in 
inhibiting vascular calcification. Such factors, which are not the direct products of genes, 
cannot be investigated by means of gene-knockout. For this reason, researchers have 
demonstrated the potential of these non-genetic factors as calcification inhibitors by 
treating animals predisposed to vascular calcification, or by performing in vitro analysis 
on vascular cells cultured in the presence of these factors. These factors will be reviewed 
here. 
 
1.9.1 Thiosulphate 
Since the 1980’s, thiosulphate has been suggested as a treatment for kidney stones 
(Yatzidis and Agroyannis, 1987). More recently, several groups have demonstrated the 
benefit of sodium thiosulphate treatment in reducing the severity of CUA and the 
development of Ca2+ x Pi stone formation in hypercalciuric rats (Hackett et al., 2009, 
Hayden and Goldsmith, 2010). In a study by Pasch et al, uremia was induced by feeding 
rats adenine for 4 weeks. Thiosulphate treatment completely inhibited aortic 
calcification, which was abundantly widespread in control mice (Pasch et al., 2008). The 
action of thiosulphate is likely to be due to the ability of the S2O3- anion to chelate Ca2+o 
and inhibit HA formation. For this reason, S2O3- can be considered as a non-genetic 
inhibitor to HA formation- similar to MGP; a genetically controlled endogenous factor. 
However, there is evidence (particularly in this publication) that thiosulphate can reduce 
bone strength, possibly by interfering with healthy mineral metabolism in these areas 
(O'Neill, 2008, O'Neill and Koba, 2010). For this reason, the potential of thiosulphate as 
an anti-VC treatment remains controversial. 
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1.9.2 Calcimimetics 
Calcimimetics such as R-568 are positive allosteric modulators at the CaSR and have 
been used extensively in vascular calcification studies (Alam et al., 2008, Ivanovski et 
al., 2009, Koleganova et al., 2009, Caudrillier et al., 2010, Chen et al., 2011). Recently 
our group demonstrated that treating bovine VSMCs in mineralising conditions with R-
568 reduced mineralisation of these cells (Alam et al., 2008). Here, bovine VSMCs were 
mineralised in the presence of β-glycerophosphate (βGP) and 1.8mM Ca2+o. 1nM R-568 
was shown to have a significant effect at reducing mineralisation of these VSMC 
cultures, although we have also shown (not published) that concentrations as low as 
100pM can also reduce mineralisation in these cultures in vitro. Additionally, in human 
coronary artery SMC cultures which were also mineralised, R-568 also reduced 
calcification, measured as Ca2+ incorporation of mineralised cell cultures (Shalhoub et 
al., 2010). Studies into vascular calcification are however not limited to in vitro studies. 
Numerous investigators have used in vivo models to observe this in animal models. 
 
In a 2008 study, Piecha et al investigated the role of R-568 and the active form of vitamin 
D, calcitriol, in vascular calcification in uremic rats. Uremia was introduced using 5/6 
nephrectomies since renal failure is often accompanied by vascular calcification in blood 
vessels such as the aorta and femoral arteries (London, 2003, Torres and De Broe, 2012). 
After the procedure, animals were fed on standard rodent diets supplemented with a 
control, R-568 (17mg/kg body weight per day) or calcitriol (3ng/kg body weight per day). 
The study reported that R-568 and calcitriol were effective at reducing PTH secretion, 
but R-568 only was effective in reducing serum Pi. Additionally, the group demonstrated 
that R-568 only was effective at increasing expression of CaSR at the mRNA and protein 
level (Piecha et al., 2008). 
 
In 2009, the same group attempted to tease out the role of CaSR in the rat cardiovascular 
system, with a specific interest in the role of CaSR in vascular calcification and vascular 
remodelling. Over a course of 12 weeks post-nephrectomy, the group firstly showed that, 
as a consequence of the nephrectomy, rats had significantly thicker aortic walls compared 
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to sham-operated rats. Additionally, calcitriol treatment (30ng/kg body weight) increased 
aortic calcification and VSMC proliferation in uremic rats compared to untreated uremic 
rats. The group also demonstrated that R-568 treatment (20mg/kg body weight per day), 
but not calcitriol, in both sham-operated and uremic rats led to a significant increase in 
CaSR expression in the intima when compared to untreated control animals in each 
group. The group concluded that calcitriol appeared to contribute to greater calcification 
and proliferation in the aortic wall using the concentration tested, whereas R-568 reduced 
both of these processes (Koleganova et al., 2009). These findings suggest that modulation 
of CaSR by calcimimetics improves the overall cardiovascular function. One way this 
protective treatment might occur is through upregulation of the CaSR protein, as 
confirmed in this study by immunohistochemical analysis. Additionally using apoE 
knockout mice, which are genetically pre-disposed to vascular calcification, 
calcimimetics also demonstrated an effective role in reducing calcification of the aorta 
(Ivanovski et al., 2009). ApoE-/- mice were fed regular rodent diets with R-568, calcitiol 
or a vehicle. It was shown that R-568 (1mg/kg body weight per day) and not calcitriol 
significantly reduced serum Ca2+o, Pi and calcification of the tunica media. 
 
With the success of such studies in animal models, clinical trials have begun in humans 
investigating the role of the calcimimetics in vascular calcification. One such trial is the 
ADVANCE study: a randomized study to determine the role of calcimimetics and low-
dose active vitamin D treatment in patients undergoing haemodialysis (Raggi et al., 2011) 
for more than 3 months with serum PTH at 100-300pg/mL, >50mg2/dL2 Ca2+ x Pi product 
receiving active vitamin D and calcium-based phosphate-binders. Coronary arterial 
calcification (CAC) was assessed in these patients using computed tomography and 
patients who scored highly for CAC from tomography analysis were placed on low-dose 
vitamin D (2µg paricalcitol per dialysis session) and 30-180mg/day cinacalcet. After 52 
weeks of treatment, patients were re-assessed for CAC scores. It was concluded that 
patients undergoing combinatory treatment of cinacalcet and vitamin D scored lower for 
CAC at the end-point in the aorta and mitral valve. These data suggest that calcimimetics 
(particularly cinacalcet) which are approved for the treatment of secondary 
hyperparathyroidism, appear to have an additional role in suppressing vascular 
calcification in human trials (Raggi et al., 2011). 
 Page 41 
 
 
In addition to the ADVANCE study, an ongoing study also assesses the effectiveness of 
cinacalcet on cardiovascular outcome function. The “Evaluation of Cinacalcet HCl 
Therapy to Lower Cardiovascular Events” (EVOLVE) trial was set up to assess the 
cardiovascular outcome of cinacalcet-treated patients suffering with CKD. Patients are 
already receiving a background of current treatments including Ca2+-based Pi-binders 
and vitamin D sterols. 3,883 patients on haemodialysis and sufferers of secondary 
hyperparathyroidism were recruited. Patients were randomized from 22 countries, and 
were found to have a significant burden of cardiovascular abnormalities and 
manifestations of CKD. This on-going study will determine whether cinacalcet treatment 
reduces cardiovascular disease severity compared to placebo-treated patients, however, 
as a global study with such a wide variety of patients on different background treatments, 
it will be difficult to make accurate comparisons between outcomes (Chertow et al., 
2012b). 
 
 
1.9.3 Vitamin D 
Vitamin D in its active form (termed calcitriol) is often prescribed to patients suffering 
from advanced CKD or renal failure to normalise the hypocalcemia which often 
accompanies this condition (Teng et al., 2005, Mathew et al., 2008). During the 
progression of CKD, serum levels of calcitriol steadily decline, facilitating the 
development of secondary hyperparathyroidism (Dusso et al., 2011). This is particularly 
due to the reduction in renal mass which reduces overall renal 1α-hydroxylase activity 
(Hu et al., 2012). Here, secondary hyperparathyroidism is an expected consequence, 
particularly since calcitriol has been shown to reduce expression of the PTH gene by 
increasing intestinal reabsorption of Ca2+. However, with deficiencies in vitamin D 
activation from the kidney, PTH becomes ineffective at restoring normocalcaemia (Dusso 
et al., 2011). As kidney disease becomes more severe, PTH becomes less effective and 
so regulating this with vitamin D analogs is often an intervention taken (Teng et al., 2005, 
Mathew et al., 2008, Bergwitz and Jüppner, 2010). However, vitamin D treatment can be 
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dangerous since this promotes vascular calcification by Pi retention and 
hyperphosphataemia, so treatment is often carefully monitored (Renkema et al., 2008). 
Indeed, there are many reports, both in the clinic and in uremic animal models 
demonstrating beneficial effects of certain vitamin D receptor agonists such as calcitriol 
and paricalcitol on vascular calcification and CKD (Teng et al., 2005, Mathew et al., 
2008, Piecha et al., 2008, Takeda et al., 2010, Olgaard et al., 2011).  
 
1.9.4 Mg2+ 
Patients suffering with advanced CKD have reduced circulating Mg2+ levels, indicating 
a possible protective role of this cation against calcification (Tzanakis et al., 1997, 
Ishimura et al., 2007). It has been shown that Mg2+ -an agonist of CaSR- reduces 
mineralisation in bovine VSMC cultures induced by 10mM βGP over 14 days (Kircelli 
et al., 2012). This was shown with a prominent reduction of 76% Ca2+ incorporation in 
VSMCs cultured in medium containing βGP in the presence of 2mM Mg2+. Further 
shown in these studies was the ability of Mg2+ to reduce ALP activity in a concentration-
dependent manner, in addition to upregulation of the expression of MGP. Mg2+ was also 
effective in reducing in the expression of Sox9 and Runx2, key regulators of 
chondrogenic and osteogenic differentiation, respectively. Kircelli et al propose that 
Mg2+ may in part promote this protective role through CaSR activation (Kircelli et al., 
2012). Kircelli et al did not investigate the use of Mg2+ because of its ability to act as a 
CaSR agonist, but because it has been observed clinically that patients suffering from 
vascular calcification have a significantly reduced serum Mg2+ concentration (Ishimura 
et al., 2007, Turgut et al., 2008). Interestingly, one should also note that Pi-binders, which 
are prescribed to patients suffering with CKD, often come in Mg2+-form. From the mid-
1980’s, magnesium hydroxide was prescribed as a Pi binder, however, patients often 
suffered from a number of side-effects including diarrhoea and mild hyperkalaemia. 
Magnesium carbonate has since been favoured with its less severe side effects 
(O'Donovan et al., 1986, Plagemann et al., 2011). A clinical trial of patients treated with 
magnesium carbonate in 1996 showed the effectiveness of Mg2+ as a reducer of serum Pi 
(Delmez et al., 1996). 
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1.9.5 La3+ 
In addition to the role of Mg2+, other polyvalent cations have been investigated to test for 
a possible involvement in vascular calcification (Zhao et al., 2011). In 2011 Zhao et al 
investigated the role of lanthanum (La3+) in bovine VSMC cultures. The group isolated 
bovine VSMCs and cultured them in medium under mineralising conditions (10mM βGP 
for up to 12 days). The addition of lanthanum chloride was sufficient to significantly 
reduce Ca2+ incorporation and mineralisation when compared to cells incubated in the 
absence of La3+. Interestingly, the effect of La3+ was biphasic, with lower concentrations 
evoking concentration-dependent reductions in mineralisation while concentrations 
greater than 0.1µM either had no effect or exacerbated calcification. The group also 
demonstrated upregulation of CaSR protein expression level when VSMC cells were 
incubated in the presence of 0.1µM La3+. In addition to these findings, Zhao et al also 
demonstrated an increase in apoptosis in VSMCs incubated in the presence of La3+, 
however, significance was only achieved in conditions where concentrations as high as 
50-200µM LaCl3 were used. In the presence of 0.1µM LaCl3 apoptosis was not 
significantly increased when compared to control conditions (Zhao et al., 2011). These 
data suggest a possible role of La3+ in the mineralisation of VSMCs through activation 
of the VSMC CaSR, particularly through ERK activation which was also demonstrated 
in this publication.  
 
 
The role of La3+ in rat VSMC mineralisation was also investigated by Shi et al in 2009. 
The group induced mineralisation in rat VSMCs with 10mM βGP and found that 
calcification was also significantly reduced in the presence of La3+ up to concentrations 
of 10µM. ALP activity was also decreased as a consequence of La3+ addition in a 
concentration-dependent manner (Shi et al., 2009). It should also be noted that lanthanum 
carbonate is often prescribed to patients with CKD to chelate serum Pi (Frazão and 
Adragão, 2012). A clinical trial using lanthanum carbonate as a phosphate binder found 
that serum Pi was significantly lowered in patients taking this drug (Al-Baaj et al., 2005). 
CKD patients with hyperphosphataemia taking 375mg LaCO3 a day for 4-weeks showed 
a 70% reduction in serum Pi to levels <1.8mM. Similar results were obtained from a 
more recent clinical trial with LaCO3 treatment over 12 weeks (Hutchison et al., 2008). 
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Since an increase in plasma Pi is linked to an increased risk of VC, these findings suggest 
that such a reduction in plasma Pi levels could also account for the reduced calcification 
as seen in mineralised VSMC cultures containing La3+. Collectively, these data suggest 
that certain polyvalent cations such as Mg2+ and La3+ have a significant effect in reducing 
mineralisation of VSMCs in vivo and in in vitro models of VC.  
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1.10 Promoters of vascular calcification 
In addition to the calcification inhibitors described, a number of calcification promoters 
exist which can drive mineral deposition or the transdifferentiation of vascular cells into 
osteoblast-like cells, and more recently, chondrocyte-like cells (Neven et al., 2010). 
Many contributors include inorganic phosphate (Pi), steroid hormones, oxidized lipids, 
BMP-2 and BMP-4 (Vattikuti and Towler, 2004) and inflammatory cytokines such as 
interleukins (Jaffe et al., 2007). Of particular interest are BMP-2 and BMP-4, which are 
produced by endothelial cells exposed to hypoxia, turbulent blood-flow and 
inflammation (Johnson et al., 2006).  
 
1.10.1 Cell plasticity 
There are currently multiple theories targeting a number of cells of the vasculature for 
initiating and propagating mineralisation and providing a niche for calcification. Namely, 
several hypotheses refer to (i) the transdifferentiation of native VSMCs in the tunica 
media (Giachelli, 2004, Alam et al., 2008, Panizo et al., 2009, Sage et al., 2011), (ii) 
calcification driven by calcifying vascular cells (CVCs); adventitial/subendothelial 
myofibroblasts with transdifferential plasticity (Radcliff, 2005, Abedin, 2006, Jaffe et 
al., 2007), (iii) circulating osteoprogenitors derived from bone marrow (Shao et al., 2005, 
Pal and Golledge, 2011), and lastly (iv) pericytes, or cells which play an integral role in 
the maintenance of the blood-brain barrier and angiogenesis (Collett and Canfield, 2005). 
It is currently believed that these highly plastic cell types exhibit great multilineage 
potential and are therefore susceptible to pro-mineralising factors, although sometimes 
distinction between them is not always clear.  
 
Sage et al have demonstrated that VSMCs isolated from mouse aortae mineralise in the 
presence of high Pi (3mM). During this process, the group showed an upregulation of the 
key osteogenic markers; BMP-2 and osteopontin. These findings demonstrate the 
plasticity of VSMCs (Sage et al., 2011). The notion that additional cells in the vascular 
wall could be responsible for calcification came from the fact that some VSMC 
preparations do not mineralise even in the presence of mineralising conditions (or at least 
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mineralise very poorly). For this reason, researchers have isolated subpopulations of the 
vessel wall which are prone to mineralising. Collett and Canfield report that 
CVC/subendothelial myofibroblasts undergo osteoblastic transdifferentiation more 
readily than VSMCs, often in the absence of mineralising conditions (Collett and 
Canfield, 2005, Abedin, 2006). These cells may be rich in Ca2+ and Pi, and may bud off 
vesicles into the ECM as matrix vesicles. Matrix vesicles are characteristic for being rich 
in phosphatidylserine. This phosphatidylserine has a high affinity for Ca2+, and so can 
act as nucleation sites for calcification (Genge et al., 2008). Circulating osteoprogenitors 
are also thought to play vital roles in initiating calcification. The presence of circulating 
bone marrow-derived osteoprogenitors has long been controversial. However, Long et al 
have successfully used antibody-based approaches to obtain cell populations expressing 
osteogenic markers from the blood (Eipers et al., 2000). Interestingly, such 
osteoprogenitors also express VSMC markers such as α-smooth muscle actin (αSMA). 
Strikingly, in a mouse model in which osteoblasts were pharmacologically ablated, 
before ‘osteoblast rescue’ (where osteoblasts were reintroduced into the mouse) 
repopulation of bone surfaces was preceded by an expansion of αSMA-positive cells 
(Kalajzic et al., 2008). These data would suggest that the osteogenic and vascular smooth 
muscle phenotypes exhibit great plasticity and some important crossover. Cottler-Fox et 
al report that the bone marrow releases these osteoprogenitor cells in response to stem-
cell mobilising cytokines (Cottler-Fox et al., 2003). These cells may then migrate in the 
vasculature to the sight of an unhealthy vessel. Within the vessel wall, these cells may 
then differentiate into osteoblasts and proliferate. Here, they undergo ectopic 
biomineralisation (Cottler-Fox et al., 2003, Pal and Golledge, 2011). Vascular pericytes 
also have the potential to migrate about the vasculature. Canfield suggests that pericytes 
are recruited at the site of angiogenesis to proliferate and group near the tip of the 
sprouting vessel. Various factors regulate this process, including vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF). However, how these 
cells are recruited and how they contribute to angiogenesis is not entirely clear (Cho et 
al., 2003, Jain, 2003, Collett and Canfield, 2005). Pericytes seem to share some features 
of adventitial myofibroblasts and since they exhibit such a great degree of plasticity, the 
distinction between the two cell types is not always clear (Collett and Canfield, 2005). 
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1.10.2 PiT-1 / matrix vesicles 
Evidence in the field of vascular pathology suggests that a major contributor of VSMC 
mineralisation is the phosphate co-transporter (PiT-1), which is somehow involved in the 
transdifferentiation of VSMCs and matrix mineralization (Jono et al., 2000). Increases in 
plasma Pi and Ca2+o levels are potent regulators of PiT-1 levels. Indeed, increases in 
[Ca2+]o cause an increase in expression levels of PiT-1 in human VMSCs (Jono et al., 
2000). Furthermore, increased plasma Pi stimulates Pi uptake by PiT-1. This rapid influx 
of Pi into the cell upregulates a number of osteogenic-related genes, including Runx2 and 
osteopontin (Li et al., 2006). Pi which is then increased intracellularly is often loaded 
into matrix vesicles as a possible rescue mechanism. These Ca2+ and Pi-rich matrix 
vesicles are later secreted by cells and promote nucleation of minerals in the ECM as 
described earlier (Giachelli, 2004, Genge et al., 2008). Interestingly, matrix vesicles are 
bodies typically responsible for normal biomineralization in a variety of tissues, 
including bone and cartilage (Anderson, 2003). Normally, these vesicles contain lipid-
dependent Ca2+-binding proteins, notably annexin-5 (Anx-5), which has been 
demonstrated to enhance mineral formation (Genge et al., 2008). 
 
1.10.4 Alkaline phosphatase 
Tissue non-specific alkaline phosphatases are enzymes typically expressed in osteoblasts 
(Liu et al., 2012). ALPs function to liberate Pi from nucleotides and proteins. In patients 
with CVD, circulating levels of ALP are significantly higher than normal levels, 
suggesting that more Pi is available for the formation of mineral deposits in the 
vasculature (Abramowitz et al., 2010). This is also seen in mineralised VSMCs of whole 
vessels of bovine and human respectively, where ALP activity is upregulated during 
mineralising conditions (Shroff et al., 2010, Kircelli et al., 2012). This is often 
contradictory though to reports seen in in vitro experiments in mice where ALP activity 
is not increased in mineralising conditions. It is therefore proposed that: (i) ALP activity 
in the mouse may be considerably lower compared to larger mammals such as cows and 
humans, (ii) mineralisation can occur still in the absence of ALP activity (Prosdocimo et 
al., 2010, Sage et al., 2011). 
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1.10.5 Vitamin D / Calcitriol 
As discussed earlier, vitamin D in its active form, calcitriol, plays a crucial role in 
extracellular Ca2+o and Pi homeostasis. Interestingly, calcitriol appears to have a biphasic 
effect on cardiovascular function. Several investigators have reported that calcitriol 
suppresses VC and atherosclerosis (Teng et al., 2005, Mathew et al., 2008, Piecha et al., 
2008, Takeda et al., 2010, Olgaard et al., 2011), whereas others report that it can 
exacerbate VC and atherosclerosis (Lopez, 2006, Koleganova et al., 2009). This apparent 
contradiction is generally ascribed to variations in the type of vitamin D analog, its 
dosage and route of administration (Hu et al., 2012). In a study in India researchers 
showed that vitamin D treatment to restore normal levels (~30ng/mL) had no benefit in 
patients with established CKD and associated cardiovascular disease (Rajasree et al., 
2001). Furthermore, they report that high-dose vitamin D treatment (>89ng/mL) was 
associated with the progression of cardiovascular disease. This can also be seen in animal 
studies where uremic rats are either injected or fed vitamin D-rich diets and develop 
arterial calcifications (Lopez, 2006, Koleganova et al., 2009). 30ng/kg (calcitriol/body 
weight) was injected every day in the Koleganova study while Lopez et al administered 
80ng/kg (calcitriol/body weight) by injection every other day, making both studies 
comparable (Lopez, 2006, Koleganova et al., 2009). 
 
1.10.6 Phosphate / Ca2+ 
Pi and Ca2+ are the two major contributors to vascular calcification. In patients suffering 
from CKD or ESRD, serum Pi and Ca2+o are typically elevated, when compared to those 
measured in normal subjects (>1.4mM and >1.2mM, respectively). These conditions 
allow for the deposition of mineral such as HA in the vasculature (Li et al., 2006, O'Neill, 
2008, Lau et al., 2010). The deleterious effects of elevated plasma Pi levels are seen in 
uremic mice where high-Pi diets rapidly enhance mineral deposition in arteries (El-
Abbadi et al., 2009). Hyperphosphataemic patients are often prescribed Pi-binders to 
removes excess Pi (Frazão and Adragão, 2012, Shigematsu et al., 2012). Preferentially, 
Pi binders which are not Ca2+-based are favourable, since the burden of additional Ca2+ 
may exacerbate calcification and mineral formation as seen in these patients who develop 
hypercalcaemia (Block et al., 1998, Renkema et al., 2008, Frazão and Adragão, 2012). 
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Such binders include lanthanum carbonate, sevelamer hydrochloride and aluminium 
hydroxide. Oral administration allows for intestinal chelation of Pi, which can then be 
excreted in faeces (Albaaj and Hutchison, 2005, Shigematsu et al., 2012). 
Hypercalcaemia also promotes the incidence of vascular calcification (Guérin et al., 
2000). In kidney disease, hyperparathyroidism-induced hypercalcaemia (>2.6mM) 
promotes significantly more calcification than that observed in normocalcaemic patients, 
however, in order for calcification to initiate, protective factors must be downregulated 
(Guérin et al., 2000, Floege and Ketteler, 2004, Hagström et al., 2009, Frazão and 
Adragão, 2012, Hu et al., 2012, Shigematsu et al., 2012). 
 
1.10.7 BMP-2 / BMP-4 
Many osteogenic markers upregulated during VC are often observed at the mRNA and 
protein level (Boström et al., 1993). Bone morphogenetic proteins were firstly described 
in the vessel walls of mice with atherosclerosis (Boström et al., 1993, Demer and Watson, 
1994). Microarray analysis of senescent VSMCs shows that cells downregulate anti-
calcifying factors such as MGP, whilst upregulating BMPs 2 and 4 (Burton et al., 2009, 
Burton et al., 2010). Upregulation of BMPs is also accompanied by a modest increase in 
the expression of other osteogenic markers, including osteoprotegrin, collagen type I and 
ALP (Burton et al., 2009). In 2010 Yao et al, investigated the effects of MGP 
overexpression or knockout. Both mouse models were bred with the apoE-/- mouse model 
of atherosclerosis. The authors showed that MGP overexpression, even in the presence 
of apoE-deficiency and a high-fat diet significantly reduced ectopic calcification of 
arteries which was also correlated with significantly reduced BMP expression. 
Conversely, the group found that in MGP/apoE-double knockout mice, high-fat diet 
feeding induced a pathological and lethal phenotype which mice could not tolerate that 
was accompanied by an upregulation in BMP-4 expression (Yao et al., 2010). In this way 
the pro-calcifying properties of BMPs have been effectively demonstrated. 
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1.10.3 VSMC Apoptosis 
VSMC apoptosis has been shown to be a major contributor of vascular calcification in 
vitro and in-vivo (Proudfoot et al., 2000, Reynolds, 2005, Shanahan et al., 2011). 
Proudfoot et al demonstrated that in vitro human VSMCs started to die rapidly by 
apoptosis after 28 days in mineralising conditions. This was confirmed with nucleic acid 
fragmentation, and was significantly reduced in the presence of the caspase inhibitor 
ZVAD.fmk (Proudfoot et al., 2000). Furthermore, the rate of calcification and mineral 
nodule development was significantly reduced in the presence of ZVAD.fmk. A similar 
result was achieved when Reynolds et al, who induced mineralisation of human VSMCs 
in the presence of high Pi or absence of the same caspase inhibitor (Reynolds, 2005). 
Importantly, these studies illustrate that apoptosis is a key event in initiating and 
promoting mineralisation. The collective involvement of all of these pro-calcifying 
factors can be observed in Figure 14. 
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Figure 14. Mechanisms of vascular calcification. Increases in Ca2+o and Pi can be triggered by PTH and 
hyperphosphatemia respectively. Additionally, secondary hyperparathyroidism can occur from CKD. Ca2+ 
and Pi can accumulate in the intima forming a nidus for atherosclerosis and atherosclerotic calcification. 
(i) Bone marrow-derived osteoprogenitor cells may migrate to the vasculature and increase local levels of 
osteogenic markers, forming a site for further calcification propagation. (ii) Ca2+ x Pi products formed, 
such as hydroxyapatite, can signal medial VSMCs to transdifferentiate and upregulate osteogenic markers. 
MGP is often upregulated initially as a protective factor, but may also be downregulated in sites of 
advanced calcification. VSMC markers SM22α and αSMA are also downregulated during calcification. 
(iii) Calcifying vascular cells, or pericytes, susceptible to osteogenic differentiation upregulate osteogenic 
markers into the surrounding tunica media. Ca2+ and Pi may also be offloaded in the form of matrix vesicles 
(Collett and Canfield, 2005, Reynolds, 2005, Shobeiri et al., 2010, Nitta, 2011, Shanahan et al., 2011).  
  
(i) 
(ii) 
(iii) 
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1.10.4 Vascular calcification inhibitors vs. promoters 
We have seen the diversity of promoters and inhibitors of vascular calcification and how 
they can be utilised in scientific research and in life. There are clearly numerous types of 
vascular cells at work, utilising a vast number of promoting and inhibiting calcification 
factors. Table 2 details common inhibitors and common promoters of calcification.  
 
 
 
Table 2. Inhibitors and promoters of vascular calcification. Osteogenic genes including BMP-2, BMP-
4, Runx2, and alkaline phosphatase; known bone-related genes and promoters vascular calcification. 
Circulating inhibitors such as Mg2+, BMP-7, PTH, fetuin A and pyrophosphate protect from calcification.  
 
  
CALCIFICATION 
INHIBITORS 
CALCIFICATION 
PROMOTERS 
Pyrophosphate Collagen Type I 
Mg2+ Sox9 
La3+ Vitamin D 
Thiosulphate RANKL 
Fetuin A BMP-2 
MGP BMP-4 
BMP-7 Ca2+ / Ca2+o 
LDR Osteocalcin 
Apolipoproteins Runx2 
Osteoprotegrin Alkaline Phosphatase 
FGF23 Osterix 
Calcimimetics (?) Warfarin 
Phosphate-binders Phosphate 
Vitamin D Oxidative Stress 
 LDL 
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1.11 Models of vascular calcification 
Vascular calcification has been extensively studied using in vitro, ex vivo and in vivo 
techniques. Interestingly, researchers often use bovine VSMCs as a model for VC, 
specifically due to high tissue availability and similar physiological activity with human 
VSMCs, however, mouse, rat and human VSMCs are often used as models for VC 
investigation in vitro, ex vivo and in vivo. 
 
1.11.1 In vitro models of VC 
Since vascular calcification occurs in the tunica media, which comprises of vascular 
smooth muscle cells, investigators often manipulate these cells in in vitro experiments. 
Primary VSMCs are typically isolated from the descending thoracic aorta of mice, rats, 
cows or taken from human biopsies. VSMCs are typically cultured in the presence of 1.2-
1.8mM Ca2+o (Shioi et al., 1995, Proudfoot et al., 1998, Olesen et al., 2006, Alam et al., 
2008, Prosdocimo et al., 2010). Then, to mimic pathophysiological conditions normally 
present during vascular calcification, experimental conditions include an increase in 
Ca2+o and/or Pi in the culture medium in the presence of pro-mineralising factors such as 
ascorbic acid, βGP or Pi. Interestingly, despite researchers using different Ca2+o 
concentrations, phosphate delivery (βGP/Pi), as well as varying FBS concentrations 
(which contains protective factors such as MGP and fetuin A), data appear fairly 
reproducible and consistent (Shioi et al., 1995, Proudfoot et al., 1998, Olesen et al., 2006, 
Alam et al., 2008, Shi et al., 2009, Prosdocimo et al., 2010). These different experimental 
conditions are described in Table 3. 
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Table 3. Mineralisation conditions used for vascular calcification experiments in vitro. Ca2+o 
concentrations tested range from 0.5mM-2.5mM. Pi is provided in an inorganic form up to 3mM, whereas 
the organic form, β-glycerophosphate, is added at concentrations between 5-10mM. FBS is provided at 
concentrations between 5-20%. The duration of the experiments can vary significantly from 7 days to 8 
weeks. 
GROUP HOST ORGANISM /CELL TYPE CONDITIONS 
(Alam et al., 2008) Bovine VSMC 
- 5mM βGP 
- 1.2/1.8/2.5mM Ca2+o 
- 5% FBS 
- 10 DAYS 
(Shioi et al., 1995) Bovine VSMC 
- 10mM βGP + 50µg / mL Ascorbic Acid 
- 1.8mm Ca2+o 
- 15% FBS 
- 14 DAYS 
(Chen et al., 2010a, Kircelli 
et al., 2012) Bovine VSMC 
- 10mM βGP + 50mg / mL Ascorbic Acid 
- 1.8mm Ca2+o 
- 15% FBS 
- 7-14 DAYS 
(Olesen et al., 2006) Human VSMC 
- 8mM βGP 
- 1.2mM Ca2+o 
- 10% FBS 
- 36 DAYS 
(Proudfoot et al., 1998) Human Placental Pericyte/CVC 
- 1.0mM Pi 
- 1.8mM Ca2+o 
- 20% FBS 
- 8 WEEKS 
(Prosdocimo et al., 2010) Rat VSMC 
- 3-5mM Pi 
- 1.8mM Ca2+o 
- 10% FBS 
- 12 DAYS 
(Shi et al., 2009) Rat VSMC 
- 10mM βGP 
- 1.2/1.8mM Ca2+o 
- 10% FBS 
- 9-12 DAYS 
(Beazley et al., 2012) Rat VSMC 
- 1.6mM Pi / 10µM Warfarin 
- 1.2 / 1.8mM Ca2+o (Not specified) 
- 1% FBS 
- 6 DAYS 
(Sage et al., 2011) Mouse VSMC 
- 3mM Pi 
- 1.2mM Ca2+o 
- 10% FBS 
- 7-14 DAYS 
(Mikhaylova et al., 2007, 
Faverman et al., 2008) Mouse VSMC 
- 5mM βGP + 25µg/mL Ascorbic Acid 
- 0.5mM Ca2+o 
- 10% FBS 
- 7 DAYS 
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1.11.2 In vivo models of VC 
As discussed previously, it has become clear that several targeted gene-knockout animal 
models have been generated in an attempt to recapture the phenotype seen in patients 
with CKD, and indeed in many cases the phenotype appears a lot more severe than in 
human patients. The MGP and OPG mouse models have shown large-scale ectopic 
calcification of blood vessels (Luo et al., 1997, Bucay et al., 1998). However, these 
models are not as informative as one would hope for since a severe phenotype develops 
quickly. For this reason, numerous research groups focus on mouse models with reduced 
morbidity and mortality, where calcification develops over time. In this manner, 
developmental regulation of the process of calcification and VSMC transdifferentiation 
can be monitored more accurately. Available in vivo models of vascular calcification are 
described overleaf in Table 4. 
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Table 4. A summary of in vivo models of vascular calcification. Traditionally, rat and mouse models 
are used, where calcification is induced either genetically, by surgery or by diet modification. 
 
 
  
GROUP HOST ORGANISM MODIFICATION PHENOTYPE 
(Price et al., 2006, 
Tamagaki et al., 2006, 
Shobeiri et al., 2010) 
Rat Adenine feeding Uremia, cardiovascular 
calcifications 
(Schurgers et al., 2007, 
Beazley et al., 2012) Rat Warfarin feeding 
Uremia, cardiovascular 
calcifications 
(Lopez, 2006, Piecha et 
al., 2008, Koleganova et 
al., 2009) 
Rat 5/6 Nephrectomy CKD / Uremia 
↑PTH 
↑Pi           
↑Creatinine 
(Massy et al., 2005, Pai 
et al., 2011, Ting et al., 
2011) 
Mouse 5/6 Nephrectomy CKD / Uremia 
↑PTH 
↑Pi           
↑Creatinine 
(Delsing et al., 2001, 
Massy et al., 2005, 
Ivanovski et al., 2009) 
Mouse ApoE-KO / High-fat diet Atherosclerosis and vascular 
calcification 
(Davies, 2003, Shao et 
al., 2005, Morony et al., 
2008, Malik et al., 
2010). 
Mouse LDLR-KO / High-fat diet 
Atherosclerosis and vascular 
calcification 
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1.11.2.1 5/6 Nephrectomised animals 
Patients with advanced CKD develop cardiovascular calcifications often in the presence 
of inappropriately raised serum Pi level, in combination with increases in PTH levels 
(Schoppet and Shanahan, 2008, Lau et al., 2010, Shanahan et al., 2011). To reproduce 
this condition in vivo, a model of uremia is created by performing two-stage 5/6 
nephrectomy. During this procedure, mice or rats have one kidney entirely removed in 
addition to removal of 2/3 of the remaining kidney. In this manner, the full complement 
of serum Pi is poorly-handled and leads to a pathological hyperphosphataemic state. 
Researchers have utilised this technique to induce vascular calcification in vivo, often in 
combination with either a high phosphate or high-fat diets (Lopez, 2006, Piecha et al., 
2008, Koleganova et al., 2009). Koleganova et al showed that 5/6 nephrectomy in rats 
induced a significant increase in serum Pi (2.78mM operated vs. 2.28mM sham-operated, 
P<0.001) in addition to increases in PTH, but not overall [Ca2+]o. The group also 
suggested that the CKD-state these rats have after operation was confirmed by an 
upregulation in serum creatinine; a marker of late CKD and ESRD (Koleganova et al., 
2009). Using this method, other investigators have come to similar conclusions (Wada et 
al., 1997b, Lopez, 2006, Kawata et al., 2008, Piecha et al., 2008). Rats are preferentially 
used for such studies, however mice are increasingly used due to the ease of genetic 
modification in addition to the induction of uremic conditions (Massy et al., 2005, Pai et 
al., 2011, Ting et al., 2011). 
 
1.11.2.2 Adenine feeding 
Adenine feeding is a relatively simple and non-invasive technique and is typically carried 
out in rats to induce CKD and vascular calcification. Supplementing rat diets with 0.75% 
adenine for as little as 4 weeks induces the formation of medial calcifications (Price et 
al., 2006, Shobeiri et al., 2010). CKD follows nephrotoxicity induced by the metabolic 
breakdown of adenine into the nephrotoxic compound 2,8-dihydroxyadenine. Pathology 
occurs when this compound precipitates and forms crystals in the microvilli and proximal 
tubular epithelia (Akintonwa et al., 1979, Price et al., 2006, Tamagaki et al., 2006). In a 
2006 study, Tamagaki demonstrated that adenine feeding to Wistar rats over a period of 
6 weeks caused a significant increase in serum Pi and creatinine, while serum Ca2+o and 
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calcitriol levels were markedly reduced. Furthermore, the parathyroid glands of these rats 
were enlarged and PTH levels were increased (Tamagaki et al., 2006). Adenine feeding 
as part of CKD induction remains popular due to its simplicity and cost-effectiveness, 
however, 5/6 nephrectomies remain more consistent and reliable for kidney failure 
simulation. 
 
1.11.2.3 Warfarin-feeding in rats 
Warfarin feeding has also proved to be an effective way at inducing vascular 
calcification, specifically through its involvement in the vitamin K cycle (Price et al., 
1998, Price et al., 2000). The vitamin K-dependent γ-carboxylation system is essential 
for converting glutamic acid (glu) residues into γ-carboxyglutamic acid (gla) residues 
(Wallin and Hutson, 2004, Schurgers et al., 2007). The anti-calcifying agent MGP is 
secreted by VSMCs and binds Ca2+o to reduce mineralisation. In order to bind Ca2+o MGP 
requires this γ-carboxylation (Proudfoot and Shanahan, 2006). Warfarin acts as a direct 
inhibitor of carboxylase reductase enzymes in the vitamin K cycle, inhibiting the proper 
function of MGP and blood coagulation proteins. In fact, Shurgers et al demonstrated a 
50% increase in arterial calcification in warfarin-treated rats compared to untreated 
controls (Schurgers et al., 2007, Beazley et al., 2012). Disruption of the vitamin K cycle 
in this way consequently leads to severe alterations in Ca2+o homeostasis in the 
vasculature and arterial calcifications, as seen in numerous studies in rats (Price et al., 
1998, Price et al., 2000, Wallin and Hutson, 2004, Schurgers et al., 2007). Limitations 
of this model are that warfarin is readily excreted and needs constant application by 
dietary supplementation. 
 
1.11.2.4 ApoE-knockout mice / high-fat diet 
Apolipoprotein E (apoE) is a component of all lipoproteins except low density 
lipoproteins (LDL). It is also a component of chylomicron particles which are 
synthesized in the liver (Zhang et al., 1992, Bro et al., 2003, Massy et al., 2005, Ivanovski 
et al., 2009). ApoE functions to mediate high-affinity binding of lipoproteins to apoE 
receptors which evoke cellular uptake of lipids and cholesterol in the liver. In the absence 
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of this, lipoproteins are free to disperse throughout the vasculature inducing a 
hypercholesterolaemic state. Elevations in plasma cholesterol induce VC, atherosclerosis 
and premature heart disease (Ghiselli et al., 1981, Delsing et al., 2001, Massy et al., 2005, 
Ivanovski et al., 2009). This model’s limitation is that often the ensuing calcification is 
secondary to atherosclerotic plaque formation, which occurs in the tunica intima. 
Although some medial calcification can occur, this is not exclusively of the tunica media. 
Consequently, any arising phenotype will be due to both atherosclerosis, inflammation 
and vascular calcification (Massy et al., 2005). 
 
1.11.2.5 LDLR-knockout mice 
The LRL receptor (LDLR) functions to remove cholesterol-rich low density lipoproteins 
(LDLs) and intermediate density lipoproteins (IDLs) from the circulation (Ishibashi et 
al., 1993). LDLs and IDLs have a key role in the delivery of cholesterol to peripheral 
tissue (Glass and Witztum, 2001). LDLs are taken up by cells via the LDL receptor 
(LDLR) by recognising and binding an N-terminal domain of apolipoprotein B (apoB) 
on the lipoprotein. Consequently, cholesterol can be taken up by cells and utilised in 
cellular processes (Go and Mani, 2012). In a mouse model lacking the LDLR, cholesterol 
remains in the vasculature, resulting in hypercholesterolaemia (Ishibashi et al., 1993, 
Binder, 2004, Demer and Tintut, 2008). As a result, atherosclerotic plaques and vascular 
calcifications occur, particularly when these mice are fed a high fat diet. The LDLR-
deficient mouse model has been used extensively to recapitulate vascular disease 
(Davies, 2003, Shao et al., 2005, Morony et al., 2008, Malik et al., 2010). However, in a 
similar manner to the apoE-/- mouse model, the LDLR-knockout mouse often 
recapitulates atherosclerosis, inflammation and vascular calcification which are not 
exclusively of the tunica media. 
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1.12 The extracellular calcium-sensing receptor (CaSR) and mammalian physiology 
Since the discovery of the significant role of Ca2+ in physiology by Sydney Ringer in the 
late 19th century, the method by which cells homeostatically regulate levels of this cation 
within the cell and its extracellular fluid has become an attractive arena for scientific 
investigation (Ringer, 1882a, Ringer, 1882b, Ringer, 1883). By mass, this divalent cation 
is categorically the most abundant mineral in the body, and contributes to numerous life 
processes (Cheng et al., 2007). The ability of free ionized Ca2+ (Ca2+o) to perform as a 
first messenger in biological processes has eluded the scientific community, that is, until 
work by Brown et al led to the discovery of a gene encoding a protein central to Ca2+o 
homeostasis (Brown et al., 1993). In 1993 the group first identified a bovine gene 
encoding a GPCR in the parathyroid gland (Brown et al., 1993). Crucially, the protein 
product of this gene was found to be abundantly expressed in parathyroid glands and 
served a role in regulating Ca2+o concentrations in extracellular fluids. This Ca2+o 
regulator is now known as the extracellular calcium-sensing receptor, with various 
polynomial acronyms including CaS, CaR and the more popular designation; CaSR 
(Brown et al., 1993, Bai and Trivedi, 1998, Chang et al., 2008).  
 
The bovine parathyroid gland (PTG) clone generated by Brown et al, designated 
BoPCaR1 had a 3,255bp open reading frame encoding a protein of 1,085 amino acids 
(Brown et al., 1993). It was found to contain three distinct domains. These are (i) a large 
hydrophilic N-terminal domain of 613 amino acids, which contained a 21 amino acid 
eukaryotic signalling peptide, (ii) a central region of 250 amino acids encoding seven 
transmembrane domains, and (iii) a hydrophilic 222 amino acid C-terminal domain 
(Brown et al., 1993). In accordance with this highly specific arrangement of domains, 
CaSR is a member of the group C GPCR superfamily and its topology is described in 
Figure 15 (Bräuner-Osborne et al., 2007). CaSR shares homology with metabotropic 
glutamate receptors (mGluRs 1-8) (Nakanishi, 1992, Kunishima et al., 2000, Gama, 
2001, Hermans and Challiss, 2001, Jingami et al., 2003), γ-aminobutyric acid receptors 
(GABABRs) (Galvez et al., 2000, Bettler et al., 2004), the bone Ca2+o-sensor GPRC6A 
(Pi et al., 2005), taste, pheromone and orphan receptors (Herrada and Dulac, 1997, 
Matsunami and Buck, 1997, Cao et al., 1998, Hoon et al., 1999, Nelson et al., 2002). 
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Furthermore, as with other members of this superfamily, the bovine CaSR shares high 
sequence homology (>90%) with other closely-related organisms including the rat, 
mouse and human CaSR which are 1,079aa (Riccardi et al., 1995), and 1,079aa (Pi et al., 
2000) and 1,078aa (Aida et al., 1995, Mei, 2004) respectively. 
 
Intriguingly, this gene thought to have a predominant role exclusively in parathyroid cells 
is ever-more demonstrating localization and potentially significant roles in Ca2+o 
homeostasis and signalling throughout the whole body. CaSR is now known to be 
expressed at variable levels in most major systems of the body including the respiratory 
(Kovacs and Kronenberg, 1997, Finney et al., 2008), cardiovascular (Weston, 2005, 
Smajilovic et al., 2006, Smajilovic et al., 2007, Alam et al., 2008, Weston et al., 2008), 
renal (Riccardi et al., 1995, Kifor et al., 1997, Bai and Trivedi, 1998, Riccardi et al., 
1998, Levin et al., 2006, Mariano et al., 2008, Riccardi and Brown, 2009, Caudrillier et 
al., 2010), digestive (Gama et al., 1997, Cheng et al., 1999, Geibel et al., 2001, Busque 
et al., 2005, Dufner et al., 2005), musculoskeletal (House et al., 1997, Chang et al., 2008, 
Aguirre et al., 2010, Christian et al., 2010) and nervous (Ruat and Molliver, 1995, Cao 
et al., 1998, Gama, 2001, Shozo et al., 2004, Vizard et al., 2008) systems. In spite of this, 
there has previously been some controversy whether this widespread expression is indeed 
true, particularly in blood vessels. However, this has since been attributed to the inherent 
difficulty in detecting CaSR at both the mRNA and protein level (Farzaneh-Far et al., 
2000, Wang et al., 2003, Weston, 2005, Peiris et al., 2006, Shalhoub et al., 2006, 
Smajilovic et al., 2006, Molostvov et al., 2007, Loretz, 2008, Pistilli et al., 2012). There 
is now such overwhelming evidence that it is difficult to refute that CaSR is expressed in 
this diverse variety of systems. 
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Figure 15. Topology of the human extracellular calcium-sensing receptor (CaSR). The seven-
membrane-spanning GPCR exhibits an extracellular N-terminus and an intracellular C-terminus. The three 
domains can be seen; extracellular, transmembrane and intracellular. Active sites for enzymatic reactions 
are demonstrated diagrammatically. Human CaSR contains 11 N-linked putative glycosylation sites (green 
diamonds), 9 of which are highly conserved in rat, human, rabbit and bovine. Also present in mature human 
CaSR are 2 putative intracellular protein kinase A sites (red circles), and 5 protein kinase C sites (blue 
circles). Conserved cysteine regions are highlighted by black dotted lines. These cysteine sites are required 
for dimerization of the protein into a homodimer. Agonist binding is attributed to the venus flytrap (VFT) 
domain of the receptor which forms during dimerization, however, allosteric modulators (calcimimetics 
and calcilytics) bind to the transmembrane domain of the CaSR homodimer (Bai and Trivedi, 1998, Ray 
et al., 1999, Hu and Spiegel, 2003, Chang and Shoback, 2004, Smajilovic and Tfelt-Hansen, 2007). 
 
HOMODIMER 
FORMATION 
SITES 
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1.13 CaSR, Vitamin D and PTH in Ca2+o homeostasis 
Since its discovery, CaSR has shown to have a crucial role in Ca2+o homeostasis (Brown 
et al., 1993, Brown and MacLeod, 2001). Under physiological conditions, chief cells in 
the parathyroid constantly secrete parathyroid hormone (PTH) which subsequently acts 
on kidney and bone to resorb Ca2+. Additionally PTH promotes the renal conversion of 
25-hydroxyvitamin D3 (25(OH)D3) to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) which 
in turn acts on the intestine to resorb Ca2+ and phosphate (Pi). These actions maintain 
levels of [Ca2+]o to approximately 1.0-1.3mM (Brown, 1991, Brown et al., 1993, Quinn 
et al., 1998). When [Ca2+]o is above ~1.0mM, it activates the CaSR which inhibits PTH 
secretion by the PTG. The whole system is stringently controlled by transcriptional 
regulation of PTH and a series of enzymes that activate endogenous vitamin D3 (VD3) 
precursors. In this section, the roles of CaSR, vitamin D and PTH will be discussed in 
Ca2+o homeostasis. 
 
1.13.1 Vitamin D 
Conversion of vitamin D precursors to active 1,25-dihydroxyvitamin D3 (calcitriol) from 
its endogenously inactive forms is crucial to Ca2+o homeostasis. In the body, calcitriol 
synthesis begins in the skin by activation of the precursor steroid 7-dehydrocholesterol 
in response to photonic stimulation by sunlight, specifically, ultraviolet radiation (Borle, 
1974, Brown, 1991, Lips, 2006). From this reaction, cholecalciferol (VD3) is produced. 
This then translocates to the liver where it undergoes a first hydroxylation, producing a 
more active metabolite (Usui et al., 1990, Nagpal et al., 2005). Initially, 25-hydroxylase, 
a cytochrome P450 enzyme present in the liver, converts VD3 to 25-hydroxyvitamin D3 
(25(OH)D3). This is then translocated again to the kidney through the circulatory system 
and this metabolite is then further converted using 1α-hydroxylase, a PTH-regulated 
enzyme present on the inner mitochondrial membrane of proximal tubules in the kidney 
(Brenza et al., 1998, Murayama et al., 1999). This finally catalyses the formation of 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), also known as calcitriol (Armbrecht et al., 1998, 
Brenza et al., 1998, Murayama et al., 1999). This active metabolite can now enter the 
cell where it binds to the vitamin D Receptor (VDR) (Sun et al., 2010). VDR has been 
reported to have both genomic and non-genomic effects. Non-genomic effects have been 
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described, for example, when a calcitriol:VDR complex induces intracellular signalling 
pathways including Ras and extracellular-regulated kinase (ERK)-1/2/5 (Dwivedi et al., 
2002). The calcitriol:VDR complex then forms a more complex VDR signalling complex 
with the retinoid X receptor (Dwivedi et al., 2002). This calcitrol:VDR:retinoid X 
receptor complex is then able to bind to vitamin D response elements (VDREs) which 
accordingly induce transcriptional changes in the nucleus, therefore, eliciting genomic 
effects on the cell (Chen et al., 2000, Canaff, 2002, Lips, 2006). VDREs have been 
documented in the promoter regions of Ca2+o-binding genes including osteocalcin and 
calbindin (Lips, 2006, Shu et al., 2010). Interestingly, research has also shown that the 
human CaSR gene also contains a VDRE in the promoter region of the gene which is 
sensitive to 1,25(OH)2D3. In mutagenic studies where this region has been mutated in 
CaSR, transcriptional upregulation of CaSR mRNA by 1,25(OH)2D3 is lost (Canaff, 
2002). 
  
1.13.2 PTH 
The role of PTH in this vitamin D cycle is deeply intertwined and carefully orchestrated. 
Its role has been well-documented over recent decades (Rader et al., 1979, Teitelbaum 
et al., 1986, Sanders et al., 2000, Castro et al., 2002, Bergwitz and Jüppner, 2010). PTH 
is secreted from chief cells of the PTG and can play a direct and indirect role in Ca2+o 
homeostasis in the kidney, intestines and bone (Chang et al., 2008). More specifically in 
the kidney and intestines, investigators have confirmed that PTH binds to its PTH/PTH-
related peptide (PTHrP) receptor, a GPCR of family B (Castro et al., 2002). PTH or 
PTHrP agonist binding induces one of many intracellular signalling pathways. Typically, 
it can activate Gq/11-mediated PLCβ leading to IP3 production, Ca2+i mobilization, protein 
kinase C (PKC) activation and activation of adenylyl cyclase (AC) through Gs which 
increases intracellular cyclic adenosine monophosphate (cAMP) (Castro et al., 2002, 
Fujita et al., 2002). In this way, PTH can regulate the transcription of crucial genes 
involved in Ca2+o homeostasis. Downstream effects of PTH signalling include changes 
in the expression of the P450C1 gene encoding 1α-hydroxylase; an enzyme responsible 
for bioactivation of 25-hydroxyvitamin D3 (Dwivedi et al., 2002), and the CYP24 gene 
encoding the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24). (Armbrecht et al., 
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1998, Dwivedi et al., 2002, Bergwitz and Jüppner, 2010). Since [Ca2+]o is, as one would 
expect, regulated to tight constraints and limits, these two enzymes are synergistically 
upregulated in response to both 1,25(OH)2D3 and PTH. Modulation is crucial as 
1,25(OH)2D3 is toxic at high levels and, in excess, can induce hypercalcaemia (Dwivedi 
et al., 2002). For this reason, 1,25(OH)2D3 is synchronously produced, bound to the VDR 
signalling complex and any excess is hastily degraded by the enzymatic actions of 
CYP24. 
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1.13.3 CaSR 
As intricately controlled as the actions of PTH and vitamin D are, their actions and acute 
regulation would be largely unregulated were it not for CaSR. In the parathyroid glands, 
CaSR acts as a master controller of PTH secretion. CaSR and its role in Ca2+o metabolism 
is described diagrammatically below in Figure 16. 
 
 
 
 
 
 
 
 
 
Figure 16.  The role of CaSR in [Ca2+]o homeostasis. Parathyroid glands secrete PTH into extracellular 
fluids. PTH acts on the kidney to increase Ca2+ absorption and on bone to release Ca2+ from bone mineral. 
Additionally, PTH in the kidney upregulates 1α-hydroxylase activity and therefore the presence of 
1,25(OH)2D3 which also increases Ca2+ resorption here and in the intestines. Once [Ca2+]o has returned to 
normal physiological concentrations (~1.2mM), PTH secretion is controlled and inhibited by Ca2+o acting 
at the CaSR. Figure adapted from (Brown, 1991, Brown et al., 1993, Chang and Shoback, 2004).  
  
1α-hydroxylase 
1,25(OH)2D3 
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The principal agonist of CaSR is Ca2+o (however, other cations can activate CaSR). The 
wide variety of extracellular agonists that activate CaSR can be categorised into two 
distinct groups. These include firstly type I orthosteric CaSR agonists, which activate 
CaSR in the absence of Ca2+o. These are positively charged agonists such as polyvalent 
cations (Brown et al., 1993, Ohanian et al., 2005, Guang-wei et al., 2011, Kircelli et al., 
2012), highly charged polyamines (Quinn et al., 1997, Wang et al., 2003, Thomsen et 
al., 2012) and positively charged aminoglycoside antibiotics (Thomsen et al., 2012). In 
addition, type II CaSR agonists, or allosteric modulators, require Ca2+o to activate the 
CaSR (Hebert, 2006). These agonists include certain L-amino acids (Conigrave et al., 
2002) and positive and negative pharmacological allosteric modulators of CaSR such as 
calcimimetics (Nemeth et al., 1998, Hebert, 2006, Francis et al., 2008) and calcilytics 
(Nemeth et al., 2001, Nemeth, 2002, Rybczyńska et al., 2010) respectively. Furthermore, 
CaSR function and sensitivity is also affected by changes in extracellular pH and ionic 
strength (Quinn et al., 2004, Riccardi and Brown, 2009). 
 
1.14 CaSR: Orthosteric agonists of the receptor 
The CaSR exists at the plasma membrane as a homodimer. During synthesis of CaSR, 
the protein product is translocated to the endoplasmic reticulum (ER). This intracellular 
transportation is co-ordinated by the CaSR signal peptide. At the ER, CaSR forms a 
homodimer through two intermolecular disulphide cysteine bonds between cys129 and 
cys132 (Ray et al., 1999, Zhang et al., 2001). Further post-translational modifications 
are then performed in the Golgi, more specifically, glycosylations to form the mature 
protein (Grant et al., 2011). After this, the fully modified homodimer is trafficked to the 
plasma membrane where CaSR activation can occur. Recently, the classification of 
ortho- and allosteric modulators has been unclear since exact binding sites of CaSR 
agonists are not fully known (Bräuner-Osborne et al., 1999, Zhang et al., 2002). 
However, it is generally believed that agonist binding occurs in the venus flytrap (VFT) 
binding pocket of CaSR (Hu and Spiegel, 2003, Chang and Shoback, 2004). 
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1.14.1 Polyvalent cations 
As the name suggests, the primary agonist of CaSR is Ca2+o however, numerous other 
polyvalent cations can stimulate the receptor including Mg2+, Sr2+, Gd3+ and La3+ 
(Riccardi et al., 1995, Brown and MacLeod, 2001). However, in this case, Mg2+ is the 
most physiologically relevant since it is naturally present in extracellular fluids in vivo 
(Brown, 1999). Although not physiologically relevant, heavier metals such as Sr2+, Gd3+ 
and La3+ have proved to be significant CaSR activators in in vitro studies and further 
illustrate the affinity of CaSR for positively charged ions. Chang et al investigated human 
embryonic kidney (HEK293) cells stably expressing a WT CaSR (HEK293-CaSR) and 
demonstrated that the addition of 5.5mM Mg2+ and 10µM Gd3+ to these cells significantly 
increases intracellular Ca2+ ([Ca2+]i) through CaSR signalling (Brown et al., 1993, Chang 
et al., 1998). 
 
1.14.2 Polyamines 
CaSR has an inherent affinity for positively charged molecules, including charged 
polyamines such as spermine, spermidine and putrescine. These polyamines have been 
shown to increase [Ca2+]i in HEK293-CaSR cells (Quinn et al., 1997). This paper showed 
the affinity of CaSR for polyamines follow the order: spermine > spermidine > 
putrescine. Furthermore, changes in Ca2+o can change the sensitivity of the receptor for 
these polyamines, and so these polyamines are often recognised as both ortho- and 
allosteric modulators of CaSR (Quinn et al., 1997). 
 
1.14.3 Aminoglycoside antibiotics 
In addition to the aforementioned CaSR modulators, aminoglycoside antibiotics (AGAs) 
are CaSR orthosteric activators (Thomsen et al., 2012). A study by McLarnon et al 
showed that human recombinant CaSR is responsive to AGAs including gentamicin, 
tobramycin, and neomycin in a concentration-dependent manner. These AGAs were 
effective with EC50 values of 258, 177, and 43 µM respectively (McLarnon et al., 2002). 
These antibiotics are nephrotoxic and the group also showed that AGAs are more 
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effective when pH is lowered to mimic that of CaSR-expressing tissue such as the 
proximal tubules of the kidney (from pH7.4 to pH6.9). These findings suggest that the 
kidney CaSR is much more sensitive to AGAs than CaSRs in other tissues, and that CaSR 
may play a role in nephrotoxicity of the kidney (McLarnon et al., 2002). 
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1.15 CaSR: Allosteric agonists of the receptor 
The first presented evidence that modulators of CaSR act allosterically came from 
research into amino acid binding sites on additional GPCRs. The metabotropic glutamate 
receptor shares significant homology with CaSR, particularly at the putative binding site 
of amino acids such as L-Phe (Miedlich et al., 2004). The binding site of L-PhE 
macromolecules to mGluRs has been localised at a triple serine motif (Ser-169-171). 
Mutagenesis experiments by this group in HEK293-CaSR cells revealed that these amino 
acid residues are crucial for L-Phe activation of CaSR in the presence of Ca2+o. These 
studies indicated that amino acids are crucial for allosterically modulating sensitivity of 
CaSR to Ca2+o (Zhang et al., 2002).  
 
1.15.1 Amino acids 
CaSR is stimulated by amino acids with L-type stereoselectivity with specific affinities 
for L-Tyr, L-Trp, L-His and L-Phe (Conigrave and Quinn, 2000, Mun et al., 2004, Mun 
et al., 2005). In human parathyroid cells, CaSR is activated by L-type amino acids in the 
order L-Trp > L-Phe > L-His > L-Ala all demonstrating receptor activation in the 
millimolar range (Conigrave et al., 2007). Using HEK293-CaSR cells, it was shown that 
L-Phe (normally effective at activating CaSR in the 0.3-30mM range in the presence of 
1.0-1.5mM Ca2+o) was ineffective at activating CaSR in the absence of Ca2+o. This study 
was important in illustrating L-Phe as a type II agonist, which activates CaSR only in the 
presence of Ca2+o. Furthermore, when CaSR is maximally activated by 5mM Ca2+o in 
HEK293-CaSR cells, L-Phe cannot further activate CaSR (Conigrave et al., 2000, 
Kobilka, 2000, Conigrave and Brown, 2006). CaSR is widely expressed in the 
gastrointestinal tract in gastrin cells in the stomach and basally on small intestine villous 
and crypt epithelial cells. These findings collectively suggest that CaSR may play a role 
in taste and digestion (Chattopadhyay et al., 1998, Buchan et al., 2001). 
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1.15.2 Calcimimetics 
Calcimimetics are compounds which bind allosterically to CaSR and they demonstrate 
their effects only in the presence of Ca2+o. In 1998, Nemeth et al first classified the role 
of allosteric modulators in CaSR activity and investigated the effects of two compounds, 
NPS R-467 and NPS R-568, as potent selective inhibitors of PTH secretion in bovine 
parathyroid cells (Nemeth et al., 1998). The group demonstrated firstly that NPS R-568 
is a more potent activator of CaSR than NPS R-467. Secondly, that the compounds have 
enantiomeric selectivity, where NPS R-568 is significantly more potent than NPS S-568. 
This is depicted in Figure 17 where a concentration response for these two agents is 
shown in bovine parathyroid cells.  
  
 Page 72 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Calcimimetics increase intracellular Ca2+ through CaSR activation in bovine parathyroid 
cells. (A) The calcimimetic R-568 and R-467 are identical with the exception of the R-group indicated by 
black arrows. (B) Concentration-response curves of NPS 568 demonstrate more potent activity compared 
to NPS 467. R-type enantiomers shown greater potency in the case of both R-467 and R-568 when 
compared to S-type enantiomers. Experiments were conducted using bovine parathyroid cells loaded with 
the Ca2+-sensitive fluorescence dye fura-2 for Ca2+-imaging experiments. Figure adapted from Nemeth et 
al 1998 (Nemeth et al., 1998). 
 
The binding site of these calcimimetics to CaSR has been investigated and evidence 
suggests that binding sites are localised to the region of amino acids 668-837 (Miedlich 
et al., 2004). This evidence comes from mutagenesis studies in HEK293-CaSR cells. 
Mutations in the receptor at the residues Phe-668, Phe-684, or Glu-837 show an enhanced 
potency of calcimimetics (Miedlich et al., 2004). Calcimimetics have proved useful tools 
from a clinical perspective. Currently, commercially available calcimimetics such as 
Cinacalcet have been approved for the treatment of secondary hyperparathyroidism; a 
condition where the parathyroid glands produce inappropriately high levels of PTH. 
Here, calcimimetics activate the PTG CaSR and suppress further PTH secretion (Sprague 
et al., 2003, Francis et al., 2008, Piecha et al., 2008, Serra et al., 2008, Rothe et al., 2011).  
B A 
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1.15.3 Calcilytics 
The discovery of positive allosteric agonists of CaSR suggested that CaSR may be 
pharmacologically modulated with antagonists. Indeed, such compounds have been 
discovered and these named calcilytics have been shown to be effective at diminishing 
CaSR activity. In 2001, Nemeth et al demonstrated the effectiveness of a CaSR 
antagonist; NPS 2143, once again in bovine parathyroid cells with an IC50 of 41nM 
(Nemeth et al., 2001). Encouragingly, this compound had an opposing effect on CaSR 
compared to calcimimetics, inducing rapid PTH secretion in bovine parathyroid cells as 
demonstrated in Figure 18. Calhex 231, another commercially available calcilytic, has 
been investigated in research to ascertain its pharmacological profile on CaSR in various 
cell types. It has been reported that acting on HEK293-CaSR, the IC50 values of both 
these calcilytics is in the region of 0.34-0.40µM, indicating similar inhibitory profiles on 
CaSR. However, the IC50 of NPS 2143 in HEK293-CaSR cells was approximately 10-
fold less than that in bovine parathyroid cells, indicating higher sensitivity of the CaSR 
in the native parathyroid gland (Nemeth et al., 2001). Comparable IC50 values were 
somewhat expected since both NPS 2143 and Calhex 231 share overlapping binding sites 
on the transmembrane domain of CaSR (Petrel et al., 2004). This has been shown 
extensively in mutagenesis experiments where modification of particular amino acid 
residues such as Phe-668, Arg-680, or Phe-684 and Glu-837 significantly reduce the 
inhibitory effect of NPS-2143 (Miedlich et al., 2004). Similarly, mutations in the 
aforementioned Phe-684 and Glu-837 residues significantly reduce the ability of Calhex 
231 to inhibit the accumulation of inositol phosphates (Petrel et al., 2003). In this regard 
it is hypothesized that both calcimimetics and calcilytics have overlapping binding sites 
on CaSR.  
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Figure 18. Calcilytics act on CaSR to increase PTH secretion in bovine parathyroid cells. (A) Two 
commercially available calcilytics, Calhex 231 and NPS 2143, act specifically on CaSR. (B) NPS 2143 
acts on bovine parathyroid CaSR to selectively stimulate PTH secretion. IC50 for NPS 2143= ~43nM. 
Figure adapted from Petrel et al 2004 and Nemeth et al 2001 (Nemeth et al., 2001, Petrel et al., 2004). 
A B 
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1.16 CaSR signalling: Ca2+o as a first and second messenger 
The CaSR is activated by polyvalent cations, polyamines, calcimimetics, calcilytics, 
antibiotics and amino acids (Brown and MacLeod, 2001, Hebert, 2006, Ward, 2011). As 
a GPCR, CaSR couples to various heterotrimeric G-proteins including the α-subunits 
Gq/11, Gi and G12/13. Heterotrimeric complexes (Gαβγ) are activated upon CaSR activation 
where the α-subunit (q11, i or 12/13) may dissociate from βγ-subunits and carry out 
signalling via secondary intracellular messengers. Interestingly, although the q11, i and 
12/13 G-protein α-subunit pathways are well established, recent evidence suggests that 
there is a CaSR-Gs pathway which may be stimulated upon receptor activation. It has 
been proposed that this Gs pathway may have directly opposing effects to the Gi pathway, 
and is activated in prostate and breast cancer cells (Mamillapalli et al., 2008, 
Mamillapalli and Wysolmerski, 2010). CaSR signalling pathways are diagrammatically 
represented in Figure 19. 
 
Recent research has shown that CaSR signalling falls into 3 major categories (Kifor et 
al., 2001, Huang et al., 2002, Ward, 2011, Thomsen et al., 2012). (i) The Gi inhibitory 
pathway may be activated, where the action of AC is inhibited, reducing the amount of 
intracellular cAMP and therefore the activation of protein kinase A (PKA). (ii) The G12/13 
pathway may also be activated where the actions of Rho and phospholipase D (PLD) 
activate phosphotidylinositol-4 kinase (PI4-K), subsequently cleaving 
phosphatidylinositol-4 phosphate (PI4) into PIP2. PIP2 within the cell is then utilised in 
further signalling cascades. (iii) Activation of the Gq11 pathway causes an activation of 
PLC. PLC catalyses the formation of diacylglycerol (DAG) and IP3 from PIP2. IP3 can 
then act on IP3Rs on the ER to liberate Ca2+ from internal stores and increase [Ca2+]i. 
When the Gq11 pathway is activated, phospholipase A2 (PLA2) is also activated. This 
membrane-bound enzyme, also stimulated by ERK1/2, catalyses the formation of AA 
which can regulate the action of PKC. DAG formed from PIP2 acts together with AA to 
activate PKC, which can initiate a mitogen-activated protein kinase (MAPK) signalling 
pathway. In this process, MAPK kinase and stress-activated protein kinase ERK kinase 
1 (SEK1) can activate ERK 1/2, jun amino terminal kinase (JNK) and p38 MAPK. These 
downstream signals can then either feed-back into the Gq11 pathway, or enter the nucleus 
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where they may carry out transcriptional regulation of genes (Kifor et al., 2001, Huang 
et al., 2002, Ward, 2011, Thomsen et al., 2012).  
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Figure 19. Signalling pathways activated by the CaSR. The CaSR is activated by polyvalent cations, 
polyamines, calcimimetics, calcilytics, antibiotics and certain amino acids. The three pathways (i), (ii) and 
(iii) illustrated are the best characterised CaSR pathways. There is evidence that a Gs pathway may also be 
activated by CaSR during malignancy, having opposite effects to the Gi pathway. Blue arrows indicate 
activation, red flat-ended arrows indicate inhibition. Abbreviations: adenylyl cyclase (AC), adenosine 
monophosphate (cAMP), protein kinase A (PKA), phospholipase D (PLD), phosphotidylinositol-4 kinase 
(PI4K), phosphatidylinositol-4 phosphate (PI4), phosphatidylinositol 4,5-bisphosphate (PIP2), 
phospholipase C (PLC), diacylglycerol (DAG), inositol triphosphate (IP3), IP3 receptor (IP3R), 
endoplasmic reticulum (ER), phospholipase A2 (PLA2), extracellular-regulated kinase (ERK 1/2), 
arachidonic acid (AA), protein kinase C (PKC), mitogen-activated protein kinase (MAPK), MAPK kinase 
(MEK), stress-activated protein kinase ERK kinase 1 (SEK1), jun amino terminal kinase (JNK). (Kifor et 
al., 2001, Huang et al., 2002, Ward, 2011, Thomsen et al., 2012).  
  
(i) (ii) (iii) 
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1.17 CaSR in disease 
Natural mutations or polymorphisms in the human CaSR gene have been widely 
described (Hendy et al., 2000, Rodrigues et al., 2011, Eldeiry et al., 2012). These 
alterations in gene sequence can predispose in affected individual to disorders of Ca2+ 
metabolism. Mutations can occur in the intracellular, transmembrane or extracellular 
domains and are more often missense mutations (Tfelt-Hansen et al., 2003, Breitwieser, 
2012). In addition to genetic determinants of CaSR function, humans may also acquire 
CaSR dysfunction through the action of autoantibodies. Here, recurring CaSR mutations 
that have been described in human patients will be described. 
 
1.17.1 Genetic disorders of CaSR  
In 2011, over 200 mutations in the CaSR gene were identified (D'Souza-Li, 2006, 
Rodrigues et al., 2011). Now it is speculated that there are significantly more. Typical 
phenotypes resulting from these genetic abnormalities include familial hypocalciuric 
hypercalcaemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). FHH is the 
result of a heterozygote inactivating mutation of CaSR. In 1972, Foley et al first 
documented asymptomatic hypercalcaemia (Foley et al., 1972). These patients have 
small but significant increases (~10%) in serum calcium brought about by a mutation 
which can partially or completely remove CaSR function on one allele (Tfelt-Hansen et 
al., 2003). Often, a single mutant allele can exert a dominant negative effect on the gene 
as a whole. As a result, the inverse sigmoidal relationship between serum PTH and blood 
Ca2+o is right-shifted in FHH patients. This can be recapitulated in normal patients on 
calcilytic treatment (Bai et al., 1999, Tfelt-Hansen et al., 2003). Similarly, NSHPT is an 
autosomal recessive disease and a consequence of an inactivating mutation in CaSR. In 
the vast majority of cases, NSHPT only surfaces when heterozygous and homozygous 
mutation of CaSR alleles occurs (Tfelt-Hansen et al., 2003). Consequently, the sufferer 
has inappropriately elevated serum levels of PTH. This is due to the fact that CaSR cannot 
be activated by Ca2+o to inhibit PTH secretion. Infants younger than 6 months of age 
suffering from NSHPT often must undergo parathyroidectomy to prevent 
hyperparathyroidism. If surgery is not conducted, consequences can be fatal (Hendy et 
al., 2000, D'Souza-Li, 2006, Rodrigues et al., 2011). 
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In stark contrast to the severity of inactivating CaSR mutations lies autosomal dominant 
hypocalcaemia (ADH); a consequence of gain-of-function mutation of the CaSR gene. 
In this way, PTH secretion is suppressed in the face of physiological Ca2+o 
concentrations, thereby resulting in sustained hypocalcaemia. Surprisingly, serum PTH 
levels are almost normal in these individuals, however Ca2+ excretion in urine is 
significantly heightened (Hendy et al., 2000, Tfelt-Hansen et al., 2003). For this reason, 
patients may suffer from renal complications including nephrocalcinosis and renal stones 
(Raue et al., 2011). Patients with ADH are often asymptomatic, however, younger 
patients may suffer from seizures as a consequence of hypocalcaemia (Tan et al., 2003). 
ADH is associated with a shift in the relationship between serum PTH and blood Ca2+o. 
During ADH, the Ca2+o/PTH sigmoidal relationship is shifted leftwards, simulating 
normal patients on calcimimetic treatment (Hendy et al., 2000, Tfelt-Hansen et al., 2003). 
Bartter’s Syndrome type V has also been documented in many patients (Watanabe et al., 
2002). This syndrome is a rare heterogeneous consequence of abnormalities in Na+ and 
Cl- absorption. Patients suffering with this syndrome often exhibit hypocalcaemia and 
hypercalciuria, renal salt wasting, metabolic alkalosis and activation of the renin-
angiotensin-aldosterone system (RAAS) (Watanabe et al., 2002). Studies have shown 
that missense mutations in 3 amino acids (L125P, C131W and A843E) of CaSR cause 
Bartter’s Syndrome type V (Vargas-Poussou et al., 2002, D'Souza-Li, 2006). 
 
1.17.2 Acquired disorders of CaSR 
A number of cases have arisen where patients have suffered from dysregulation in Ca2+o 
metabolism when genetic mutations in the CaSR gene have not been found. Autoimmune 
hypoparathyroidism (AH) occurs as a consequence of the presence of CaSR auto-
antibodies resulting in hypocalcaemia and hyperphosphataemia. One study showed that 
56% of 25 sufferers of AH exhibited a specific CaSR epitope essential for PTH binding 
(Li et al., 1996c). These data suggest that CaSR acts as an antigen to direct an immune 
response against the parathyroid gland. PTH deficiency in these patients is a result of 
destruction of the parathyroid gland as an autoimmune inflammatory reaction (D'Souza-
Li, 2006). This extracellular domain of CaSR has also been shown to be an antigen not 
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only for parathyroid destruction, but for interfering with normal activation of the 
receptor. As a result, patients suffer from hypercalcaemia through a significant increase 
in PTH secretion. In this manner, CaSR-directed antibodies themselves can be considered 
as partial agonists of the CaSR (Pallais et al., 2004, D'Souza-Li, 2006). 
 
 
1.18 CaSR in the cardiovascular system: a role in vascular tone 
Traditional anatomy shows that blood vessels, particularly different arteries, are 
anatomically very similar. In recent years however, functional studies on an array of 
vessel types including pulmonary vessels, aortae, mesenteric arteries, the 
brachiocephalic, carotid and femoral arteries have demonstrated significantly unique 
characteristics in not only their ability to maintain vascular tone (Ohanian et al., 2005, 
Smajilovic et al., 2007, Harno et al., 2008), but the genes which they express as a whole. 
In terms of arteriolar tone, smaller resistance vessels with diameters typically less than 
500µm play crucial roles in maintaining vascular resistance by responding to endogenous 
hormones including bradykinin, endothelin, angiotensin II and prostacyclin (Weiss and 
Putney, 1978, Adams et al., 1989, Furchgott and Vanhoutte, 1989, Masaki, 1995). In 
addition to this, arteries carry out Ca2+-dependent contraction in a concentration-
dependent manner as shown by various investigators (Wonneberger et al., 2000, 
Smajilovic et al., 2007). Interestingly, other investigators have reported Ca2+-dependent 
dilation (Wu and Bohr, 1991). Regardless of the role Ca2+ plays in vascular tone in these 
vessels, it is clear that a mechanism for Ca2+o-sensing is at work which can modulate 
vessel tone.  
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1.18.1 CaSR and vascular tone (ex vivo studies)  
It has become relatively clear how CaSR function controls systemic Ca2+o homeostasis 
from the parathyroid gland, however, less well-defined is the role of CaSR in the 
cardiovascular system. To characterise the role of CaSR here, researchers have adopted 
a variety of experimental approaches in vivo, ex vivo and in vitro to determine the role of 
CaSR in endothelial and vascular smooth muscle cells in a variety of different vessel 
types. Since Ca2+ is a player in setting the cardiovascular tone (Bukoski et al., 1997), the 
idea of CaSR, a sensor of Ca2+o, playing a role in overall cardiovascular function seems 
extremely plausible. For this reason, the roles of CaSR in the cardiovascular system has 
been investigated over the past 15 years. 
 
 
1.18.1.1 Small arteriole myography 
The very first indication that CaSR may play a role in vascular tone modulation was 
suggested by Bukoski et al (Bukoski et al., 1997). This group investigated the role of 
CaSR in rat mesenteric arteries. Initially, immunohistochemical analysis revealed that 
CaSR was only expressed in the perivascular nerves localised in the adventitia of these 
arteries. Additionally, western blotting and RT-PCR confirmed CaSR expression in the 
adventitia, where dorsal root ganglia are situated (Bukoski et al., 1997). Wire myography 
experiments showed that whole mount mesenteric vessels with an intact adventitia 
achieved Ca2+-dependent relaxation in a concentration-dependent manner with an EC50 
of 2.47mM ± 0.17. Bukoski et al reported that this relaxation was endothelium-
independent, chiefly due to relaxation persisting in the presence of the nitric oxide 
synthase inhibitors (Bukoski et al., 1997). The group concluded that these responses were 
due to a CaSR present in the perivascular nerve network. This study was crucially 
important in initiating cardiovascular research into CaSR. 
 
In 2005, Ohanian et al investigated the presence and possible role of CaSR in rat 
subcutaneous vessels (Ohanian et al., 2005). Evidence that Ca2+ is a major player in 
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vasodilation is well-established (Lopez-Jaramillo et al., 1990, Bukoski et al., 1997) and 
so the group set out to investigate whether these observed effects were CaSR-mediated. 
Subcutaneous vessels of <250µm diameter were isolated from rats and biphasic dilation 
and contraction was measured using pressure myography where luminal pressure was set 
to 70mmHg to recapitulate in vivo conditions. It was shown that Ca2+o used at 
concentrations up to 10mM, induced concentration-dependent contraction followed by 
dilation indicated by an increasing luminal diameter. Mg2+ was also shown to induce 
dilation in these vessels. Furthermore, the role of additional CaSR agonists in vascular 
tone were investigated. Using the aminoglycoside antibiotics neomycin and kanamycin 
as alternative activators of CaSR, vasodilation could be detected using up to 10mM of 
these antibiotics in rat subcutaneous vessels (Ohanian et al., 2005). In support of the idea 
that these effects could be mediated through CaSR, CaSR protein was detected in 
subcutaneous vessels. What is perhaps the most fundamental difference between these 
two studies by Ohanian and Bukoski, is that Ohanian et al did not pre-contract their 
vessels with phenylephrine. Instead, subcutaneous vessels were maintained at 
physiological luminal pressure (70mmHg) until the myogenic tone was stable. At this 
point, concentration-response curves using CaSR agonists were performed (Ohanian et 
al., 2005).  
 
Since the studies by Bukoski et al and Ohanian et al, additional ex vivo functional studies 
have been performed on rat vessels. Weston et al in 2005 experimented on rat mesenteric 
arteries of the second and third order (sizes between 150-250µm) and demonstrated that 
a functional CaSR was at work more specifically in endothelial cells. The group showed 
this by RT-PCR using CaSR-specific primers, immunohistochemical staining of CaSR 
immunoreactivity in blood vessels and through functional ex vivo electrophysiological 
experiments (Weston, 2005). The group used CaSR activators such as Ca2+o and calindol 
at concentrations of 3.0mM and 100nM respectively. In electrophysiology experiments, 
the authors measured hyperpolarisation in response to these CaSR agonists, which is 
commonly known to be associated with subsequent dilation or relaxation of vascular 
smooth muscle cells. However, despite measureable hyperpolarisation, calindol was 
unable to relax mesenteric vessels when placed on a wire myograph. The Weston group 
largely attribute this paradoxical finding to theory of K+ clouds. For example, during α1-
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adrenergic activation by phenylephrine, or muscarinic M3 receptor activation by 
acetylcholine, K+ channels are activated and cause K+ efflux from the VSMCs or ECs 
respectively. Consequently, vasodilation by VSMC hyperpolarisation is theoretically 
inhibited due to local extracellular K+ clouds generated by VSMCs. Using calindol, 
Weston et al showed that, in the presence of the α1-adrenergic receptor agonist 
phenylephrine, the ability of calindol to hyperpolarise VSMCs was reduced. The group 
theorised that K+ clouds generated by phenylephrine would prevent sustained 
hyperpolarisation of ECs and therefore prevent dilation by calindol. To investigate this, 
the group then used iberiotoxin in combination with phenylephrine to inhibit BKCa 
channels present on VSMCs. The group reported that the hyperpolarising effect of 
calindol in the presence of iberiotoxin was significantly enhanced suggesting that this 
was indeed the case. The group further investigated whether these effects were mediated 
through the EC-CaSR by denuding the endothelium in these vessels. EC removal 
removed the hyperpolarising effects of calindol suggesting that an EC-CaSR is at work 
in mesenteric arteries. Interestingly, the group also investigated the role of the calcilytic 
calhex 231. Results showed that addition of calhex 231 reduce hyperpolarisations 
induced by calindol, indicating the existence of possible competitive binding between 
these two pharmacological agents (Weston, 2005).  
 
When considering the role of vascular CaSRs, vessel type and experimental conditions 
are crucially important. Large conductance vessels and small resistance vessels are not 
only morphologically different, but also contain different numbers of cells, specifically, 
the ratios of endothelial to vascular smooth muscle cells. Conductance vessels such as 
the aorta contain VSMCs which far outnumber endothelial cells. Conversely, endothelial 
cells and VSMCs in small resistance vessels are present in near equal numbers in two 
separate monolayers (Wagenseil and Mecham, 2009, Wagenseil et al., 2009, Wagenseil 
et al., 2010). For this reason, in order to be able to draw conclusions from different 
studies, comparable experimental protocols must be applied in like-for-like vessels. In 
this regard, the Ohanian et al. and Weston et al. studies are largely dissimilar since (i) 
different vessel types were used, and (ii) both studies used different starting conditions 
before the addition of CaSR agonists. Research from Weston et al clearly states that large 
conductance K+ channels play a role in maintaining membrane potential, which has 
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significant implications on the intrinsic ability of vascular cells to undergo hyper- or 
depolarisation. If this is true, then pre-constricted vessels vs. unconstricted vessels will 
have significantly different basal resting membrane potentials. It is therefore highly likely 
that these factors, in combination with any CaSR-mediated effects, produce the 
differential results seen between these studies. 
 
 
1.18.1.2 Aortic myography 
In a 2007 paper, Smajilovic et al demonstrated CaSR-evoked relaxation of rat aortae 
using traditional wire myography. The group showed that the calcimimetic AMG 073 
acted directly on CaSR present in both the endothelium and vascular smooth muscle cells. 
Experiments were conducted using a buffer containing 1.5mM Ca2+o. Crucially, this 
concentration was selected as it lies within the mid-range of activation of CaSR. The 
group selected this concentration from a Ca2+o concentration response curve in the rat 
aortae where Ca2+o induced concentration-dependent contraction in the presence of 
phenylephrine. Although this Ca2+o concentration response curve started from 10µM (no 
contraction) to ~3mM (maximum contraction), previous data points below 0.5mM were 
excluded since this is below the threshold of CaSR activation. The group firstly showed 
that this Ca2+-dependent contraction of rat aortae was diminished in the presence of 3µM 
AMG 073, suggesting that calcimimetics may have a role in vasodilation and relaxation. 
Secondly, using rat aortae pharmacologically pre-contracted with 3 x 10-6 M 
phenylephrine, the group demonstrated that AMG 073 induced a concentration-
dependent relaxation up to 45.8 ± 2.9% relative to phenylephrine pre-constriction. This 
was observed from a concentration of 1µM to ~20µM (exact maximum concentration 
not stated in the publication). Also reported was the inability of this calcimimetic to relax 
vessels which were not phenylephrine pre-constricted, although data were not shown. 
Interestingly, this ability of calcimimetics to relax rat aortae was partially endothelium 
dependent as suggested by the fact that endothelium-induced relaxation was reduced 
when using L-NAME and indomethacin which block NOS and prostaglandins, 
respectively. These data suggest that relaxation could be mediated synergistically via 
endothelial and vascular smooth muscle CaSRs. However, Smajilovic et al further 
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suggested that CaSR activation, and subsequent relaxation, could be endothelium-
derived hyperpolarising factor-dependent. This idea comes from similar experiments 
where aortae were pre-contracted with 125mM KCl. Under these supraphysiological 
conditions, AMG 073 relaxation responses were absent, suggesting that this effect was 
dependent on endothelium-derived hyperpolarising factors (EDHFs) which were 
inhibited in the presence of this high K+. Together, these data suggest that in the rat aorta 
calcimimetics have both endothelium-dependent and -independent effect on relaxation 
(Smajilovic et al., 2007). However, the group maintain that these effects may be by 
CaSR-specific, or CaSR- non-specific mechanism since higher concentrations of AMG 
073 were used (>1µM). The group speculate that there may be some non-specific Ca2+-
channel mediated effects present. Further evidence supporting the role of Ca2+ as a 
vasoconstrictor in the aorta is presented in other publications. For example, Ito et al used 
guinea pig aortae to demonstrate Ca2+ as a vasoconstrictor when used at concentrations 
from 0.1-2.5mM Ca2+o. Of note, the group started from a base-line buffer containing no 
Ca2+o (Ito et al., 1991).  
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1.18.2 CaSR and vascular tone (in vivo studies)   
A study by Fryer et al in 2007 looked extensively at the role of CaSR in hypertension 
(Fryer et al., 2007). In this study, the group showed that the calcimimetic cinacalcet (1, 
3 and 10mg/kg with 30 min of each concentration) acutely increased mean arterial blood 
pressure in both 5/6 nephrectomised rats and control animals. Animals were infused 
intravenously over 90 min with cinacalcet and demonstrated significant increases in 
carotid and mesenteric vascular resistance. Data from this study would therefore suggest 
that CaSR activation by calcimimetics appears to have a pro-hypertensive role. The 
authors suggested that this may be due to inhibition of synthesis of nitric oxide. This is 
thought to be the case since cinacalcet infusion decreases [Ca2+]o in a dose-dependent 
manner through PTH inhibition in the PTGs (Fryer et al., 2007). Interestingly, 
nephrectomised rats also attained a reduction in PTH secretion in response to [Ca2+]o in 
the presence of increasing concentrations of cinacalcet. For this reason, the effects of 
cinacalcet on vascular tone and blood pressure in this study are thought to be secondary 
to parathyroid gland CaSR stimulation, and not by vascular CaSR stimulation directly 
(Fryer et al., 2007). 
 
Nakagawa et al also investigated the role of calcimimetics in blood pressure modulation, 
looking specifically at R-568 and S-568. The group investigated mean arterial pressure 
and heart rate from the femoral artery. Infusion of 0.7mg/kg R-568 over 10 minutes into 
the femoral vein was not sufficient to effect either mean arterial blood pressure and heart 
rate, although infusion of either R-568 or S-568 (2.1mg/kg over 3 minutes) was sufficient 
to reduce blood pressure and heart rate with R-568 having greater effects (Nakagawa et 
al., 2009). Comparatively, this group observed short-term (over the course of 3 minutes) 
hypotensive effects of calcimimetics whereas Fryer et al observed hypertensive effects 
of calcimimetics in a more long-term treatment (over 90 minutes). Similarly, a study by 
Rybzynska et al showed that intravenous injection of 1mg/kg R-568 in normal wild-type 
rats was sufficient to reduce serum [Ca2+]o and urinary phosphate excretion and mean 
arterial blood pressure (Rybczyńska et al., 2006). These findings were also shown by the 
same group in spontaneously hypertensive rats, which became hypotensive in response 
to R-568 administration of 1mg/kg intravenously (Rybczyńska et al., 2005). From these 
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studies it is clear that many factors effect vascular tone, including the calcimimetic 
compound itself, the dose used and the duration of treatment. Furthermore, since CaSR 
is so widely expressed, especially in such abundance in the PTGs, it is extremely difficult 
to identify whether or not vascular CaSR are playing a role in this process. 
 
The role of calcilytics has also been investigated in blood pressure modulation. 
Rybczynska et al had previously seen that, in spontaneously hypertensive rats, R-568 
decreased mean arterial pressure (Rybczyńska et al., 2005), however, the group believe 
this to be a consequence of activation of the parathyroid CaSR and not relating to vascular 
CaSRs. Using normal wild-type rats, the group perfused animals intravenously with 
calcilytic NPS 2143 (1mg/kg). The group concluded that 2 hours post-perfusion, there 
was a significant increase in serum [Ca2+]o. This was also associated with a significant 
increase in serum PTH and mean arterial pressure. Interestingly, the group believe this 
results to be due to secretion of hypertensive factors from the parathyroid glands 
(Rybczynska et al., 2006). Collectively, these in vivo studies illustrate the importance of 
CaSR activation by allosteric modulators. However, it still remains unclear whether 
changes in blood pressure arise from vascular CaSR activation, parathyroid CaSR 
activation or a combination of these. 
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1.19 CaSR: a role in the cardiovascular system? 
We have seen how CaSR modulation plays a significant role in blood vessels tone 
modulation and calcification through a variety of different models. Previously discussed 
has been the extensive role of CaSR in the body and in the vasculature. Currently, there 
is no clear and discernable role for the CaSR in the cardiovascular system, or a role of 
the receptor in vascular diseases such as calcification in vivo although several studies 
suggest that the vascular CaSR might play an important role in preventing cardiovascular 
pathology (Bukoski et al., 1997, Weston, 2005, Smajilovic et al., 2006, Smajilovic et al., 
2007, Alam et al., 2008, Weston et al., 2008). A current hypothetical overview of CaSR 
function in the cardiovascular system is demonstrated in Figure 20. 
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Figure 20. Potential roles of the CaSR in the cardiovascular system. (A) CaSR might play a role in 
maintaining vascular tone. Activation of CaSR in endothelial cells causes release of Ca2+ from internal 
stores (Weston, 2005). Consequently, the NOS/NO pathway is activated, causing inhibition of constriction 
and promotion of vasodilation through gap junctions. Endothelial CaSR is therefore likely to play a role in 
reducing blood pressure. Similarly, CaSR activation on VSMCs can lead to increases in VSMC [Ca2+]i 
leading to Ca2+i-dependent myosin bridging and vasoconstriction. It is therefore likely that VSMC CaSR 
plays a role in blood pressure modulation too (Smajilovic et al., 2011). (B) In the presence of physiological 
[Ca2+]o, CaSR agonists may cause increases in [Ca2+]i and bridging of myosin. It is likely that this action 
A 
EC 
B 
VSMC 
VSMC 
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maintains the VSMC contractile phenotype and upregulation of actin products. Additionally, Ca2+ influx 
may occur to facilitate this contractile phenotype progression by the actions of BKCa and VGCCs (Weston 
et al., 2008). Where high [Ca2+]o is present, this may activate CaSR for more myosin bridging. Excess 
Ca2+o may be poorly handle by MGP. Consequently, surplus Ca2+ may bind phosphate over time and create 
small calcification nucleation sites.  
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1.19.1 Project scope and overview 
In this introduction I have presented evidence for the role of the CaSR in the vasculature, 
specifically in vascular smooth muscle cells. Additionally, I have described how studies 
in the field have been conducted illustrating the importance of CaSR in blood pressure 
modulation and in vascular calcification. Vascular calcification is associated with 
numerous deleterious cardiovascular health complications including atherosclerosis, 
ventricular hypertrophy, high blood pressure and, of course, CKD. Furthermore, we have 
seen how CaSR modulation with pharmacological agents such as calcimimetics have 
demonstrated potential protective roles against both calcification and hypertension. 
Current findings reviewed in this thesis suggest that the extracellular calcium-sensing 
receptor, CaSR, is an attractive area of research in the area of cardiovascular physiology 
and disease which has been explored fairly little. It would appear that CaSR modulation 
in vivo, ex vivo and in vitro has significant implications on the anatomy and physiology 
of blood vessels and cells that impart them. 
 
1.19.2 Aims 
The overall aims of this PhD are:  
(i) To determine the physiological role of the CaSR in the cardiovascular system, 
and its involvement in cardiovascular pathology. 
(ii) To determine whether allosteric modulators of the CaSR, the calcimimetics, 
affect the vascular CaSR. 
 
These will be tested adopting a number of in vitro, ex vivo and in vivo approaches using 
our newly developed mouse model of targeted CaSR ablation from VSMCs. 
  
 Page 92 
 
1.19.2.1 CaSR ablation in vascular smooth muscle cells 
The major aim of this PhD research is to determine whether CaSR plays a role in vascular 
physiology and VC by characterising a new transgenic mouse model with selective 
ablation of CaSR in VSMCs. CaSR comprises 7 exons however, only exons 2-6 are 
transcribed and translated to make the mature CaSR protein (Rodrigues et al., 2011). 
Exon 7 encodes the entire transmembrane domain of the receptor which allows (i) the 
receptor to be membrane-bound, and (ii) allows binding of agonists such as 
calcimimetics. Using a transgenic mouse model developed and provided by Dr. Wenhan 
Chang et al at UCSF (Chang et al., 2008), floxed ‘loxP’ sites are incorporated either side 
of exon 7 of CaSR, as described in Figure 21. In this way, cre recombinase, an exogenous 
bacterial-derived enzyme, can be driven by tissue-specific promoters. When switched on 
by a tissue-specific promoter, the cre recombinase enzyme is produced specifically in 
that cell type. For this particular mouse model, the cre enzyme is driven by the modified 
SM22α promoter, produced by Li et al (Li et al., 1996b). Li et al found that the SM22α 
promoter (a promoter expressed in multiple smooth muscle cell lineages) could be 
modified in such a way that selecting just a 445bp 5’ region of this promoter could drive 
specific vascular smooth muscle cell, cardiac and early skeletal muscle expression of any 
genes flanking this promoter. Importantly, the group reported that, although this 
promoter was sufficient to have minor activity in early embryonic skeletal muscle (E9.5 
and E12.5), expression of this promoter in development thereafter to adulthood is 
restricted to vascular smooth muscle cells (Li et al., 1996a). The publication from 1996 
showed this visually using a reporter mouse for lacZ under the control of this modified 
SM22α promoter (∆SM22α). Currently, this method of VSMC-knockout of floxed genes 
using endogenously expressed cre recombinase under the control of this ∆SM22α 
promoter is the most specific in vivo knockout strategy available. In combination with 
the floxed CaSR mouse which was provided by Dr. Wenhan Chang et al (Chang et al., 
2008), ∆SM22α-driven cre allows specific knockout of CaSR in vascular smooth muscle 
cells, as illustrated in Figures 22 and 23. 
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Figure 21. CaSR gene topology and ∆SM22α-driven CaSR knockout. The CaSR gene comprises 7 
exons and 6 introns. Exons 2-4 encode the Venus flytrap (VFT) domain as described in Figure 15 (residues 
36-513aa) which has a significant role in CaSR activation. Exon 4 also encodes the cysteine-rich domain 
(542-598aa) which helps maintain the structure and subsequent function of the receptor. Exon 7 contains 
agonist binding domains encoded within the transmembrane domain (TMD) and is flanked by loxP sites 
(purple arrows). Li et al ∆SM22α promoter drives the cre recombinase transgene in VSMCs to knock out 
this exon 7 (Li et al., 1996a, Chang et al., 2008). 
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Figure 22. ∆SM22α-lacZ reporter mouse demonstrates cardiovascular specific expression of 
∆SM22α. Transgenic mice harbouring the pSM2735/1093-1acZ sequence were stained for ∆SM22α 
expression. (A) LacZ activity detected in the outflow tract of the heart (ot) and bulbus cordis (bc) at E8.75. 
(B) By E9.0 LacZ staining was visible in the descending aorta (da). (C) lacZ staining was apparent in 
somites (so) by E10.0. (D, E, F) LacZ was visible at E11.5, 13.5 and E14.5 respectively in the following 
locations: aa, aortic arches; ba, basilar artery; bc, bulbus cordis; ca, carotid artery; da, dorsal aorta; ia, iliac 
artery; iv, intercostal vessel; ot, outflow tract; so, somite; ta, truncus arteriosus; u, umbilical vessel; v, 
ventricle; va, vertebral artery. Adapted from Li et al (Li et al., 1996b). 
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Figure 23. ∆SM22α-lacZ reporter mouse shows lacZ expression specifically in the tunica media of 
the descending aorta and pulmonary artery. (A, B, C) lacZ is visibly expressed specifically in vascular 
smooth muscle cells in the aorta. (D) lacZ expression is also visible in the pulmonary artery. LacZ 
expression was not seen in visceral of venous smooth muscle (v). m, smooth muscle; en, endothelium; da, 
dorsal aorta; lu, lung; es, oesophagus, v, vena cava; pa, pulmonary artery. Scale bar (A and D) 100µm, (B) 
200µm. Mice age: E13.5. Adapted from Li et al (Li et al., 1996b). 
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1.19.3 Part I 
In order to determine whether CaSR ablation in VSMCs has an effect on reproduction, 
survivability and normal development of organs and tissues, in vivo characterisation of 
this novel mouse model is required. In the first part of this research, the SM22α x fl CaSR 
transgenic mouse model will be used for this in vivo characterisation.  
 
In vivo analysis aims to: 
(i) Carry out initial characterisation of the SM22α x fl CaSR mouse model 
by observing general size, weight, appearance and viability. 
(ii) Determine whether Mendelian transmission is maintained during breeding 
of VSMC-CaSR WT and VSMC-CaSR KO mice by genotyping the 
offspring. 
(iii) Determine whether genotype affects genders of offspring and litter size. 
(iv) Determine whether CaSR protein is knocked out in VSMC-CaSR KO 
mice compared to VSMC-CaSR WT mice. 
(v) Carry out biochemical analysis of the serum of mice over time. 
(vi) Carry out measurements of bone mineral density in VSMC-CaSR WT and 
VSMC-CaSR KO mice. 
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1.19.4 Part II 
It has previously been demonstrated that activation of CaSR by allosteric agonists in rat 
subcutaneous vessels causes hyperpolarisation (Weston et al., 2008). For the second part 
of the project, my aim is to determine the physiological role of CaSR in the vasculature, 
and its potential role in maintaining myogenic tone. The hypothesis is that (i) CaSR in 
VSMCs may play an important role in vasoconstriction and relaxation, and that (ii) CaSR 
ablation from VSMCs may have repercussions on the effects of CaSR agonists to induce 
either contraction or relaxation. These hypotheses will be tested using the following 
techniques: 
 
Ex vivo analysis aims to: 
(i) Determine the effects of CaSR ablation from VSMCs on aortae and 
mesenteric arteries isolated from VSMC-CaSR WT and VSMC-CaSR KO 
mice. 
(ii) Determine whether CaSR ablation affects the contractile tone in acutely 
isolated aortae and mesenteric arteries. 
(iii) To determine the effects of CaSR ablation from VSMCs on the responses 
of orthosteric and allosteric modulators of CaSR on vascular tone of aortae 
and mesenteric arteries acutely isolated from VSMC-CaSR WT and 
VSMC-CaSR KO animals. 
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1.19.6 Part III 
Using the SM22α x fl CaSR mouse as an experimental model, WT-CaSR and KO-CaSR 
VSMCs will be isolated and cultured in vitro. Proliferation, apoptosis, mineralisation, 
gene expression and transdifferentiation will be investigated in these cells, which will be 
cultured in a variety of conditions in vitro. Specifically, primary WT-CaSR and KO-
CaSR VSMCs will be cultured in the presence of physiological and pathophysiological 
concentrations of Ca2+o with the addition of a variety of Pi concentrations, also, designed 
to recapitulate Ca2+o and Pi dysregulation in vivo. These conditions are similar to in vitro 
models described by other groups which recapitulate vascular calcification in vitro. 
 
    In vitro analysis aims to: 
(i) Establish an in vitro culture system of mouse VSMCs. 
(ii) Isolate VSMCs from VSMC-CaSR WT and VSMC-CaSR KO mice. 
(iii) Confirm that CaSR is deleted in cultured VSMCs from VSMC-CaSR KO 
mice by PCR and immunofluorescence. 
(iv) Determine the effects of targeted CaSR ablation from VSMC on cell 
proliferation by cell counting and cell apoptosis using 
immunofluorescence techniques. 
(v) Determine the effects of CaSR ablation on the role of Ca2+o and 
calcimimetics on cell proliferation and apoptosis. 
(vi) Determine the effects of CaSR ablation on mineralisation and Ca2+ 
incorporation using different concentrations of Ca2+o, Pi and the 
calcimimetic R-568 in VSMC-CaSR WT and VSMC-CaSR KO VSMCs. 
(vii) Determine whether mineralisation is associated with transdifferentiation 
of VSMCs by up-regulation of osteoblast-specific genes by VSMC-CaSR 
WT and VSMC-CaSR KO VSMCs in mineralised cultures. 
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CHAPTER 2:  
METHODS 
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2.1 Breeding of SM22α x fl CaSR transgenic mice.  
SM22α x fl CaSR mice, provided by Dr. Chang and colleagues, were of a mixed inbred 
background. Floxed and Cre mice were bred together to maintain genetic consistency of 
the C57BL/6J and 129S1/SvImJ background across all mice of the colony. WT SM22α 
x fl CaSR mice carry two WT CaSR alleles. Floxed mice contain two floxed CaSR alleles 
flanking Exon 7 (∆Exon 7). The cre transgene is required to knock out Exon 7 of genomic 
CaSR DNA. To obtain VSMC-CaSR WT mice, VSMC-CaSR floxed Cre-/- WT mice are 
bred with one another. In this way, cre is not available for inheritance in offspring, but 
control mice still contain the floxed alleles. Table 24 shows expected Mendelian ratios 
of offspring from WTxWT, WTxKO and KOxKO matings. Since heterozygote 
floxed/WT CaSR mice were not investigated in this study, this breeding strategy was 
adopted to prevent production of heterozygote mice. Hereafter, VSMC-CaSR WT mice 
and VSMC-CaSR KO mice will be referred to as WT and KO mice respectively. 
Figure 24. Mendelian inheritance of floxed and cre alleles in the SM22α x fl CaSR mouse model. 
Punnet square diagrams demonstrate the ratios VSMC-CaSR WT (green) to VSMC-CaSR KO (red) 
offspring from 3 matings carried out during this project. (A) WTxWT breeding. (B) WTxKO breeding. (C) 
KOxKO breeding. Red: VSMC-CaSR KO mice. Green: VSMC-CaSR WT mice. 
 
Flox/Cre- Flox/Cre- Flox/Cre- Flox/Cre- 
Flox/Cre- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre/- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
 
 
Flox/Cre+ Flox/Cre+ Flox/Cre- Flox/Cre- 
Flox/Cre- Flox/Flox Cre+/- Flox/Flox Cre+/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre+/- Flox/Flox Cre+/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre+/- Flox/Flox Cre+/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre+/- Flox/Flox Cre+/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
 
 
Flox/Cre+ Flox/Cre+ Flox/Cre- Flox/Cre- 
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Flox/Cre- Flox/Flox Cre+/- Flox/Flox Cre+/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
Flox/Cre- Flox/Flox Cre+/- Flox/Flox Cre+/- Flox/Flox Cre-/- Flox/Flox Cre-/- 
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2.2 Determination of mouse whole body weight.  
Mice were weighted from birth onwards at monthly intervals in a large plastic tub on a 
scale. Mice were left for approximately 5 minutes (min) to rest before body weight 
measurements were tabulated. After this time, five consecutive weight measurements 
were taken over the course of 2 minutes when mice were still. Body weight was 
determined by taking an average of these weights. 
 
2.3 Genomic DNA (gDNA) isolation from SM22α x fl CaSR mice. 
As part of the routine mouse identification, SM22α x fl CaSR mice were humanely 
scruffed and ear biopsies were obtained by an ear clip. Ear biopsies placed in 0.5 mL 
eppendorf tubes with 200 µL Ear Digest (Viagen) and 8 µL proteinase K (10mg/mL) 
(Bioline). Samples were incubated at 55ºC overnight. Reactions were terminated the next 
day by incubating at 85ºC for 45 min. The resulting solution containing gDNA was used 
as a template for genotyping PCRs. 
 
2.4 Genotyping SM22α x fl CaSR transgenic mice.  
PCRs were optimised for MgCl2 concentration, annealing temperature and number of 
PCR cycles. All PCR reagents for mouse genotyping were provided in the Bioline BIOtaq 
DNA Polymerase kit. Each PCR reaction comprised of; 1.5 µL ear biopsy gDNA 
(obtained previously), 0.2 mM dNTPs, 1U BIOtaq DNA Polymerase, 4mM MgCl2, 2.5 
µL 10X PCR Buffer (MgCl2-free), 100nM Forward Primer, 100nM Reverse Primer, 17.0 
µL RNase/DNase- free dH2O (total 25µL reactions). Genotyping primers for floxed 
CaSR allele detection were: Forward fl CaSR 5’-GTGACGGAAAACATACTGC-3’, 
and Reverse fl CaSR 5’-CGAGTACAGGCTTTGATGC-3’. Genotyping primers for cre 
transgene detection were: Forward Cre 5’-CAGACACCGAAGCTACTCTCCTTCC-3’, 
and Reverse Cre 5’-CGCATAACCAGTGAAACAGCATTGC-3’. The PCR conditions 
were: an initial denaturation at 95ºC for 5 min, thermal cycling parameters were: 
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denature; 95ºC x 5 min, anneal 50ºC/Cre and 46ºC/fl CaSR x 30 seconds, extend 72ºC x 
2 min for 40 cycles. Final extension was carried out at 72ºC for 10 min then reactions 
were kept at 4ºC. Expected products were: Cre transgene amplicon; 500bp, WT CaSR 
amplicon; 133bp, fl CaSR amplicon; 167bp. 
 
2.5 Detection of gDNA/cDNA amplicons by gel electrophoresis.  
To each 25 µL PCR reaction, 6 µL of 5X gel loading dye was added. A gel 
electrophoresis tank was filled with 1X Tris Borate EDTA (TBE). Agarose was added to 
100 mL 1X TBE in a conical flask to make a 100mL agarose gel. Throughout the project, 
different percentage gels were used for the optimal spread of different amplicons. 
Amplicons <200bp were run on 2.5% agarose gels, whereas products >500bp were run 
on 1% agarose gels. The agarose mixture was microwaved until it had dissolved. After 
cooling to ~55ºC, 5µL SafeView (NGS Biologicals) was added to the melted agarose and 
mixed until homogeneous. The mixture was then poured into a gel cast and allowed to 
polymerize for 30 min. The polymerized gel was immersed in 1X TBE within the 
electrophoresis tank. Previously prepared samples were loaded in each well, with an 
appropriate sized DNA ladder as a standard (DNA HyperLadders I, II, III, IV and V, 
Bioline). Gels were run at 10V/cm until the gel loading dye was visible approximately 
80% towards the positive electrode. Gels were visualised and photographed using an 
ultraviolet transilluminator (Chemi-doc, BIORAD).  
 
2.6 Determination of mouse organ weights.  
Mice were culled at the age of 6 or 18 months. Organs, including the heart, liver, stomach, 
kidneys and spleen, were briefly washed in dH2O then dried before recording the wet 
weight of the organ. Since male and female organ weights were not statistically different 
(not shown), they were grouped together for analysis. 
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2.7 Serum biochemical analysis of SM22α x fl CaSR mice.  
Mice were culled at the age of 3 months and 18 months. Hearts were then exsanguinated 
for blood collection (performed by Martin Schepelmann at Cardiff University). Blood 
samples were allowed to coagulate for 30 min at room temperature before centrifugation 
for 5 min at 5,000g. Serum was extracted from the supernatant and snap frozen in liquid 
nitrogen for future use. Samples were sent to collaborators at AstraZeneca for 
biochemical analysis using photometric or ELISA-based systems. Analyses carried out 
were for Na+, Cl-, Mg2+, K+, Ca2+ and FGF23.  
 
2.8 Calculation of bone density by microcomputerised tomography (µCT).  
A cohort of mice at the age of 3 months were kept at UCSF by Dr Wenhan Chang. Male 
mice were culled at this age and bones were collected. The distal femur (a site rich in 
trabecular bone) and the tibia-fibula junction (TFJ) (rich in cortical bones) were analysed. 
Prior to scanning, the bones were fixed in 10% phosphate-buffered formalin for 24 hours 
then transferred to 70% ethanol. The bones were then scanned in tubes containing 70% 
ethanol using a Scanco vivaCT scanner (Scanco Medical, Basserdorf, Switzerland). For 
trabecular scans, 100 serial cross-sectional scans were performed from the end of the 
growth plate. 100 serial cross-sectional scans were also performed in cortical bone. For 
µCT analysis, thresholds in the manufacturers’ software were applied to remove 
mineralised bone, focusing only on soft tissue. Experiments were conducted by Dr 
Wenhan Chang group, as described previously (Chang et al., 2008). 
 
 
  
 Page 104 
 
2.9 Wire myography on acutely isolated mouse aortae and mesenteric arteries.  
Aortae and mesenteric arteries of third order were isolated from VSMC-CaSR WT and 
VSMC-CaSR KO mice which were humanely killed by the Schedule one method of CO2 
inhalation in accordance with Home Office regulations. Aortae were placed in ice cold 
Krebs buffer (NaCl; 118mM, KCl; 3.4mM, CaCl2; 1.0mM, KH2PO4; 1.2mM, MgSO4; 
1.2mM, NaHCO3; 25mM, Glucose; 11mM) and continuously oxygenated by O2:CO2 
95% O2:5% CO2) gas bubbling on the side of the myography bath. Adventitia and fat 
were carefully removed and aortae were cut into 2mm rings. Rings were loaded onto a 
4-channel wire myograph (DMT) with 40µm stainless steel wire. In the myograph well, 
aortic rings were incubated with Krebs buffer at 37ºC, once again with constant O2:CO2 
gas bubbling for the whole experiment. Wires were adjusted to stretch rings 100µm every 
~20 seconds until a tone of 4 milliNewtons (mN) was achieved. Rings were then exposed 
to drugs and chemicals such as KCl, phenylephrine (PhE), acetylcholine (Ach), Ca2+o, R-
568, spermine and L-NAME. Drugs were prepared in Krebs buffer and either applied in 
a concentration-dependent manner, or at specific concentrations. Data were recorded as 
changes in tone in units of mN. 
 
2.10 Immunofluorescence of primary mouse VSMCs and fixed mouse aortae.  
Primary VSMCs cultured in standard conditions (DMEM containing 1.2mM Ca2+o and 
10% FBS) were trypsinised through 0.05% Trypsin EDTA / PBS (pH 7.4) treatment and 
plated onto 13mm glass coverslips in 4-well plates (Nunc) at a maximum of 15,000 cells 
per well. Cells were allowed to adhere and were routinely maintained in standard 1.2mM 
Ca2+o DMEM with 10% FBS. After a few days, when the cells had reached 75-100% 
confluency, they were fixed in 4% paraformaldehyde in 1X PBS (pH 7.4) for 10 min at 
4ºC. Cells were permeabilised using 0.5% Triton-X in 1 X PBS. Cells were then washed 
in 1X PBS three times for 5 min for each wash. A blocking buffer (1% BSA/1 X 
PBS/0.5% Triton-X) was subsequently applied for 60 min. Primary and secondary 
antibody incubations were carried out for 60 min with three 1 X PBS washes of 5 min 
each in between. Antibodies were diluted in the same blocking buffer and were used in 
1:100-1:250 dilutions (according to the manufacturer’s instructions). Antibodies used 
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were: rabbit anti-CaSR (Anaspec, Cat #53286), goat anti-SM22α (Abcam, Cat 
#ab14106), and either Alexa488 or Alexa594 (Molecular Probes) secondary antibodies 
which were raised in the appropriate species according to the primary antibody selected. 
For tissue fixation, organs were removed after the animal was culled. Excised tissues 
were washed in 1 x PBS, then fixed for 60 min in 4% PFA. Organs were embedded in 
OCT mounting medium, then frozen at -80ºC. Once frozen, a Leica CM1950 cryostat 
was used to generate 6µm cross-sectional slices. Sections were allowed to adhere to 
microscope slides and hydrophobic pens were used to seal off the tissue area. Immuno-
staining was then performed following the same protocol as the VSMC staining described 
above. 
 
2.11 Isolation of mouse primary vascular smooth muscle cells (VSMCs).  
3 month old male mice were terminated by Schedule one in accordance with Home Office 
regulations. Each mouse carcass was splayed out and pinned down on a wax disc using 
25-gauge needles. Aortae were dissected as shown in Figure 25. After removal of the 
fibrotic adventita, 2mm rings were prepared and allowed to adhere to the base of a T25 
flask (Corning/BD Falcon) in the absence of medium for 10 min at 37ºC. While still 
moist, explants were carefully covered in Ca2+o-free DMEM (Invitrogen Cat#21068-028) 
containing 1.2mM Ca2+o (supplemented by CaCl2), 10% Fetal bovine serum, (FBS) 
(Thermo-Fisher), 50U/mL Penicillin/Streptomycin, 2.5µg/mL Fungizone®, 2mM L-
glutamine and 1mM sodium pyruvate. FBS was always heat-inactivated at 56ºC for 30 
min before adding to medium. All cell culture reagents, excluding FBS, were provided 
by Invitrogen. Explants kept at 37ºC in a humidified incubator with 5% CO2/95% O2. 
 
Explants were then left in the incubator for up to 2 weeks in order for the primary VSMCs 
to migrate out onto the plastic base of the flask (Figure 26). To split cells, cells were 
washed in 1X PBS and explants were removed gently using a sterile 25-guage needle. 
Cells were incubated with 0.05% Trypsin EDTA (Invitrogen) in 1X PBS for 3-5 min. 
After incubation with trypsin, equal volumes of fresh medium were added. This medium 
was the same as previously described however, after the first initial passage Fungizone® 
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was always removed thereafter. This medium is hereafter referred to as standard (i.e., 
1.2mM Ca2+o) DMEM with 10% FBS. The trypsin-medium suspension was then 
centrifuged at 1,500g for 4 min to collect cells. The supernatant was then removed and 
cells were resuspended in the same medium and plated onto a single well of a 6-well 
plate. Cells had medium routinely changed every 3-4 days and were split to larger flasks 
when appropriate cell density was reached. 
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Figure 25. Explant isolation of primary mouse VSMCs. Mice were killed by a Schedule One procedure 
(i.e., cervical dislocation) in accordance with Home Office regulations. Organs were removed as shown 
(A-D) to allow access to the thoracic descending aorta. (A) The thoracic abdomen was cut open to reveal 
the heart (h), auricles (a) and lungs (l). (B) Lungs were removed and discarded, leaving the oesophagus (o) 
in view. (C) Auricles and oesophagus were removed to reveal the thoracic descending aorta (da). (D) The 
heart was removed at the base of all outward-extending vessels (vena cava, pulmonary vein, pulmonary 
artery and ascending aorta). (E) The descending aorta was dissected by cutting away from the spine in 
posterior-to-anterior direction. (F) Aorta in 1X PBS in a 100mm Petri dish. (G) Care was taken to remove 
the adventitia and fibrotic tissue from the vessel. The vessel was also squeezed from one end to another to 
disrupt the endothelial cell layer. (H) The aorta was cut into sagittal sections of approximately 2mm in 
length. 
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Figure 26. Explant culture of primary mouse VSMCs in vitro. Explants similar to those illustrated in 
Figure 25 are placed in the standard (1.2mm Ca2+o) DMEM with 10% FBS with 2.5U/mL Fungizone®. 
(A) Explants were lifted using a 25-guage needle and placed onto the base of a Corning/BD Falcon vented 
T25 cell- flask approximately 5mm apart. (B) Moist explants are sealed in the flask placed in an incubator 
with controlled humidity conditions and temperature of 37ºC (5% CO2/95% O2) for 10-20 min to adhere 
to the plastic whilst ensuring that they did not dry out completely. After adherence, ~5mL of fresh, pre-
warmed DMEM was added slowly and gently to explants until they were immersed. (C) Explants were 
cultured for approximately 2 weeks to allow VSMCs to migrate out from the explant with careful medium 
changing every 4-5 days. While at “passage 0”, cells were routinely maintained at in this medium 
containing Fungizone®. However, from passage 1 onwards, Fungizone® was removed from the culture 
medium  
 
 
Mouse primary VSMCs 
A 
B
C ~2 weeks 
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2.12 Quantification of total SM22a in WT and KO VSMCs by western blot. 
Confluent WT and KO VSMCs cultured in standard DMEM containing 10% FBS and 
1.2mM Ca2+o were lysed in 1X RIPA lysis buffer at 4ºC for 10 minutes. Cell lysates were 
spun down for 5 minutes at 12,000g, and supernatants were removed. Protein was 
quantified using a BCA assay kit according to manufacturers’ instructions (Pierce). 5µg 
of protein was loaded onto a 10% SDS-PAGE gel (10% acrylamine, 0.5% bis-
acrylamide, 0.1% SDS, 0.3% ammonium persulfate in Tris-HCl pH8.8). 25µL of 
TEMED was added to the mix to polymerise. Proteins were run by western blot at 200V 
for up to 45 minutes. Proteins were then transferred onto a PVDF membrane at 40V for 
90 minutes in transfer buffer (3g tris, 15g glycine and 150mL methanol in 850mL dH2O). 
PVDF membranes were blocked with 3% BSA in TBS-Tween (8.8g NaCl, 0.2g KCl, 2g 
tris and 500µL tween-20 in 1L dH2O) for one hour before performing antibody 
immunostaining. SM22α protein was detected using a goat anti-SM22α antibody (abcam, 
1:1000) in the blocking buffer described for 1 hour incubation. Membranes were washed 
in TBS-Tween three times for 5 min in between antibody incubation. A β-actin antibody 
was also run on duplicate samples as a positive control. A secondary anti-goat HRP-
conjugated antibody was used (1:10,000) for 10 hour before washing membranes again 
in TBS-Tween. Signal was then produced by incubating membranes in an ECL western 
blotting substrate. Chemiluminescence was detected using BIORAD chemidoc system. 
Images were scanned and analysed in ImageJ software where densitometry was carried 
out on bands. 
 
2.13 gDNA isolation of primary mouse vascular smooth muscle cells (VSMCs) for 
cellular genotyping.  
VSMC-CaSR WT and VSMC-CaSR KO primary mouse VSMCs were cultured until 
they reached confluency in 24-well plates. Upon confluence, a mix of cell lysis buffer 
and proteinase K was prepared. For each well, 75µL “DirectPCR Lysis Reagent [Cell]” 
(Viagen) was added with 0.5mg/mL Proteinase K (Bioline). The cell lysis suspension 
was incubated at 55ºC overnight then the reaction was terminated by incubating the 
mixture at 85ºC for 45 min. The resulting gDNA was used as a template for PCR for the 
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detection of specific CaSR products. Forward primer P4 5’- 
CCTCGAACATGAACAACTTAATTCGG-3’ and Reverse primer P3L 5’- 
CGAGTACAGGCTTTGATGC-3’. PCR followed the same PCR cycle method 
mentioned earlier, however, 4mM MgCl2 was used with an annealing temperature of 
55ºC. β-actin primers were also run on the same samples in a PCR reaction as positive 
controls. The same conditions were used, except an annealing temperature of 54ºC was 
used. Forward primer β-actin 5’- TCCTAGCACCATGAAGATC -‘3, and reverse 
primer β –actin 5’- AAACGCAGCTCAGTAACAG-3’. 
 
2.14 Cell viability detection of primary mouse VSMCs.  
VSMCs were plated at 2,000 cells per well in a 96-well plate and allowed to adhere for 
24 hours. After 24 hours, cells were quiesced by maintaining them in 1.2mM Ca2+o 
DMEM with 1% FBS. 48 hours after original plating, medium was switched to medium 
medium containing different concentrations of the CaSR agonists; (A) Ca2+o or (B) Ca2+o 
with R-568, both in standard DMEM with 10% FBS. In some cases, phosphate was also 
added at the final concentration of 1.4, 2.0 or 3.0mM to assess cell viability in 
mineralising conditions. When medium was added, this was considered day 0. Cells were 
incubated for 7 days in these medium at which point 0.5mg/mL Thiazolyl Blue 
Tetrazolium Bromide (MTT) was added for a further 2 hours. After 2 hours, media were 
removed and cells were washed gently in PBS. MTT crystals were then solubilised in 
50µL DMSO per well and plates were quantified for absorbance at 570nm on a 96-well 
plate reader (Optima). 
 
2.15 Cell-counting of primary mouse VSMCs.  
Primary mouse VSMCs were plated into 24-well plates at 15,000 cells per well. Cells 
were allowed to adhere for 24 hours in standard DMEM containing 1.2mM Ca2+o and 
10% FBS, then cells were qiesced by switching them into a medium containing medium 
1% FBS. After a further 24 hours, medium was switched to media containing 10% FBS 
in the presence of different concentrations of Ca2+o (1.2mM, 1.8mM and 2.5mM Ca2+o). 
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Ca2+o manipulations in the culture medium were achieved by the addition of suitable 
volumes of 1M CaCl2 stock solution (or equivalent volumes of water as the vehicle 
control). 
 
2.16 Apoptosis detection in primary mouse VSMCs by DNA fragmentation 
(TUNEL). 
WT and KO primary mouse VSMCs at passage 6 were trypsinised as described and 
plated on glass coverslips in 24-wel plates. 25,000 cells were plated per condition which 
was near confluent. This way proliferation would be kept to a minimum and would 
prevent interference of proliferation with apoptotic readout. Cells were allowed to adhere 
for 24h before placing in standard DMEM with 1.2mM Ca2+o, however containing just 
1% FBS. After a further 24h, medium was changed to contain either 1.2, 1.8 or 2.5mM 
Ca2+o in the presence of 1mM Pi or 3mM Pi. VSMCs were also either treated with 10nM 
R-568 or a 0.001% DMSO vehicle. VSMCs were left in medium for 48h before fixation 
in 4% PFA. After fixation, cells were washed three times in 1X PBS. To permeabilise 
VSMCs, 0.2% Triton-X in PBS-Tween (0.05%) was added for 30 minutes. Cells were 
washed three times in 1x PBS-Tween. Cells were then acclimatised to the TUNEL 
reaction buffer for 10 minutes. Buffer contained 25mM tris-HCl, 200mM sodium 
cacodylate, 0.25mg/dL BSA and 1mM cobalt chloride). After this time, 640U/reaction 
terminal transferase (TdT, Roche Diagnostics) and 180pM Biotin-16-dUTP (Roche 
Diagnostics). Negative reactions contained the same reaction mix, but no TdT enzyme. 
After 2 hours incubation of cells with the reaction mix at 37ºC, reactions were terminated 
using a stop solution containing 300mM NaCl and 30mM sodium citrate. Cells were then 
washed three times in PBS-Tween for 5 min. Labelling was then performed by adding 
1:500 FITC-Avidin (abcam) in PBS for 30 minutes. Cells were washed again with PBS-
Tween before staining nuclei with 1mg/mL Hoescht (diluted 1:10,000) in PBS-Tween 
and fixed in prolong gold mounting medium (Invitrogen). Slides were sent to Vienna for 
Martin Schepelmann to quantify dead nuclei by a TissueFAX automated fluorescence 
cell counting system. 
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2.17 Mineralisation of primary mouse VSMCs.  
VSMCs were plated at 40,000 cells per well in a 24-well plate in standard 1.2mM Ca2+o 
DMEM with 10% FBS, as previously described, and were allowed to reach confluency. 
When confluent, medium was removed and cells were washed with 1 X PBS. 
Mineralisation medium was then added, which contained 1.4mM, 2.0mM or 3.0mM 
inorganic phosphate (Stock 1M NaPi: 30.96mL 1M Na2HPO4 and 9.04mL 1M 
NaH2PO4.). Multiple conditions were set up where in addition to phosphate, medium also 
contained 1.2mM or 1.8mM in the presence or absence of the calcimimetic R-568 
(10nM), or 2.5mM Ca2+o. Ca2+o was manipulated by the addition of suitable volumes of 
a 1M CaCl2 stock solution. Cells were cultured for 10 days with medium changing taking 
place every 3-4 days. After 10 days incubation in the different experimental conditions, 
cells either underwent quantification of mineralisation (by alizarin red staining), 
immunostaining, or processed for RNA or protein isolation, as described previously.  
 
2.18 Quantification of mineralisation of primary mouse vascular smooth muscle 
cells (VSMCs) using the O-Cresolphthalein complexone Ca2+ method. 
VSMCs were cultured as described in mineralising conditions for 10 days in 24-well 
plates. After 10 days, cells were washed twice in 1 X PBS then decalcified at 37ºC for 3-
5 hours in 0.6N HCl (500µL/well). After wells were decalcified, HCl was removed and 
stored at -20ºC. The remaining cell monolayer in each well was solubilised in 1% SDS 
in 0.1M NaOH. Solubilised samples were quantified using a BCA assay quantification 
kit and protein content was expressed in µg/mL. For calcium quantification, HCl samples 
were thawed and 5µL of each sample was mixed with 100µL AMP Buffer and 100µL 
Colour reagent in a 96-well plate. Standards for Ca2+o quantification were prepared using 
7.5, 10.0, 12.5, 25.0 and 50.0mg/dL of CaCO3 and mixed in the same way as samples. 
Once buffer and colour reagent were added, samples were incubated at room temperature 
for 15 minutes. After this time, sample absorbance on a 96-well plate reader (Optima) at 
570nm wavelength was carried out. 
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For the purpose of analysing gene expression of VSMC and osteoblast markers in these 
mineralisation conditions, cDNA was prepared from osteoblasts and VSMCs and primer 
sets for smooth muscle cells, osteoblasts and chondrocytes were optimised for qPCR 
quantification of transdifferentiation. Due to time constraints, the only gene that was 
analysed for gene expression experiments in mineralising conditions was the master 
osteoblast transcription factor Runx2 (Chapter 6).  
 
2.19 RNA isolation from primary VSMCs.  
Cells were cultured for the purpose of experiments, I.e. for general RNA detection in 
confluent VSMC cultures, or for the detection of transdifferentiation at the transcriptional 
level in mineralised primary mouse VSMC cultures. When RNA was required at the end-
point of these experiments, cells were removed from incubators and medium was 
removed. Cells were washed twice briefly in 1X PBS and TRIzol® reagent was added. 
To each sample 1mL TRIzol® Reagent, 0.2mL chloroform was added and the solution 
was shaken vigorously for 15 seconds, then left at room temperature for 5 min. RNA was 
then centrifuged at 12,000g for 15 min at 4ºC. Following centrifugation, aqueous and 
phenol phases were separated and RNA was carefully removed from the upper clear 
supernatant phase. To this, 0.5mL propan-2-ol was added and RNA was left to precipitate 
for 1 hour at -80ºC. Samples were then centrifuged at 12,000g for 30 min at 4ºC. The 
supernatant was removed and RNA pellets were allowed to dry at 55ºC. RNA was then 
resuspended in 20µL RNase/DNase- free dH2O. 
 
2.20 DNase digestion of RNA.  
A recombinant DNase kit was used (Ambion) for DNase digestion. RNA previously 
prepared was quantified using a Nanodrop. DNase digestion was carried out by adding 
up to 10µg RNA to 5µL DNase I Buffer and 1µl DNase enzyme in a final volume of 
50µL with RNase/DNase- free dH2O. Reactions were incubated for 30 min at 37ºC. After 
this time, 50µL of Phenol:Chloroform:Isoamyl alcohol was then added to terminate the 
reaction. RNA was pelleted at 12,000g for 5 min at 4ºC. The upper aqueous supernatant 
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was transferred to a fresh eppendorf tube. 0.1 volumes of 3M sodium acetate (pH 5.2) 
were added with 3.0 volumes of 100 % ice cold EtOH. This was mixed and precipitated 
overnight at -20 ºC. The pellet was spun down the next day at 12,000g for 30 min at 4ºC. 
The supernatant was removed and the pellet was allowed to dry at 55ºC. This pellet was 
resuspended in 20 µL RNase/DNase- free H2O. 
 
2.21 cDNA synthesis of isolated RNA.  
DNase-digested RNA was quantified using a Nanodrop. RNA was converted to cDNA 
using a “cDNA Synthesis Kit” (Bioline). Up to 1µg of RNA was used for each reaction, 
however, when samples were grouped, (e.g. RNA samples from mineralised VSMCs in 
different conditions) the same maximal amount of RNA was used for each reaction. RNA 
was obtained by the TRIzol® method described and was DNase-digested to remove 
genomic DNA contaminants. Using the kit, up to 1µg RNA was mixed with 50ng random 
hexamers and 10mM dNTPs. Reactions were made up to 10µL in RNase/DNase- free 
H2O. RNA was incubated at 72ºC for 10 minutes. After incubation, the 10µL primed-
RNA samples were placed at 4ºC for 2 minutes. Then, to each reaction 10U Ribosafe 
RNase inhibitor, 4µL of 5X RT buffer and 50U reverse transcriptase enzyme was added. 
Negative control samples were also prepared where RNA was added but no reverse 
transcriptase enzyme was added to the reaction mix. Reactions were then placed at 42ºC 
for 30 min. Reactions were terminated at 85ºC for 5 min before storing at 4ºC. cDNA 
was stored at -20 ºC for long term storage or used immediately for PCR. 
 
2.22 Gel extraction of PCR amplicons for plasmid preparation.  
After PCR amplification and amplicon separation using gel electrophoresis, bands were 
visualised on an ultraviolet transilluminator and excised using a sharp scalpel. Gel 
fragments (<1g) were placed in 1.5mL Eppendorf tubes and amplicons were extracted 
using the QIAquick Gel Extraction Kit (Qiagen). Gel pieces were incubated with 3 
volumes per weight Buffer QG. The mixture was incubated at 50ºC for 10 min or until 
the gel had solubilised. To this mix, 1 volume of propan-2-ol was added and the solution 
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was loaded into a 2mL spin column. The reaction was spun at 12,000g for 1 min and the 
flow-through was discarded. The column was then washed with 0.75mL ethanol-
containing Buffer PE and also spun for 1 min. After discarding the flow-through the 
column was spun again to remove residual ethanol. 50µL of elution buffer was then 
applied to the column containing 10mM Tris-HCl pH8.5 and amplicons were collected 
by centrifuging for 1 min at 12,000g. Amplicons were stored at -20ºC long-term or used 
immediately for ligation in a pGEM-T plasmid vector. 
 
2.23 Preparation of qPCR recombinant plasmid standards using pGEM-T vector 
ligation. 
Previously purified DNA amplicons were used for vector ligation in a pGEM-T 
transformation kit (Promega). Ligation reactions were prepared by taking 1µL of PCR 
product, with 5µL 2 X Rapid Ligation Buffer, 1U T4 DNA Ligase, 1µL pGEM®-T 
vector, and 3U T4 DNA Ligase made up to 10µL in dH2O. Reactions were left for 1 hour 
at room temperature. After this time, JM109 E. coli competent cells were thawed on ice, 
then 50µL of cells were added to the ligation mix. These cells were heat-shocked at 42ºC 
for 45 seconds in a water bath, then returned to ice where the mix was made up to 1mL 
using 950µL SOC medium (Promega). Reactions were then placed in a shaking incubator 
at 37ºC for 90 min. The resulting transformed bacteria were then plated onto Luria-
Bertani (LB) plates with 100µg/mL ampicillin. LB plates also had 50µL 
100µM (isopropyl thiogalactoside) IPTG and 20µL 50mg/mL X-gal dried into the 
surface of them before bacteria were spread. This was to ensure that induction of the lacz 
operon could occur and that colour selection could also occur. Plates were incubated at 
37ºC overnight. Successfully cloned white colonies were selected and inoculated into LB 
broth with 100µg/mL ampicillin overnight. The resulting E. coli culture was used for 
plasmid mini-prep purification. 
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2.24 Plasmid mini-prep purification.  
Transformed plasmids from overnight cultures were pelleted at 4,000g for 5 min. The 
LB supernatant was removed and discarded in Virkon disinfectant solution. Using a 
Plasmid Mini Kit (Qiagen), the pellet of transformed cells was lysed and genetically 
modified plasmids were purified using the manufacturers’ instructions exactly. Plasmids 
were eluted in elution buffer containing 10mM Tris-HCl pH8.5 and were quantified using 
a Nanodrop. Plasmids were sent to Cardiff DNA Sequencing Core for DNA sequencing 
and only plasmids with 100% sequence homology to known cDNA sequences were used 
for further quantitative analysis. 
 
2.25 Confirmation of vector ligation and transfection into chemically competent E. 
coli cells using colony PCR for amplification. 
Previously optimised conditions for each primer set were used in a standard PCR reaction 
to confirm the presence of the specific amplicon in each plasmid. A 20µL pipette tip was 
dipped into the overnight transformed E. coli culture and placed into 10µ dH2O. The 
sample was boiled at 95ºC for 10 minutes. This was then used as a DNA template for 
amplification using the primer conditions in Table 5. 
 
2.26 Quantification of transcriptional regulation by qPCR.  
Control plasmids previously prepared had been quantified and the weights of 
recombinant plasmids were calculated using the following formula:  
 
(Number of base pairs of plasmid vector + Number of base pairs of insert)  
x (1.096 x 10-21) 
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From this equation, the number of grams of plasmid in each mini-prep stock was 
calculated. Serial dilutions (1:10) were prepared from a stock containing 1 x 109 plasmid 
copies per µL (from 1 x 108 - 1 x 101 copies per µL). The diluted plasmids were used in 
a qPCR reaction to generate a standard curve: 12.5µL SYBR Green Mix with no MgCl2 
(Sigma Aldrich), 50nM forward primer, 50nM reverse primer, 2µL 25mM MgCl2, 1µL 
plasmid, RNase/DNase- free dH2O to 25µL. Data were used for statistical analysis when 
the R2 efficiency of the plasmid standard curve for that primer set was >0.98. Primer sets 
to be used in qPCR amplification are listed in Table 5. 
 
 
Table 5. Primer sets for qPCR amplification of gene-specific products from RT-PCR. Amplicons are 
ligated into pGEM-T plasmid vectors. All primers were designed to span exon-exon junctions. Green= 
VSMC genes. Blue= Osteoblastic genes. Purple= Chondrogenic genes. Pink= Housekeeping genes. 
  
GENE FORWARD PRIMER (5’3’) REVERSE PRIMER (5’3’) SOURCE 
αSMA CAGGCATGGATGGCATCAATCAC ACTCTAGCTGTGAAGTCAGTGTCG (Lee and Kim, 2007) 
SM22α ACCAAGCCTTCTCTGCCTCAAC GCCACACTGCACTACAATCCAC (Lee and Kim, 2007) 
MGP TGCGCTGGCCGTGGCAACCCT CCTCTCTGTTGATCTCGTAGGCA (Boström et al., 2001) 
CaSR 4-5 GAGGCCTGGCAGGTCCTGAA TGATGGAGTAGTTCCCCACC Tom Davies 
CaSR 6-7 GTGGTGAGACAGATGCGAGT GCCAGGAACTCAATCTCCTT Tom Davies 
Osterix GATGACGGGTCAGGTAGAGTGAGCTG CTTGAGGTTTCACAGCTTCTGGCTGG (Nakano-Kurimoto et al., 2009) 
Runx2 GACGAGGCAAGAGTTTCACC GTCTGTGCCTTCTTGGTTCC Debbie Mason 
Osteoprotegrin GAGTGTGAGGAAGGGCGTTAC GCAAACTGTGTTTCGCTCTG Debbie Mason 
Osteocalcin CAGACAAGTCCCACACAGCA CTTGGCATCTGTGAGGTCAC Debbie Mason 
ALP GCTGGCCCTTGACCCCTCCA ATCCGGAGGGCCACCTCCAC Marisol Vazquez 
Collagen II-α1 GGCCTCGCGGTGAGCCATG GCCTCCTGGGCATCCTGGCC Tom Davies 
18S rRNA GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA Marisol Vazquez 
GAPDH GACGGCCGCATCTTCTTGTGCA TGCAAATGGCAGCCCTGGTGAC Marisol Vazquez 
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2.27 Statistical analysis. 
Statistical analyses were carried out using GraphPad Prism 5. Data are all expressed as 
the mean ± the standard error of mean (SEM). When data were normally distributed, 
comparisons between two sets of data were performed using a two-tailed t-test. When 
the comparisons were performed between the means of two or more samples, one way 
ANOVA was performed. Two way ANOVA was performed when there were more than 
one independent variable for analysis. Additionally, numerous repeats were conducted 
which allowed for the chance of a rare event to occur which would reject the null 
hypothesis. In this incidence Bonferroni’s post-test was used where stated, particularly 
in analyses with multiple conditions or more than one independent variables. 
Significance levels were assigned using the standard scientific nomenclature: P<0.05=*, 
P<0.01=** and P<0.001=***. 
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CHAPTER 3:  
IN VIVO CHARACTERISATION OF THE SM22α X fl 
CaSR MOUSE MODEL WITH SELECTIVE ABLATION 
OF CaSR IN VASCULAR SMOOTH MUSCLE CELLS 
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CHAPTER 3: GENERAL INTRODUCTION 
CaSR is an important GPCR involved in systemic [Ca2+]o homeostasis (Brown et al., 
1993). To ascertain the function of the VSMC-CaSR, our collaborators at UCSF (Chang 
et al., 2008) generated for us a new transgenic mouse model with selective ablation of 
the CaSR in VSMCs. To determine the role of the CaSR in the cardiovascular system, 
the first part of my studies involved an initial characterisation of the in vivo phenotype 
of these mice, specifically, of body weights, organ weights, bone densities and serum 
biochemistries.  
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CHAPTER 3: RESULTS 
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Figure 27. SM22α x fl CaSR mouse weights over time. Male and female mouse weights were taken at 
monthly intervals up to 6 months. 18 Months weights were also recorded for long-term characterisation of 
male mice. Female weights at 18 months were not tabulated as these mice were not kept for experiments. 
Mice were weighed on scales 5 times at each time point and average weights were calculated to correct for 
mouse movement. The number of animals used were as follows. 1 month: WT ♂N=49, ♀N=35; HET 
♂N=9, ♀N=4; KO ♂N=21, ♀N=21. 2 month: WT ♂N=37, ♀N=33; HET ♂N=10, ♀N=5; KO ♂N=21, 
♀N=19. 3 month: WT ♂N=65, ♀N=36; HET ♂N=17, ♀N=7; KO ♂N=27, ♀N=17. 4 month: WT ♂N=27, 
♀N=19; HET ♂N=7, ♀N=4; KO ♂N=21, ♀N=13. 5 month: WT ♂N=42, ♀N=25; HET ♂N=10, ♀N=7; 
KO ♂N=19, ♀N=15. 6 month: WT ♂N=25, ♀N=8; HET ♂N=6, ♀N=3; KO ♂N=8, ♀N=6. 18 month: 
WT ♂N=3; KO ♂N=3. Data are expressed as mean ± SEM. Statistical analysis: two-way ANOVA with 
Bonferroni’s post-test. P<0.01=**. 
A      Male SM22α x fl CaSR Mice 
B      Female SM22α x fl CaSR Mice 
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Figure 28. SM22α x fl CaSR wild-type, heterozygote and knockout mice are not observably 
different. Mouse bodies are not observably different in terms of external morphology in terms of colour, 
shape or size. All mice had comparative digit numbers with no apparent developmental abnormalities. 
They also showed equal signs of alertness, mobility, feeding and drinking habits. 
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SM22α x fl CaSR WT and KO mice have no observable phenotype and demonstrate 
normal body weights throughout their lifespan. 
To determine whether the VSMC-CaSR KO had more widespread effects on the body of 
SM22α x fl CaSR and to determine whether this had any significant effect on body 
weights, male and female mice were weighed at monthly intervals. Male mice were 
heavier than female mice at all intervals, however no significant difference in body 
weights or observable trends were seen between any genotypes except for female mice 
at 1 month of age. In this group, comparisons reveal that 1 month old female KO mice 
are significantly lighter compared to WT mice (Figure 27, P<0.01). 
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Figure 29. Male and female SM22α x fl CaSR mouse ratios in litters. Mouse litters were counted and 
the ratio of male:female mice was calculated. Data were tabulated from 48 different breedings between 
WTxWT, WTxKO, KOxKO mice. Litter number: N=48, mouse number: n=391. Data are expressed as 
mean ± SEM. Statistical analysis: unpaired two-tailed t-test. ns= not significant. 
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Figure 30. Genotype ratios in offspring from a WTxKO SM22α x fl CaSR mouse breeding. WT and 
KO mice were bred and offspring WT and KO ratios of each litter were calculated. Litter numbers for WT 
and KO was N=7. Data are expressed as mean ± SEM. Statistical analysis: one-way ANOVA. ns= not 
significant. 
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Figure 31. Genotype ratios in offspring from a KOxKO SM22α x fl CaSR mouse breeding. KO and 
KO mice were bred and offspring WT and KO ratios of each litter were calculated. Litter number: N=8. 
Data are expressed as mean ± SEM. Statistical analysis: one-way ANOVA. ns= not significant. 
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Figure 32. Litter sizes of SM22α x fl CaSR mouse breedings. Male and female mice were bred with 
partners of matching genotypes. From these breedings litter numbers were plotted to determine possible 
influence of the genotypes on litter size. Litter number: WT: N=7, HET: N=8, KO: N=9. Data are expressed 
as mean ± SEM. Statistical analysis: one-way ANOVA. ns= not significant. 
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Figure 33. Confirmation of targeted-deletion of VSMC-CaSR in SM22α x fl CaSR mice by PCR. 
Mouse ear biopsies were lysed overnight for the isolation of genomic DNA Upper panel: PCR 
amplification of the exogenous cre transgene (500bp) detected in heterozygote (HET) and knockout (KO) 
mouse tissue only. Lower panel: PCR amplification of a portion of CaSR (untranslated genomic DNA 
downstream of exon 7) shows the presence of small WT amplicon with no loxP site, and a larger loxP-
containing amplicon flanking exon 7 of CaSR. LoxP sites are present in wild-type, heterozygote and 
knockout mice. Heterozygotes show both WT and floxed amplicons. 
  
500bp ∆SM22α Cre 
167bp ∆CaSR allele 
133bp WT CaSR allele 
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SM22α x fl CaSR WT and KO mouse breeding show expected Mendelian 
inheritance for gender number of offspring. 
If no selective gender preference during development is present we would typically 
expect all pups born to be 50:50, male:female. This was shown to be the case with no 
significant differences overall. Data were 52.53% Males ± 2.35 vs. 47.47% Females ± 
2.35 (N=48 litters, n=391 mice, Figure 29). When WT and KO mice were bred, expected 
Mendelian inheritance would predict the ratio between WT and KO offspring to be 50:50. 
Indeed, this was found to be the case and all offspring followed this trend, with 54.10% 
± 2.41 WT vs. 45.90% ± 2.41 KO (Figure 30). However, in the case of KOxKO 
breedings, the expected Mendelian inheritance for the ratio of WT:KO should be 25:75. 
This was however rarely seen, and statistical analysis by one-way ANOVA revealed 
these genotypes to be no different from one another; 40.13% ± 2.60 vs. 59.87% ± 2.68 
(Figure 31). There was a very visible trend (albeit not significant) for KO mice to be 
more prevalent in these litters than WT mice. 
 
In addition to measuring the ratios of genotypes of all offsprings, it was also important 
to measure the litter sizes of breedings from parents of different genotypes. This way, we 
could observe whether CaSR-ablation in VSMCs affects embryonic development and/or 
uterine function. Analysis of litter sizes showed there to be no significant difference 
between pups from WTxWT, HETxHET and KOxKO. Average litter sizes were 8.57 ± 
0.48, 7.00 ± 0.41, 7.33 ± 0.24. These differences were not significantly different (Figure 
32). Of course, it was also important to confirm whether mice had CaSR knocked out in 
VSMCs. For this reason, biopsies of each mouse were obtained and DNA was digested 
for PCR amplification of either the cre transgene or floxed alleles. Figure 33 
demonstrates the effective detection of the cre transgene in HET and KO mice only. 
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Figure 34. SM22α x fl CaSR WT and KO mouse organ weights at 6 months of age. Mice were 
humanely culled by Schedule one in accordance with Home Office regulations. Organs were dissected, 
washed briefly in Krebs buffer (described in methods) then dried before weighing. (A) Heart, WT N=8, 
KO N=6; (B) Kidney, WT N=8, KO N=7; (C) Stomach, WT N=8, KO N=7; (D) Spleen, WT N=8, KO 
N=6; (E) Liver, WT N=8, KO N=7. Data are expressed as mean ± SEM. Statistical analysis: unpaired two-
tailed t-test ANOVA. ns= not significant.  
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Figure 35. SM22α x fl CaSR WT and KO mouse organ weights at 18 months of age. Mice were 
humanely culled by schedule 1 in accordance with Home Office regulations. Organs were dissected, 
washed briefly in Krebs buffer (descriebd in methods) then dried before weighing. (A) Heart, WT N=5, 
KO N=4; (B) Kidney, WT N=6, KO N=4; (C) Stomach, WT N=6, KO N=4; (D) Spleen, WT N=6, KO 
N=4; (E) Liver, WT N=6, KO N=4. Data are expressed as mean ± SEM. Statistical analysis: unpaired two-
tailed t-test. P<0.05. ns= not significant.  
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Ageing SM22α x fl CaSR KO mice have heavier hearts compared to WT mice. 
Hypertrophy of the heart is a key indicator of cardiovascular disease, kidney disease and 
vascular calcification (Nitta et al., 2004, Nitta, 2011). Therefore, we weighed mouse 
hearts to determine whether any hypertrophy or hyperplasia of heart tissue had occurred 
in SM22α x fl CaSR WT or KO mice over time. Data retrieved from wet weights of all 
organs at 6 months of age revealed no significant difference between the hearts of WT 
and KO mice, nor any of the other organs investigated (Figure 34). Wet weights of WT 
and KO mouse hearts at 18 months showed a significant increase in heart weight in KO 
mice compared to WT mice (P<0.05, Figure 35). Conversely, other organ weights were 
recorded and showed no significant differences in wet weight at 3 and 18 months of age.  
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Figure 36. Biochemical analysis of WT and KO SM22α x fl CaSR male mouse serum at 3 months of 
age. (A) Serum Na+ levels; 146.40mM ± 0.85 WT (N=11) vs. 147.30mM ± 1.11 KO (N=4). (B) Serum K+ 
levels; 9.88mM ± 0.38 WT (N=11) vs. 11.60mM ± 0.75 KO (N=6), P<0.05=*. (C) Serum Cl- levels; 
110.6mM ± 0.97 WT (N=11) vs. 111.50mM ± 3.23 KO (N=4). (D) Serum Ca2+ levels; 2.28mM ± 0.10 WT 
(N=11) vs. 3.05mM ± 0.27 KO (N=6), P<0.01=**. (E) Serum Mg2+ levels; 1.06mM ± 0.03 WT (N=11) 
vs. 1.14mM ± 0.09 KO (N=6). Data are expressed as mean ± SEM. Statistical analysis: unpaired two-tailed 
t-test. P<0.05=*. P<0.01=**. ns= not significant. 
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Figure 37. Biochemical analysis of WT and KO SM22α x fl CaSR male mouse serum at 18 months 
of age. (A) Serum Na+ levels; 149.00mM ± 2.08 WT (N=3) vs. 146.30mM ± 1.76 KO (N=3). (B) Serum 
K+ levels; 10.64mM ± 0.35 WT (N=3) vs. 11.88mM ± 1.45 KO (N=3). (C) Serum Cl- levels; 114.30mM 
± 0.67 WT (N=3) vs. 111.00mM ± 2.08 KO (N=3). (D) Serum Ca2+ levels; 2.34mM ± 0.08 WT (N=3) vs. 
2.99mM ± 0.20 KO (N=3), P<0.05=*. (E) Serum Mg2+ levels; 1.65mM ± 0.10 WT (N=3) vs. 2.04mM ± 
0.19 KO (N=3). Data are expressed as mean ± SEM. Statistical analysis: un-paired two-tailed t-test. 
P<0.05=*.. ns= not significant. 
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Figure 38. SM22α x fl CaSR KO male mice have increased FGF23 serum levels at the age of 3 months 
compared to WT mice. Mouse sera retrieved from WT and KO mice at 3 months of age were collected 
by centrifugation and quantified off-site at AstraZeneca with our collaborators João Graҫa and Dr. Sally 
Price. WT FGF23: 145.00pg/mL ± 10.99 (N=11). KO FGF23: 384.40pg/mL ± 83.49 (N=6). Data are 
expressed as mean ± SEM. Statistical analysis: unpaired two-tailed t-test. P<0.01=**. 
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Figure 39. SM22α x fl CaSR KO male mice have increased FGF23 serum levels at the age of 18 
months compared to WT mice. Mouse serum retrieved from WT and KO mice at 18 months of age were 
collected by centrifugation and quantified using an FGF23 kit. WT FGF23: 131.10pg/mL ± 26.27 (N=3). 
KO FGF23: 330.00pg/mL ± 28.68. Data expressed as mean ± SEM. Statistical analysis: un-paired two-
tailed t-test. (N=3). P<0.01=**.  
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SM22α x fl CaSR KO mice exhibit mild hypercalcaemia and elevated levels of 
FGF23 compared to WT mice. 
Biochemical analyses (performed by collaborators at AstraZeneca) revealed that KO 
mice exhibited hypercalcaemia at both age-points. At 3 months of age, WT mice have 
serum [Ca2+] of 2.28mM ± 0.10 compared with serum [Ca2+] levels of KO mice, which 
were 3.05mM ± 0.27 (Figure 36, P<0.01). This hypercalcemia in KO mice was 
maintained at 18 month, where serum [Ca2+] was 2.34mM ± 0.08 in WT mice compared 
with serum [Ca2+] of 2.99mM ± 0.20 in KO mice (Figure 37, P<0.05). Also observed was 
mild hyperkalemia in 3 month old mice 9.88mM ± 0.38 in WT compared with 11.61mM 
± 0.74 in KO mice (Figure 36, P<0.05). This however, was not apparent in 18 month old 
mice. 
 
Whether hypercalcaemia was modulated by components of the Ca2+o/Pi/Vitamin D/PTH 
axis also required investigation. FGF23 levels were shown to be significantly increased 
in KO mice compared with WT mice. In 3 month mice, WT serum concentrations were 
145.00pg/mL ± 10.99 vs. 384.40pg/mL ± 83.49 in KO mouse serum (Figure 38, P<0.01). 
These differences were also maintained in 18 month mice where WT serum FGF23 
concentrations were 131.10pg/mL ± 26.27 vs. 330.00pg/mL ± 28.68 (Figure 39, P<0.01). 
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Figure 40. µCT analysis of 3 month old SM22a x fl CaSR mice distal femurs reveals reduced 
trabecular bone in KO mice compared to WT mice. Distal femurs were scanned in 70% ethanol using 
a Scanco vivaCT system. Trabecular bone was calculated by removing hard bone mineral from 3D-
reconstructed images. (A) Trabecular bone length x Tissue volume. (B) Trabecular bone length x Bone 
volume. (C) Trabecular bone length x (Bone volume / Tissue volume). (D) Trabecular bone length / 
Trabecular bone thickness. (E) Trabecular bone length / Trabecular connectivity density. Abbreviations: 
Trabecular bone length (Tb); Tissue volume (TV); Bone volume (BV); Trabecular bone thickness (Th); 
Trabecular bone spacing (Sp); Trabecular connectivity density (CD) (N=7 WT, N=6 KO). Data are 
expressed as mean ± SEM. Statistical analysis: unpaired two-tailed t-test. P<0.05=*. ns= not significant. 
These experiments were performed by Dr. Wenhan Chang, UCSF. 
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Figure 41. µCT analysis of 3 month old SM22a x fl CaSR mice tibia-fibula junctions reveals reduced 
cortical bone in KO mice compared to WT mice. Distal femors were scanned in 70% ethanol using a 
Scanco vivaCT system. Cortical bone was calculated by removing hard bone mineral from 3D-
reconstructed images. (A) Cortical bone length x Tissue volume. (B) Cortical bone length x Bone volume. 
(C) Cortical bone length x (Bone volume / Tissue volume). (D) Cortical bone length x Cortical bone 
thickness. (E) Cortical bone length x Bone mineral density. Abbreviations: Cortical bone length (Ct); 
Tissue volume (TV); Bone volume (BV); Cortical bone thickness (Th); Bone mineral density (BMD) (N=7 
WT, N=6 KO). Data are expressed as mean ± SEM. Statistical analysis: unpaired, two-tailed t-test. 
P<0.05=*. ns= not significant. These experiments were performed by Dr. Wenhan Chang, UCSF. 
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SM22α x fl CaSR KO mice exhibit significant reductions in bone tissue compared 
with WT mice. 
Data show that SM22α x fl CaSR mice exhibit hypercalcaemia. To investigate whether 
the source of this Ca2+ was from the bone, µCT was performed in collaboration with Dr. 
Wenhan Chang to determine bone densities on the transgenic SM22α x fl CaSR mouse 
model. Three month old WT and KO mice were culled and both distal femurs and tibia-
fibula junctions were scanned using µCT. The results for the distal femur are illustrated 
in Figure 40. The Tb.TV was not significantly reduced in KO femurs compared to that 
of WT femurs from 2.08mm3 ± 0.09 (N=7) WT vs. 1.88mm3 ± 0.07 (N=6) KO. Tb.BV 
was significantly reduced in KO femurs compared to WT femurs; 0.32mm3 ± 0.02 (N=7) 
WT vs. 0.25mm3 ± 0.02 (N=6) KO, P<0.05. Tb.BV/TV was not significantly decreased 
in KO compared with WT; 0.16% ± 0.01 (N=7) WT vs. 0.130% ± 0.008 (N=6) KO. 
Tb/Th was not significantly different between WT and KO; 0.040mm ± 0.001 (N=7) WT 
vs. 0.040mm ± 0.001 (N=6) KO. In contrast, Tb/CD was significantly reduced in KO 
femurs compared to WT femurs; 1425.00g/cm3 ± 9.03 (N=7) WT vs. 1396.00g/cm3 ± 
7.29 (N=6) KO.  
 
The tibia-fibula junction bone density data are reported in Figure 41 and show some 
minor differences between WT and KO mice. Ct.TV was not different in WT mice 
compared with KO mice; 0.34mm3 ± 0.01 (N=7) WT vs. 0.38mm ± 0.02 (N=6) KO. 
Ct.BV was not different in WT mice compared with KO mice; 0.26mm3 ± 0.01 (N=7) 
WT vs. 0.250mm3 ± 0.01 (N=6) KO. Ct.BV/TV was not different in WT mice compared 
to KO mice; 0.67% ± 0.01 (N=7) WT vs. 0.66% ± 0.01 (N=6) KO. Ct/Th was also not 
different in WT mice compared with KO mice; 0.24mm ± 0.01 (N=7) WT vs. 0.23mm ± 
0.01 (N=6) KO. However, Ct.BMD (g/cm3) was significantly reduced in KO mice 
compared with WT mice; 1425.00g/cm3 ± 9.03 (N=7) WT vs. 1,396.00g/cm3 ± 7.29 
(N=6) KO, P<0.05. 
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CHAPTER 3: DISCUSSION 
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SM22α x fl CaSR ablation in VSMCs does not significantly affect genders of 
offspring in offspring or expected Mendelian inheritance. 
My experiments show that VSMC-CaSR knockout does not significantly affect the 
reproductive ability and survival rates of mice (Figure 27, 28). Data show that 
male:female ratios are not different from one another in all breedings (Figure 29). In 
addition to this, litter sizes between WT, HET and KO mice were shown to not be 
different (Figure 32). Mendelian inheritance of the cre recombinase and floxed alleles 
was also shown to not be affected in WT and KO matings (Figure 30). Analysis of 
WTxKO matings shows that the percentage WT and KO offspring are not significantly 
different from the expected inherited ratio. Conversely, KOxKO matings seem to differ 
from the expected Mendelian inheritance ratio (Figure 31). One would at least expect the 
ratios of WT to KO pups to be significantly different which was not seen. The fact that 
the WT:KO ratio was nearer 40%:60% than the expected 25%/75% suggests that there 
is some selectivity in WT pups over KO pups. However, the spread of the data was quite 
broad across the breedings tabulated. In some cases it was seen that 83.33% of offspring 
in KOxKO breedings were actually KO, while other times there were only as few as 
13.33%. The total number of KOxKO breedings used for this analysis was 8. Further 
breeding will increase the number of observations and conclusively determine Mendelian 
transmission for gender and offspring numbers. Whether there is some embryonic 
lethality or not has not yet been investigated. However, embryonic lethality might not be 
so surprising since during pregnancy, the cardiovascular system of the mother and child 
become intertwined for efficient delivery of nutrients and oxygen. A vascular phenotype 
would therefore affect embryonic development in utero. To clarify this, it would be both 
beneficial to carry out more breedings and also investigate embryonic lethality in the 
future. 
 
SM22α x fl CaSR ablation in VSMCs does not affect organ or body weights. 
Using the cre-lox system, we aimed to specifically knock out the CaSR in vascular 
smooth muscle cells. Although this deletion is shown to be specific to the cardiovascular 
system postnatally, according to the full characterisation by Li et al (Li et al., 1996b), it 
is possible that a cardiovascular phenotype resulting from this deletion could affect other 
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organs, particularly since blood vessels penetrate all organs for blood delivery. Indeed, 
if the blood delivery mechanism is altered, one could expect loss of functions or changes 
in size or morphology of organs. Gathering mouse weights over time and weighing 
organs has demonstrated that CaSR deletion from VSMC produces a phenotype. Despite 
there being no significant differences in body weight between WT, HET and KO mice, 
it was seen that body weights of just female mice at 1 month of age showed a significant 
reduction in body weight (in KO mice compared to WT mice, Figure 27). This finding 
suggests a possible developmental regulation by the VSMC-CaSR in female mice only. 
Further research is required into the embryonic development of these mice. Conversely, 
from 2 months onwards body weights are not different between any genotypes or sexes 
suggesting that, if any abnormalities were present early on in life, these are corrected or 
compensated for towards adulthood (Figure 27). At 3 months of age onwards, there were 
no differences between mouse body weights. Consistent with these findings, Martin 
Schepelmann in our research group has reported that mice of 3 months of age show that 
there is no significant difference in food and water consumption in KO mice compared 
to WT mice. In contrast, faecal excretion is significantly increased in KO mice compared 
with WT mice (p<0.05, data not shown). These data could reflect changes in water 
retention by the colon of KO animals, thereby mildly affecting body weights in young 
female mice. 
 
SM22α x fl CaSR ablation in VSMCs produces heavier hearts in ageing mice. 
My data show that VSMC-CaSR KO mouse hearts are heavier compared to VSMC-CaSR 
WT mouse hearts at 18 month of age (Figure 35). It is well-documented that one of the 
major manifestations of cardiovascular disease is left ventricular hypertrophy (Davies 
and Hruska, 2001, Nitta, 2011). During vessel calcification, VSMCs become rigid and 
lose the characteristic elastic phenotype. Consequently, systolic blood pressure is 
elevated and systemic blood-flow around the body is impeded. This can lead to cardiac 
remodelling to compensate for this deleterious state (Brunet et al., 2011, London, 2011). 
From in vitro and in vivo studies where CaSR has shown to have a protective role against 
calcification in healthy blood vessels (Alam et al., 2008), we would hypothesize that 
CaSR ablation in KO mice plays a role in early calcification of arteries. One can assume 
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that, if the vessels were to mineralise in a similar manner to what is observed during heart 
disease, expected outcomes such as increased blood pressure and hypertrophy may also 
develop. It is therefore likely that heavier hearts may be an indicator of cardiac 
remodelling and hypertrophy of the left ventricle. This observation is particularly 
interesting for two reasons; (i) pressure and force exerted by cardiac myocytes in the left 
ventricle must be significant enough to pump all blood leaving the heart around the whole 
body, in stark contrast to the right ventricle which delivers blood more locally to the 
pulmonary system (Stewart et al., 2012); (ii) these data suggest that the VSMC-CaSR 
might play a role in the regulation of blood vessel tone and/or vascular calcification. If 
the left ventricle does indeed remodel to a hypertrophic state later in life, one might 
speculate that we will also detect differences in blood pressure in VSMC-CaSR KO 
animals compared to VSMC CaSR-WT animals. However, to further elucidate a role of 
the VSMC-CaSR in blood pressure modulation and cardiac remodelling further studies 
need to be conducted. Specifically, blood pressure measurement of young and ageing 
mice should be performed in addition to magnetic resonance imaging (MRI) to confirm 
ejection fractions from the left ventricle. 
 
SM22α x fl CaSR mice exhibit hypercalcaemia, reduced bone integrity and elevated 
serum FGF23 levels. 
Cardiovascular complications occur with poor diet, ageing, abnormal Ca2+o homeostasis 
and genetic predisposition (Lloyd-Jones et al., 2008, Lloyd-Jones et al., 2009, Lloyd-
Jones et al., 2010b, Roger et al., 2011, Roger et al., 2012). During advanced CKD, 
secondary hyperparathyroidism can occur which is often the leading cause of 
hypercalcaemia (Moe, 2004). It has been well-documented that CaSR knockout in the 
parathyroid gland causes hypercalcaemia (Chang et al., 2008). During CaSR-ablation in 
the parathyroid gland, PTH suppression through CaSR activation does not occur, 
resulting in overall hypercalcaemia by hyperparathyroidism (Chang et al., 2008). The 
∆SM22α cre mouse model shows expression in VSMC through development and post-
natally (Li et al., 1996b), therefore, in our mouse model we should only achieve CaSR-
KO in VSMCs, however, one should not assume that there is no leakage of this promoter. 
Hyprcalcaemia we observe in VSMC-CaSR KO mice should be a consequence of the 
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vascular phenotype itself and not related to the parathyroid glands. It should be noted that 
Chang et al have reported reductions in CaSR expression in other tissues in the PTG-
CaSR knockout. This is possibly due to hypercalcaemia downregulating CaSR 
expression in these organs (Chang et al., 2008) which has also been shown in vitro in 
primary bovine VSMCs (Alam et al., 2008). Furthermore, the parathyroid-specific cre-
lox CaSR knockout developed by Dr. Chang and colleagues shows marked reductions in 
osteoblast CaSR expression. These unexpected findings suggest that there may be more 
complicated signalling mechanisms at work and that PTG-CaSR activation may 
somehow be linked to the regulation of CaSR at both the mRNA and protein level in 
more unrelated tissues and cell types (Chang et al., 2008). Importantly, this should be 
considered in regard to the SM22α x fl CaSR mouse model where similar alterations in 
expression of other CaSRs in other tissues may also occur. 
 
Another important finding in these studies was that KO mice have significantly reduced 
bone mineral density. Figure 40 shows that the distal femurs of KO mice have lower 
trabecular bone volume, thickness and spacing. When considering that KO mice have 
hypercalcaemia this is perhaps not so unexpected, and one could suggest that the 
observed elevated [Ca2+] levels could be a consequence of Ca2+ resorption from bone. It 
is also interesting to note that trabecular bone is highly vascularised, and so the VSMC-
CaSR may play a crucial role in the co-ordination of Ca2+ deposition from the blood to 
bones and vice versa (Chang et al., 2008). For example, the VSMC-CaSR may play a 
role in mediating Ca2+ resorption from bone in areas rich in vascularised bone. In this 
instance it is not surprising that FGF23 levels are also elevated (Figures 38 and 39) since 
Pi is liberated during this bone resorption. Considering the presence of high [Ca2+], 
FGF23 and low bone density, it seems most likely that hypercalcaemia of KO mice is 
derived from bone demineralisation. Alternatively or in addition, CaSR ablation from 
VSMC could also lead to an impaired renal function, with decreases in 1,25(OH)2D3 
synthesis associated with hypercalcaemia. This latter hypothesis will need to be tested in 
greater detail by measuring 1,25(OH)2D3 levels and characterising the renal phenotype 
of the SM22α x fl CaSR mouse. 
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It has been reported that CaSR is linked to Ca2+ exchangers and transporters including 
the Na+/Ca2+ exchanger and plasma membrane Ca2+ ATPase (PMCA) (Blankenship et 
al., 2001, Ba and Friedman, 2004). Studies have demonstrated that, in kidney cells, CaSR 
activation by agonists causes a reduction in the influx of Ca2+o into the cell (Blankenship 
et al., 2001, Kip and Strehler, 2003). It may therefore be possible that in the absence of 
a CaSR, this signalling does not occur or this process is disturbed. At the VSMC level, 
this would be crucial if the CaSR is indeed, as previous studies have shown, protective 
against vascular calcification (Alam et al., 2008). It may be the case that CaSR exerts its 
effects locally on Ca2+-channels expressed in VSMCs. Voltage-gated Ca2+-channels and 
Ca2+-activated channels play a significant role in the transport of Ca2+ in and out of the 
cell. It has recently been shown that CaSR, which is expressed in human VSMCs, 
mediates increases in cytosolic Ca2+ when Ca2+o is applied in extracellular solutions in a 
concentration-dependent manner (Chow et al., 2011). The same group showed that when 
a dominant-negative CaSR was transfected into these VSMCs, Ca2+ entry and increases 
in cytosolic Ca2+ were significantly reduced. Furthermore, the use of PLC inhibitors in 
WT VSMCs simulated this effect (Chow et al., 2011). If this is also true in our SM22α x 
fl CaSR mouse model, it may be likely that KO VSMCs have less Ca2+i or a reduced 
uptake of Ca2+o from extracellular environments in response to CaSR ablation when 
compared to WT VSMCs. In this instance, it could be speculated that KO VSMCs would 
have less contractile tone compared to WT VSMCs which will be investigated in Chapter 
4 and Chapter 5.  
  
Consequences of hyperkalaemia in SM22α x fl CaSR KO mice. 
Additionally observed in KO mice at 3 months of age was slight hyperkalaemia 
compared to WT mice. Although this was not seen in older mice, it may be an indication 
that renal function is disturbed in younger mice. Often, increases in serum K+ indicate 
kidney dysfunction, possibly due to an alteration in the renin-angiotensin-aldosterone 
system (RAAS). Typically, renin promotes the conversion of angiotensinogen from the 
liver to angiotensin I. Angiotensin I then undergoes a conversion by angiotensin 
converting enzyme (ACE) to angiotensin II. Ultimately angiotensin II has effects on 
increasing K+ excretion and water retention. Additionally, aldosterone secreted by the 
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adrenal glands in response to angiotensin II promotes these actions. Problems with renin 
and angiotensin activation would cause such increases in K+ retention (Schmieder et al., 
2007, Sevá Pessôa et al., 2012). Indeed, if K+ is elevated, this would suggest that 
aldosterone is either downregulated or dysfunctional. To confirm whether this is true and 
if RAAS is dysfunctional, renin, ACE and aldosterone levels should be investigated in 
the future. 
 
The role of the VSMC-CaSR on FGF23 secretion. 
In addition to hypercalcaemia, FGF23 was significantly and consistently upregulated at 
3 and 18 months of age. In order to understand how FGF23 can affect cardiovascular 
physiology, one must consider its role in the bone-parathyroid-kidney axis. FGF23 is 
typically produced by osteocytes and osteoblasts in response to high Pi or in the presence 
of 1,25(OH)2D3 where it enters the circulatory system (Bergwitz and Jüppner, 2010). In 
terms of parathyroid interactions, the co-receptor of FGF23, Klotho, has been shown to 
be localised in the parathyroid where it binds FGF23 (Iddo et al., 2007). FGF23 acts 
directly on the parathyroid gland to decrease PTH secretion through the inhibition of 
PTH mRNA, having downstream consequences of reducing serum Ca2+o, 1,25(OH)2D3 
and increasing Pi excretion (Iddo et al., 2007). In regards to the SM22α x fl CaSR mouse 
model this seems somewhat contradictory since both Ca2+ and FGF23 levels are 
synchronously and inappropriately elevated. Since Ca2+o is up- or down-regulated in 
response to many regulating factors including Pi, PTH, FGF23 and 1,25(OH)2D3, it is 
clear that one mechanism in this system dominates such that hypercalcaemia and high 
FGF23 levels can both be present and sustained. This once again suggests a possibility 
of high serum Pi possibly resorbed from bone, or retained in the kidney. It is possible 
that Pi may be the driver of both FGF23 secretion and hypercalcaemia by driving PTH 
secretion from the PTG. It was also shown that KO mice of 18 months of age have 
significantly heavier hearts compared to WT mice. FGF23 has been shown to promote 
left ventricular hypertrophy and cardiac remodelling in CKD patients (Gutiérrez et al., 
2009). If there is indeed a kidney phenotype in KO mice, this could also explain heavier 
hearts as a consequence of elevated FGF23 levels through adulthood. These possible 
hypotheses will be addressed in Chapter 7. 
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CHAPTER 3: CONCLUSION 
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In vivo phenotypic characterisation of the SM22a x fl CaSR mouse model. 
Together my observations thus far include:  
 
VASCULAR CALCIFICATION FEATURE 
 
SM22α X fl CaSR 
Hypercalcaemia (>2.5mM) √ 
Elevated FGF23 levels (>200pg/mL) √ 
Increased heart mass √ 
High Ca2+ / High FGF23 together √ 
 
Table 6. The relevance of the SM22α x fl CaSR mouse as a model of vascular calcification. Key 
features of vascular calcification are listed in the left column. Ticks indicate the presence of the abnormality 
detected in the in vivo analysis. Further research remains to fully elucidate the effectiveness of this model 
and confirmation of CaSR playing a role in VC, CKD and blood pressure modulation. 
 
These observations point towards a role for CaSR in vascular physiology, maintenance 
of vascular tone and modulation of vascular calcification. These will be tested in the 
following experiments in Chapters 4-6. 
 
It is clear that the SM22α x fl CaSR meets a significant proportion of the criteria essential 
for the development of vascular calcification. Although more extensive research remains 
to be conducted, it appears from this initial in vivo study that the VSMC-CaSR does play 
a significant role in the development, or events leading to vascular calcification.  
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CHAPTER 3: FUTURE WORK 
Future work required to ascertain the role of the VSMC-CaSR in this in vivo system 
would be to analyse serum PTH, Pi and 1,25(OH)2D3. Additionally, it would be 
beneficial to look for ectopic mineralisation in isolated blood vessels using specific 
mineral stains such as alizarin red. However, our collaborators have looked for 
calcification in KO mice at the age of 12 months and saw no calcification by µCT (data 
not shown). It is therefore likely that (i) µCT is not a sensitive enough method to detect 
small calcifications in blood vessels, or (ii) there is an upregulation of protective factors 
in response to VSMC-CaSR ablation preventing ectopic calcification. These issues can 
be addressed by analysing mouse serum for protective factors such as MGP and fetuin-
A. Finally, since blood pressure is often a key indicator of altered cardiovascular 
function, it would make sense to analyse this in WT and KO mice. Tail cuff apparatus 
should be used to determine any differences between WT and KO blood pressures. In 
addition to this, myogenic tone should be investigated in both WT and KO mouse 
arteries. This will be performed in Chapter 4. 
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CHAPTER 4:  
EX-VIVO CHARACTERISATION OF THE SM22α X fl 
CaSR MOUSE MODEL: MODULATION OF TONE IN 
RESPONSE TO VASOCONSTRICTORS AND 
VASORELAXANTS 
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CHAPTER 4: GENERAL INTRODUCTION 
To further characterise the effects of CaSR ablation in vascular smooth muscle cells, ex 
vivo myography experiments were performed. This approach offers a unique 
experimental advantage of observing the effects and consequences of this gene knockout 
on vascular tone modulation. In this chapter, the effects of vasoconstrictors and 
vasorelaxants in isolated aortae and mesenteric arteries will be investigated. Blood 
vessels from both WT and KO mice will be assessed for their contractile responses to 
these vasoconstrictors and vasorelaxants. Wire myography (See Methods: 2.9 Wire 
myography on acutely isolated mouse aortae and mesenteric arteries) will be used to 
determine relaxation but not dilation since the apparatus does not measure this. 
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CHAPTER 4: RESULTS 
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Figure 42. CaSR ablation in mouse VSMCs decreases the luminal diameter of thoracic descending 
aortae and mesenteric arteries. WT and KO mouse aortic rings and mesenteric artery rings were obtained 
from 5-6 month old animals. Vessels were pre-warmed to 37ºC in Krebs buffer containing 1.0mM Ca2+o 
as described in methods and mounted onto a wire myograph with either 40µm or 25µm diameter steel wire 
or gold wire (for aortae and mesenteric arteries respectively). Aortic rings were stretched by 100µm every 
30 seconds, and mesenteric arteries by 20µm until a plateau was reached. For vessel acclimatisation to the 
myograph and buffer, the internal diameter of the vessel was set to a resting tension equivalent to that 
generated at 0.9 times the diameter of the vessel which was 40 mmHg for mesenteric arteries and 100 
mmHg for aortae. This initial normalisation was performed in all myography experiments hereafter. 
Tension was recorded in milliNewtons (mN) and diameters were calculated using “Basic Normalisation” 
software (DMT, Danmark). (A) Luminal diameters of WT and KO aortae. (B) Luminal diameters of WT 
and KO mesenteric arteries. (C) Circumferences of WT and KO aortae. (D) Circumferences of WT and 
KO mesenteric arteries. Data expressed as average ± SEM. Statistical analysis: unpaired two-tailed t-test. 
P<0.05=*. P<0.01=**.  
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KO SM22α x fl CaSR mice have narrower aortae and mesenteric arteries compared 
to WT SM22α x fl CaSR mice. 
In order to assess whether the VSMC-CaSR plays a role in vascular wall thickness, I used 
normalisation software provided by DMT for the analysis of luminal diameters and 
circumferences of rodent arteries. This software includes LaPlace’s equation for the 
normalisation of tension in blood vessels. The assumption of this equation is that the 
tension (T) of the wall of the blood vessel is directly proportional to its radius (r) and 
pressure (p). This tension can be calculated as follows: 
T (kg/s2) = p (kPa) x r (mm) 
In order to use LaPlace’s equation to calculate the tension and diameter in a specific 
blood vessel, the micrometer dial is twisted to stretch wires apart by defined amounts. 
Using the wire myography mounted with, e.g. an aortic segment, I achieved the 
normalised internal circumference. This is the circumference one would expect to 
achieve in the resting vessel tension in the body. In the mouse, this is at 100mmHg and 
40mmHg in aortae and mesenteric arteries respectively. Using LaPlace’s equation, which 
plots tension and vessel radius, I defined this normalised internal circumference (IC100) as 
the point at which the experimental data from the vessel ring meet with this on LaPlace’s 
line. This value is taken as the resting vessel radius or circumference, and from this one can 
record vessel diameters or circumferences in WT and KO blood vessels. This can be 
demonstrated below: 
 
 
 
 
 
 
Junction (IC100) =  
Actual vessel radius 
Experimental data points from 
vessel 
LaPlace’s equation assumptions of 
equilibrium at a given pressure 
(100mmHg or 40mmHg; aorta and 
mesenteric artery) 
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One should note that since this is not a closed in vivo circulatory system and only a small 
ring segment, this needs to be considered in the mathematics. For this reason, it is 
suggested that the internal circumference is set at 0.9 times the circumference one would 
expect under this pressure in vivo. Furthermore, since the tension required for each vessel 
is different, LaPlace’s linear line will vary accordingly and is calculated using the 
following equation: 
Tension (“X” mmHg) = “X” x (

) 
For the aorta, this would be “40 x (

)” using the experimental data to generate the linear 
line to which the IC100 is calculated. Using this initial normalisation, one can calculate 
the normalised internal circumference specifically for each vessel ring, however for all 
experiments resting tension for the aorta was provided at 4mN and 2mN for mesenteric 
arteries since this is widely regarded as acceptable. Although the normalisation process 
was carried out, this was specifically to calculate the dimensions of the vessels and to 
elude any differences between WT and KO blood vessels. 
 
In all experiments it was found that body organ weights and vessel diameters in male and 
females were not significantly different (data not shown), so male and female mouse data 
were pooled per genotype. Aortae and mesenteric vessels from mice were stretched 
~100µm or ~20µm respectively every 30 seconds or when needed to reach the plateau. 
After each stretch, vessel tone was allowed to plateau and values of tension were 
tabulated against the distance the wires were apart. These values were entered into the 
DMT software where LaPlace’s equation generated a graph as shown on the previous 
page for each ring segment. This procedure generated internal diameters and 
circumferences for all rings used. All aortic rings were considered for analysis, however, 
due to the selection process involved in dissecting mesenteric arteries and the inherent 
variance in vessel size and number in the gut, only mesenteric arteries of 2nd and 3rd order 
(between 100 and 200µm diameter) were considered and were selected for statistical 
analysis. For the aorta, diameters were 1025.00µm ± 12.72 (WT; N=8) vs. 955.00µm ± 
10.51 (KO; N=6), while the average circumferential diameters were calculated by 
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multiplying these values by π. These were 3219.00µm ± 39.96 (WT; N=8) vs. 3000.00µm 
± 33.02 (KO; N=6). Both parameters were significantly different at P<0.01 (Figure 42). 
For mesenteric arteries diameter (between 100-200µm) were 182.50µm ± 4.20 (WT; 
N=8) vs. 163.10µm ± 5.03 (KO; N=5) with circumferential diameters of 573.20µm ± 
13.20 (WT; N=8) vs. 512.50µM ± 15.79 (KO; N=5). Both parameters were significant at 
P<0.05. 
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Figure 43. Selective CaSR ablation from mouse VSMCs decreases the vascular tone of mouse aortae 
in response to phenylephrine but not in the presence of L-NAME. WT and KO mouse aortic rings from 
5-6 month old mice were mounted onto a wire myography as described in methods. Once vessels were 
manually stretched to 4mN, phenylephrine was applied to the bath in the myography chamber. 
Concentrations used ranged from 1 x 10-8M to 3 x 10-6M. After each application, vessel tone was allowed 
to stabilise by leaving tone to plateau before applying the next concentration. Experiments were either 
conducted in the absence (A) or presence (B) of 100µM of the eNOS inhibitor L-NAME. (A): N=5 WT 
(EC50= 1.82 x 10-7M); N=5 KO (EC50= 1.98 x 10-7M). (B) N=4 WT L-NAME (EC50= 9.56 x 10-8M); N=5 
KO L-NAME (EC50= 9.32 x 10-8M. Sigmoidal lines of best fit are applied to data and data are expressed 
as mean ± SEM. Statistical analysis: two-way ANOVA. P<0.05=*. ns= not significant. 
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Figure 44. Selective CaSR ablation from mouse VSMCs does not affect concentration-response 
sensitivity to phenylephrine in mouse aortae in the presence or absence of L-NAME. Data presented 
are from aortic rings from the previous figure and have been normalised to the maximum concentration of 
phenylephrine used 3 x 10-6M (3µM). For each vessel, the highest tone achieved was considered 100% 
with an application of 3 x 10-6M phenylephrine. All lower concentrations of phenylephrine are expressed 
as percentages of this total maximum value from the starting point of 4mN (0%). Experiments were either 
conducted in the absence (A) or presence (B) of 100µM L-NAME. (A): N=6 WT (EC50= 2.01 x 10-7M); 
N=5 KO (EC50= 1.71 x 10-7M). (B) N=5 WT L-NAME (EC50= 9.24 x 10-8M); N=5 KO L-NAME (EC50= 
9.61 x 10-8M). Sigmoidal lines of best fit are applied to data and data are expressed as mean ± SEM. 
Statistical analysis: two-way ANOVA. ns= not significant. 
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Figure 45. Selective CaSR ablation from mouse VSMCs does not affect phenylephrine concentration-
responses in mesenteric arteries. WT and KO mouse mesenteric arteries from 5-6 month old mice were 
mounted onto a wire myograph as described in methods. Once vessels were manually pre-constricted to a 
force of 2mN, phenylephrine (PhE) was then applied: (A) in a concentration-dependent manner from 1 x 
10-9M to 3 x 10-5M. For each vessel, the highest tone achieved was considered 100% with an application 
of 3 x 10-5M (30µM) phenylephrine. All lower concentrations of phenylephrine are expressed as 
percentages of this total maximum value from the starting point of 2mN (0%). (A): N=8 WT (EC50= 2.07 
x 10-6M); N=7 KO (EC50= 2.60 x 10-6M). (B): N=8 WT (EC50= 2.03 x 10-6M); N=7 KO (EC50= 2.39 x 10-
6M). Sigmoidal lines of best fit are applied to data and data are expressed as mean ± SEM. Statistical 
analysis: two-way ANOVA. ns= not significant. 
A 
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Figure 46. Selective CaSR ablation from mouse VSMCs significantly reduces KCl-induced 
vasoconstriction in the aorta in the absence, but not the presence of L-NAME. WT and KO mouse 
aortic rings from 5-6 month old mice were mounted onto a wire myograph as described in methods. Once 
vessels were manually normalised to 4mN, 40mM KCl was applied for 3 minutes until tone reached 
plateau. Tone from the 4mN starting point was calculated. (A) KCl-induced constriction in WT and KO 
aortic rings. (B) KCl-induced constriction in WT and KO aortic rings in the presence of 100µM L-NAME. 
(A): N=8 WT; N=5 KO. (B): N=5 WT L-NAME; N=6 KO L-NAME. Data are expressed as mean ± SEM. 
Statistical analysis: unpaired two-tailed t-test. P<0.001=***. ns= not significant. 
 
A 
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Figure 47. Selective CaSR ablation from mouse VSMCs does not reduce KCl-induced 
vasoconstriction in mesenteric arteries. WT and KO mouse mesenteric arteries from 5-6 month old mice 
were mounted onto a wire myograph as described in methods. Once vessels were manually pre-constricted 
to a force of 2mN, 40mM KCl was applied for 3 minutes until tone reached plateau. Differential tone from 
the 2mN starting point (0mN) was calculated. N=8 WT; N=5 KO. Data are expressed as mean ± SEM. 
Statistical analysis: unpaired two-tailed t-test. ns= not significant. 
  
 Page 165 
 
KO SM22α x fl CaSR mouse aortae have less contractile tone in response to 
phenylephrine and KCl when compared to WT SM22α x fl CaSR mouse aortae. 
To determine whether a cardiovascular phenotype was present in KO mice, I assessed 
contractility of both WT and KO aortae and mesenteric arteries in response to 
vasoconstrictors phenylephrine and KCl. For the aorta, rings were manually stretched in 
Krebs buffer with 1.0mM Ca2+o, tensioned to 4mN and allowed to plateau. Typically, 2 
aortic rings were used in every experiment per animal per condition. This meant that for 
an experiment with N=5 there were n=10 separate aortic rings. Data from all aortic rings 
from one mouse were averaged to get a representation of the whole aorta. However, in 
experiments using L-NAME, only one aortic ring was used per animal. 
 
In mouse aortae, there was an observable trend for KO aortic rings to contract less than 
WT aortic rings in the presence of both phenylephrine and KCl (Figure 43 and 46). 
Phenylephrine was applied at concentrations ranging from 1 x 10-8M to 3 x 10-6M with 
each concentration added approximately every 2 minutes when the vascular tone reached 
plateau. Only in the presence of 1 x 10-6M and 3 x 10-6M phenylephrine were these 
differences significant (P<0.05; Figure 43A). These were: (i) for 1 x 10-6M phenylephrine 
5.05mN ± 0.57 (WT: N=5) vs. 3.20mN ± 0.38 (KO: N=5); (ii) for 3 x 10-6M 
phenylephrine 5.76mN ± 0.61 (WT: N=5) vs. 3.94mN ± 0.48 (KO: N=5). These 
differences were not observed in the presence of L-NAME where both WT and KO aortic 
rings reached maximum tension at 7.14mN ± 0.51 (WT: N=4) vs. 6.74mN ± 0.53 (KO: 
N=5; not significant; Figure 43B). Data from these experiments were also normalised to 
determine whether WT and KO aortae were responding differently to these 
vasoconstrictors. Tone between the 4mN baseline and tone achieved from the maximal 
3µM phenylephrine concentration represented a range of 0-100% contraction 
respectively. Tone achieved by each concentration of phenylephrine in both WT and KO 
aortic rings was therefore a % value within this range. In this way, it was shown that 
although KO aortae had reduced contractile tone, both WT and KO aortae responded to 
phenylephrine the same way (Figure 44), suggesting that the number of α1-adrenergic 
receptors and their signal transduction machinery downstream of receptor activation was 
not affected by CaSR ablation from VSMCs. 
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In addition to the receptor-dependent vasoconstrictor phenylephrine, KCl was applied to 
determine any differences in vascular tone in WT and KO aortae through cell 
depolarisation through ion channels. As previously shown, phenylephrine was less 
effective at contracting KO aortic rings, with less contraction compared to WT aortic 
rings. In these experiments, it also was shown that KCl contracted KO aortic rings less 
than WT aortic rings. In the absence of L-NAME, maximal tone from 40mM KCl was 
3.20mN ± 0.10 (WT: N=8) vs. 2.44mN ± 0.14 (KO: N=5), which was significant 
(P<0.001, Figure 46). In the presence of L-NAME this was not significantly different. In 
the presence of L-NAME, tone achieved by 40mM KCl addition was 3.28mN ± 0.35 
(WT: N=5) vs. 2.98mN ± 0.30 (KO: N=6, Figure 46). 
 
There is no significant difference in the contractile tone between WT and KO 
SM22α x fl CaSR mouse mesenteric arteries in response to phenylephrine or KCl. 
Mesenteric arteries from WT and KO mice were also assessed for differences in 
phenylephrine and KCl responses. The same protocol was carried out for this experiment, 
except mesenteric arteries were manually tensioned to 2mN (vs. 4mN in the aorta). 
Concentration response curves to phenylephrine ranging from 1 x 10-9M 3 x 10-5M were 
performed in the presence of 1.0mM Ca2+o. At a maximal concentration of 3 x 10-5M 
phenylephrine, tone achieved was 7.70mN ± 0.22 (WT: N=8) vs. 7.46mN ± 0.29 (KO: 
N=7) which was not significant (Figure 45). Similarly, when assessing the normalised % 
tone achieved for each concentration of phenylephrine compared to the maximum 
concentration of 30µM, there were no significant differences in these responses between 
WT and KO mesenteric arteries (Figure 45). Additionally, 40mM KCl did not evoke any 
significant differences between contractile tone in WT and KO mesenteric arteries. For 
40mM KCl addition, vascular tone in mesenteric arteries was 1.78mN ± 0.23 (WT: N=8) 
vs. 1.78mN ± 0.50 (KO: N=5, Figure 47). 
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Figure 48. Selective CaSR ablation from mouse VSMCs does not significantly affect acetylcholine-
induced relaxation in mouse aortae, but may reduce contraction in the presence of L-NAME. WT 
and KO mouse aortic rings from 5-6 month old mice were mounted onto a wire myograph as described in 
methods. Once vessels were manually tensioned to 4mN, 70% of the maximum tone was applied. In all 
cases, this was 300nM phenylephrine and once the tone had reached plateau, a concentration response of 
acetylcholine was performed of concentrations 1 x 10-9M to 3 x 10-5M. Percentage relaxation to 
acetylcholine of the phenylephrine pre-constricted aortic rings was calculated. (A): N=5 WT (EC50= 6.93 
x 10-8M); N=5 KO (EC50= 5.55 x 10-7M). (B): N=4 WT L-NAME (EC50= 7.41 x 10-7M); N=5 L-NAME 
(EC50= 5.72 x 10-7M). Trends in the absence of L-NAME were not significant (A), however, trends in the 
presence of L-NAME were significant (B; P<0.001). Sigmoidal lines of best fit are applied to data and data 
are expressed as mean ± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s post-test. 
P<0.05=*, ns= not significant. 
A 
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Acetylcholine is equally effective at relaxing both WT and KO SM22α x fl CaSR 
mouse aortae. 
In order to assess changes in tone of the aorta in response to vasorlaxants and to determine 
whether any pathological conditions such as vessel stiffening or CaSR-knockout could 
interfere with tone, acetylcholine concentration-response curves were carried out on WT 
and KO aortic rings. To assess the role of vasorelaxants, acetylcholine was used for these 
experiments. Aortic rings were mounted in a wire myograph in the presence of 1.0mM 
Ca2+o as described, manually stretched to reach passive tension of 4mN before applying 
phenylephrine to obtain ~70% of the maximal vascular tone. This was determined 
previously by the phenylephrine concentration response curve, in all cases the 
concentration of phenylephrine required to achieve 70% of tone was 300nM. After the 
tone had stabilised and reached a plateau, an acetylcholine concentration-response was 
carried out as described using concentrations of the drug (1 x 10-9M – 3 x 10-6M). For 
aortic rings in the absence of L-NAME, there was no significant difference between WT 
and KO at any concentration (P>0.05). There was, however, a difference between the 
EC50 values of WT (6.93 x 10-8M) and KO (5.55 x 10-7M) aortic rings. It was also 
observed that, after a concentration of approximately 3 x 10-7M acetylcholine, which has 
often been shown to contract vessels (Lüscher and Vanhoutte, 1986, Vanhoutte et al., 
2005), KO aortic rings appeared to contract more than WT aortic rings. It was however 
interesting to see that the maximal percentage relaxation achieved on average in both WT 
and KO aortic rings were very similar. This was seen at the concentration of 3 x 10-7M 
acetylcholine with 63.39% ± 10.01 (WT; N=5) vs. 64.29% ± 11.81 (KO; N=5). These 
values were not significantly different to one another (Figure 48). 
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Acetylcholine is more effective at contracting WT aortae in the presence of L-
NAME than KO aortae from SM22α x fl CaSR mice. 
The eNOS inhibitor L-NAME was used (100µM; Figure 48B) to determine whether 
nitric oxide signalling was altered in the relaxation or contraction of WT and KO aortae. 
L-NAME suppressed acetylcholine-induced relaxation and evoked contraction at 
concentrations greater than 1 x 10-7M in both WT and KO aortae. It was seen that only 
in the presence of 100nM acetylcholine were differences in tone different between WT 
and KO aortae: 1 x 10-7M was -17.44% (contracted) ± 4.02 (WT: N=4) compared with 
10.90% (relaxed) ± 12.82 (KO: N=5). However, a two-way ANOVA of the WT and KO 
curves shows that there is a significant trend for WT aortae to contract more in the 
presence of L-NAME compared to KO aortae (P<0.001), indicating once again that KO 
aortae have reduced contractile tone. This trend was shown when the two-way ANOVA 
compared WT vs. KO aortae at all concentrations of acetylcholine tested. Contraction 
achieved by maximum concentrations of acetylcholine (3 x 10-5M) was not significantly 
different. Percentage tone achieved at 3 x 10-5M acetylcholine was: -56.56% (contracted) 
± 5.451 (WT; N=4) vs. -31.93% (contracted) ± 6.44 (KO; N=5; Figure 48B). 
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Figure 49. Selective CaSR ablation from mouse VSMCs significantly delays the acetylcholine-
induced relaxation in mesenteric arteries. WT and KO mouse mesenteric arteries from 5-6 month old 
mice were mounted onto a wire myograph as described in methods. Once vessels were manually tensioned 
to 2mN, 70% of the maximum tone was applied. In all cases, this was 3µM phenylephrine. Once the tone 
had reached plateau, a concentration response of acetylcholine was performed (1 x 10-9M to 3 x 10-5M). 
Percentage relaxation from the phenylephrine pre-constricted aortic rings was calculated. (A): N=7 WT 
(EC50= 7.50 x 10-8M); N=5 KO (EC50= 5.65 x 10-7M). Sigmoidal lines of best fit are applied to data and 
data are expressed as mean ± SEM. Statistical analysis: two-way ANOVA. P<0.001=***. ns= not 
significant. 
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Mesenteric arteries in KO SM22α x fl CaSR mice exhibit an impaired response to 
acetylcholine compared to WT SM22α x fl CaSR mesenteric arteries. 
Mesenteric arteries were pre-contracted with 300nM phenylephrine (to achieve ~70% 
tone) before an acetylcholine concentration response was performed in the same way as 
aortic rings. Once tone had stabilised, vessels were exposed to an acetylcholine 
concentration response with concentrations ranging from 1 x 10-9M – 3 x 10-5M. 
Interestingly, significant differences were seen at the concentrations of 1 x 10-7M and 3 
x 10-7M acetylcholine, where KO mesenteric arteries relax less than WT arteries. 
Relaxation at these concentrations were: 57.20% ± 9.40 (WT: N=7) vs. 16.60% ± 5.90 
(KO: N=5) at 1 x 10-7M and; 77.5% ± 7.70 (WT: N=7) vs. 36.10% ± 10.50 (KO: N=5) 
at 3 x 10-7M. For both of these concentrations, differences were significant using a two-
way ANOVA test (P<0.001; Figure 49). Despite these differences, when the maximum 
concentration of 3 x 10-5M acetylcholine was applied, both WT and KO mesenteric 
arteries reached the same amount of maximum relaxation compared to the initial 2mN 
tone. These values at 3 x 10-5M were: 91.20% ± 3.50 (WT: N=7) vs. 87.90% ± 3.40 (KO: 
N=5). Due to time constraints, the role of L-NAME on acetylcholine-induced relaxation 
in mesenteric arteries was not investigated. 
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CHAPTER 4: DISCUSSION 
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VSMC-CaSR ablation in SM22α x fl CaSR mice reduces blood vessel size in mice of 
6 months. 
CaSR ablation from VSMCs resulted in a reduction in the luminal diameter and 
circumference of aortae and mesenteric arteries (Figure 42). These data suggest that the 
VSMC-CaSR may play an important role in VSMC proliferation, vasculogenesis and 
vascular tone modulation. One can presume that differences observed in both conducting 
and resistant vessels could come from increases in VSMC numbers within the vascular 
wall, possibly brought about by increases in proliferation. Tunica media thickening by 
VSMC proliferation may cause minor occlusion of arteries. In fact, several studies have 
shown that specific activation of CaSR by calcimimetics is associated with a reduction 
in VSMC proliferation (Wada et al., 1997b, Smajilovic et al., 2006). If CaSR activation 
is associated with a reduction in VSMC proliferation, this would suggest that in the 
absence of a CaSR, VSMCs may proliferate at greater rates, unhindered by CaSR. If this 
is indeed the case, this hypothesis can be tested by isolating WT and KO VSMCs and 
determining proliferation rates in vitro (investigated in Chapter 6). Indeed, it has been 
well-documented that VSMC proliferation is associated with vascular disease where 
vascular damage, atherosclerosis, calcification and transdifferentiation can increase 
proliferation rates (Simionescu et al., 2005). However, more importantly in context of 
the CaSR, other investigators have shown that the VSMC-CaSR is a critical modulator 
of proliferation, where activation by CaSR agonists can increase proliferation 
(Molostvov et al., 2008). To investigate whether VMSC populations are greater in KO 
compared to WT mouse arteries further studies are required to determine their ability to 
proliferate in vitro, and to measure the media thickness of blood vessels in both WT and 
KO age-matched animals. 
 
VSMC-CaSR ablation in SM22α x fl CaSR mice reduces contractile tone in the 
aorta but not in the mesenteric arteries. 
Reduced vessel diameters seen in vessels from KO animals may be responsible for the 
reduced contractile force. It was shown in KO aortae that there was less contractile force 
in response to phenylephrine and KCl, only in the presence of NO (Figure 43, Figure 46). 
If the VSMC population of the tunica media is significantly different between WT and 
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KO animals, then this will presumably affect the contractile responses of these cells. 
Additionally, this may correlate with fewer features associated with normal vessel 
contraction. For example, a reduction in the total cell number would suggest less total 
myosin and α1-adrenergic receptors for phenylephrine-induced contraction of the whole 
VSMC population in the tunica media. For this reason, it would perhaps not be so 
surprising that contractility was reduced significantly in KO mouse aortae. Contrary to 
this, L-NAME treated WT and KO vessels had the potential to contract to the same 
capacity in response to phenylephrine (Figure 43B). This would suggest that a factor may 
be at work which inhibits the full contraction in the absence of L-NAME. For this reason, 
one could speculate that KO vessels have increased NO activity, and so the relative 
VSMC number or potential differences in media thickness may not be such major 
contributors to reductions in vessel contractility. To test this hypothesis, future work is 
required to measure the transcriptional regulation of eNOS in KO mice, in addition to 
NO activity within vessels. 
 
It is also important to remember that KO mice exhibit hypercalcaemia (Figure 36D, 
Figure 37D). Hypercalcaemia in patients with inactivating mutations of CaSR is often 
associated with hypertension (Frank-Raue et al., 2011). Conversely, it is also reported 
that increases in dietary intake of Ca2+ induce a hypotensive effect in both humans and 
animals (Allender et al., 1996, Buassi, 1998). However, since our SM22α x fl CaSR 
mouse is not a full inactivating mutant and has localised receptor ablation within the 
VSMCs, it is difficult to determine whether this hypercalcaemia evokes hyper- or 
hypotensive effects in these mice without having carried out blood pressure 
measurements. However, from the data in-hand, the reduced contractile tone in KO 
vessels would suggest a hypotensive phenotype of our KO animals.  
 
In the experimental setup, the buffer that vessels were immersed in contained 1.0mM 
Ca2+o. Since we know from in vivo serum analysis that KO mice have hypercalcaemia, it 
would be interesting and informative to try and match the Ca2+o concentrations observed 
in vivo in the ex vivo setup. i.e. keep the base-line Ca2+o concentration for WT and KO 
vessels the same as observed in vivo. The fact that hypercalcaemia is present in KO mice 
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and that KO vessels contract less is somewhat more difficult to interpret. It is possible 
that elevated total serum [Ca2+] in KO mice promotes the NO pathway in endothelial 
cells leading to decreased contraction. Importantly, CaSR-KO VSMCs are acclimatised 
in vivo to higher total [Ca2+] (~3.0mM Ca2+; Figure 36D, Figure 37D). It is crucial to note 
that this 3.0mM [Ca2+] represents both free ionized and bound Ca2+. Free ionized Ca2+ 
should be half this value (~1.5mM). If this is true, placing them in the presence of 1.0mM 
Ca2+o in the experimental buffer would presumably impair the base-line contractile 
response observed in vivo. It would be beneficial to quantify the precise free-ionized Ca2+ 
concentration in WT vs. KO mice. It may also be the case that VSMCs in KO mice have 
adapted and remodelled significantly in response to life-long CaSR ablation in these cells 
in combination with hypercalcaemia.  
 
Interestingly, significant reductions in tone were not observed in KO mesenteric arteries 
with phenylephrine (Figure 45) or KCl (Figure 47), even when KO mesenteric vessels 
were, overall, narrower than WT mesenteric vessels (P<0.05). Mesenteric arteries are 
much smaller and narrower than the aorta, and so contain less VSMCs in the tunica media 
(Miller et al., 1987, Wagenseil and Mecham, 2009, Wagenseil et al., 2009, Wagenseil et 
al., 2010). For this reason, the EC:VSMC ratio is different to that of the aorta, although 
it should be noted that in both the aorta and mesenteric arteries there is one luminal 
monolayer of endothelial cells. Therefore, it may not be so surprising that differences 
observed in the WT and KO aorta were not also observed in mesenteric arteries. 
Additionally, it should be noted that both ECs and VSMCs express a CaSR which may 
play different and contrasting roles to one another (Weston, 2005, Alam et al., 2008). 
Since there were no significant differences in contractile tone between WT and KO 
mesenteric arteries, it is plausible that the VSMC-CaSR plays a minimal role in tone 
modulation of resistance arteries which may or may not be detectable using wire 
myography. For this reason, we may need to measure such responses in these blood 
vessels using a different and more sensitive setup, possibly by employing 
electrophysiological techniques. By using such a setup, one could measure 
electrochemical currents in WT and KO VSMCs in response to vasoconstrictors, 
vasorelaxants and CaSR agonists. 
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VSMC-CaSR ablation in SM22α x fl CaSR mice does not significantly affect 
acetylcholine-induced relaxation but reduces contraction in the presence of L-
NAME. 
In WT and KO aortic rings exposed to an acetylcholine concentration-response in the 
absence of L-NAME, there was no significant difference (Figure 48A). This could be 
due to the relatively small numbers of animals. According to the power calculation, the 
sample size should be between 8 and 10 to indicate significance at P<0.05. Despite this, 
the EC50 values were different from one another (WT 6.93 x 10-8M vs. KO 5.55 x 10-7M) 
suggesting that acetylcholine is more potent in KO aortic rings. If this is indeed true, this 
would suggest that KO aortae may have greater NO activity in response to lower 
concentrations of acetylcholine. In the presence of L-NAME there was a significant 
difference in contractile ability between WT and KO aortae exposed to an acetylcholine 
concentration-response (P<0.001). Once again, less contractile tone was observed in the 
KO compared to WT aortae. Since this was seen in the presence of L-NAME, these 
differences should not be attributed to NO activity. It is therefore likely that there is either 
an upregulation of EDHFs in the aorta to prevent contraction, or that the decreased 
luminal diameter of KO aortae affects the contractile effects of acetylcholine in this way. 
It is also entirely possible that other endothelium-dependent dilation and relaxation 
pathways are different in KO arteries. 
 
VSMC-CaSR ablation in SM22α x fl CaSR mice reduces the relaxation response of 
mesenteric arteries. 
KO mesenteric arteries were shown to have a delayed concentration-dependent 
relaxation in response to acetylcholine when compared to WT mesenteric arteries. This 
meant that the cumulative response curve to acetylcholine was shifted to the right in KO 
arteries compared with WT arteries. Figure 49 shows that acetylcholine-induced 
relaxation in WT vessels started at approximately 3 x 10-9M, while in KO vessels this 
started later at concentrations of 3 x 10-8M. This result would suggest that acetylcholine 
is not as effective at producing a response in KO arteries compared to WT arteries. This 
may be due to a number of reasons. Firstly, acetylcholine binds to M3 GPCRs present on 
the endothelium. Since responses were shifted approximately 10-fold (EC50 values: 7.50 
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x 10-7M WT vs. 5.65 x 10-7M KO) stated, it may be that M3 receptors present in the 
endothelium of KO vessels are downregulated, therefore, relaxation following M3 
receptor binding is less effective when compared to WT vessels. Conversely, upregulated 
M3 receptors may enhance the sensitivity of ECs to acetylcholine. Acetylcholine is 
associated with efflux of K+ through SKCa and IKCa channels and it has been speculated 
that local K+ clouds which form in myoendothelial environments can inhibit K+-induced 
hyperpolarization and dilation of VSMCs by numerous groups (Busse et al., 2002, 
Edwards and Weston, 2004). It has also been reported that NO, which plays a significant 
role in endothelium-dependent dilation and relaxation in larger vessels such as the aorta, 
plays less of a role in mesenteric arteries. These studies have shown that although NO is 
effective at inducing hyperpolarization in mesenteric arteries, this does not always result 
in relaxation (Garland and McPherson, 1992, Bolz et al., 1999, Buus et al., 2000). In 
relation to the previous hypothesis of NO upregulation in the aorta, is seems plausible 
that this may also be the case in mesenteric arteries, however, here it is not able to relax 
vessels as effectively. 
 
Another important observation in these studies was that KO mesenteric arteries had a 
significantly narrower lumen compared to WT mesenteric arteries. This may also play 
an important role in inhibiting the relaxation response in numerous ways: (i) less 
endothelial cells due to a reduced luminal area that line these narrower vessels are present 
to respond to acetylcholine; (ii) vessel narrowing might be ascribed to thickening of the 
tunica media or a less developed tunica media; (iii) endothelium-dependent 
hyperpolarisation factor release may be suppressed in the mesenteric arteries from KO 
mice; and (iv) acetylcholine-dependent relaxation is partially impaired in KO mesenteric 
arteries. Each of these potential mechanisms would presumably alter the ability of 
VSMCs to co-ordinate vasocontractile or relaxation responses from adjacent ECs in 
mesenteric arteries.  
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The VSMC-CaSR plays a significant role in the modulation of vascular tone in 
response to pharmacological agonists ex vivo. 
Basic physiological responses from vasoconstrictors and vasorelaxants are very different 
across WT and KO aortae and mesenteric arteries. My results clearly demonstrate the 
important role of the VSMC-CaSR in vessel tone regulation as previous investigators 
have suggested (Ohanian et al., 2005, Rybczyńska et al., 2005, Weston, 2005, Smajilovic 
et al., 2006, Smajilovic et al., 2007). We have seen that, under the conditions tested, KO 
vessels generally exhibit less contractile tone, likely due to an increased basal level of 
NO compared to WT vessels. It is unclear whether this is the case in vivo and whether 
this may play a role in cardiovascular defects such as vascular calcification, 
atherosclerosis, or transdifferentiation of native VSMCs. The data suggest that the 
VSMC-CaSR is important in maintaining contractile response. When this is lost, 
contractile responses are reduced. My results suggest that VSMC-CaSR KO may reduce 
blood pressure, however, this remains to be investigated. If reductions in blood pressure 
are observed in vivo, it may be possible that the hypercalcaemia observed in KO mice 
contributes to this by promoting endothelium-dependent relaxation, or by switching the 
phenotypes of VSMCs to a less-contractile state.  
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CHAPTER 4: FUTURE WORK 
My studies have shown that activation of adrenergic and muscarinic receptors in the 
VSMCs by their appropriate agonists has yielded different results when comparing WT 
and KO arteries. It would therefore be beneficial to test mRNA expression and protein 
levels of such receptors, in addition to other Ca2+-channels such as CaV 1.2 which is 
highly expressed in VSMCs (Mangoni et al., 2003, Rhee et al., 2009). Additionally, 
eNOS expression and NO activity should be measured to confirm whether NO activity 
is significantly altered in KO vessels compared with WT vessels. Such experiments 
would be required in both aortae and mesenteric arteries in the presence and absence of 
L-NAME. If the observed hypotensive effects are true in vivo, this should be tested by 
carrying out blood pressure measurements on mice. 
 
Also mentioned were the possible effects of differential baseline [Ca2+]o used in 
myography experiments. If, indeed, the vasculature has acclimatised somehow to a 
hypercalcaemic environment in vivo then it is possible that numerous Ca2+-related genes 
and proteins have been accordingly disturbed. Since WT VSMCs in vivo will be 
acclimatised to a total [Ca2+] of ~2.3mM (Figure 36D), and KO VSMCs in vivo will be 
acclimatised to a total [Ca2+] of ~3.0mM (Figure 36D), this hypercalcaemia seen in the 
KO would effectively act as the in vivo physiological base-line. After determining the 
[Ca2+]o in vivo in both WT and KO mice, experiments should be repeated using these 
respective in vivo [Ca2+]o as a baseline before application of contracting and dilatory and 
relaxation agents. 
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CHAPTER 5:  
EX-VIVO CHARACTERISATION OF THE SM22α X fl 
CaSR MOUSE MODEL: MODULATION OF TONE 
USING CaSR AGONISTS 
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CHAPTER 5: GENERAL INTRODUCTION 
In order to determine the role of the CaSR in the modulation of vascular tone, it was 
crucial to conduct experiments where agonists of the receptor were used and to test the 
possibility that they might evoke differential responses in aortae and mesenteric arteries 
from WT and KO mice. In this chapter, the role of agonists of CaSR including Ca2+o, 
spermine and the calcimimetic R-568, will be investigated in the aorta and mesenteric 
artery using the ex vivo wire myography protocol. This way, consequences of activation 
at either the EC-CaSR or VSMC-CaSR can be determined in terms of vessel tone. In the 
aorta, the role of the VSMC-CaSR will also be investigated by excluding responses to 
NO using L-NAME.  
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CHAPTER 5: RESULTS 
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Figure 50. Selective CaSR ablation from mouse VSMCs reduces Ca2+o-induced vasoconstriction in 
the aorta. Mouse aortic rings were isolated as described and maintained in 1.0mM Ca2+o Krebs buffer. WT 
and KO aortic rings were incubated in the presence of 1.0mM Ca2+o or 1.5mM Ca2+o for 20 minutes before 
applying 300nM phenylephrine- which had previously been determined as the concentration required to 
achieve ~70% tone from a phenylephrine concentration response curve (Figure 43). Once tone had 
stabilised, differential tension was recorded for each vessel in the absence (A) or presence of L-NAME 
(100 µM) (A). WT N=4; KO N=4. (B) WT L-NAME N=3; KO L-NAME N=4. Data are expressed as mean 
± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s post-test, P<0.01=**. ns= not significant. 
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Effects of Ca2+o on the modulation of phenylephrine-induced contraction. 
It has previously been suggested that the CaSR might play a role in the modulation of 
vascular tone (Weston, 2005, Rybczynska et al., 2006, Smajilovic et al., 2006, Smajilovic 
and Tfelt-Hansen, 2008), In this set of experiments, the effects of [Ca2+]o on the ability 
of aortae and mesenteric arteries from WT and KO animals to contact or relax was 
determined. For this purpose, 1.0mM Ca2+o (low activation of CaSR) and 1.5mM Ca2+o 
(high activation of CaSR) were used. Aortic rings were pre-incubated for 20 minutes with 
Krebs buffer containing either 1.0mM Ca2+o or 1.5mM Ca2+o then contracted using 
300nM phenylephrine. After vessel tone had reached plateau (after approximately 3 
minutes), the tension values before and after phenylephrine addition were recorded. For 
aortae in the absence of L–NAME, tension values were: 4.71mN ± 0.61 WT (N=4) vs. 
2.39mN ± 0.42 KO (N=4, 1.0mM Ca2+o) and; 5.07mN ± 1.02 WT (N=4) vs. 2.64mN ± 
0.57 KO (N=4, 1.5mM Ca2+o). In the presence of L-NAME tension values were: 6.57mN 
± 0.32 WT (N=3) vs. 5.90mN ± 1.14 KO (N=4, 1.0mM Ca2+o) and; 8.87mN ± 1.03 WT 
(N=3) vs. 5.65mN ± 1.28 KO (N=4, 1.5mM Ca2+o). Although direct 1.0:1.5 mM Ca2+o 
comparisons in the absence of L-NAME were not significantly different, the ANOVA 
revealed that there was a significance difference (P<0.01) for WT:KO comparison for 
both Ca2+o concentrations, confirming observations in the previous chapter where WT 
aortic rings contract significantly more than KO aortic rings. Interestingly, in the 
presence of L-NAME a different set of observations was made. Firstly, it was 
consistently seen that all vessel rings contracted more with 100µM L-NAME (also seen 
in previous studies with phenylephrine concentration response curves) and secondly, 
although not significant, WT aortic rings contracted more in the presence of 1.5mM Ca2+o 
compared to 1.0mM Ca2+o. This trend was not observed in KO aortic rings.  
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Figure 51. Selective CaSR ablation from mouse VSMCs prevents non-cumulative Ca2+o-induced 
vasocontraction. Aortic rings were isolated as previously described and incubated in Krebs buffer 
containing 1.0mM Ca2+o. Vessels were pre-constricted using 300nM phenylephrine to achieve 70% of 
maximum tone. After tone had reached a plateau, this point was considered the “0%” base-line. Ca2+o was 
then added to the solution to achieve concentrations of 1.5, 2.0, 3.0 and 5.0mM Ca2+o. After each addition, 
the response of the aortic rings was registered for 3 minutes. Time controls were also run in parallel where 
vessels did not have Ca2+o added with vehicle controls. These values were subtracted from each Ca2+o-
supplemented well to remove normal tone drift responses. Once data had been recorded, wells were 
carefully washed with buffer and allowed to return to normal tone. Phenylephrine was applied freshly each 
time to perform a non-cumulative concentration response curve. (A) Ca2+o non-cumulative concentration 
response curve in the absence of L-NAME. (B) Ca2+o non-cumulative concentration response curve in the 
presence of 100µM L-NAME. (A) WT N=5 (EC50= 3.53mM); KO N=5 (EC50= 2.74mM). (B) WT L-
NAME N=5 (EC50= 3.75mM); KO L-NAME N=5 (EC50= 3.41mM). Sigmoidal lines of best fit are applied 
to data and data are expressed as mean ± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s 
post-test. P<0.05=*. P<0.001=***. ns= not significant.  
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Ca2+o induces vasoconstriction followed by vasorelaxation in aortic rings from WT 
mice, but only vasorelaxation in aortic rings from KO mice. 
In order to investigate the role of Ca2+o (the principal agonist of CaSR) on vascular tone, 
Ca2+o concentration-response experiments were conducted. Two protocols were 
followed. Firstly, non-cumulative Ca2+o concentration response curves to ascertain the 
significance of immediate application of a set concentration of Ca2+o (Figure 51), and 
secondly; cumulative Ca2+o concentration response experiments were carried out to 
determine the role of gradual Ca2+o application over time. Ca2+o is known to play different 
roles in tone modulation. It has been demonstrated that Ca2+o induces vasoconstriction 
(Bohr, 1963, Crystal et al., 1998, Wonneberger et al., 2000) while others have reported 
it to induce relaxation (Bukoski et al., 1997, Weston, 2005, Smajilovic et al., 2006). In 
numerous studies, Ca2+o is applied to vessels including the aorta where it induces 
relaxation, and it has since become widely accepted that Ca2+o can induce endothelium-
dependent relaxation of VSMCs (Bukoski et al., 1997, Weston, 2005, Smajilovic et al., 
2006). However, some controversy remains as to the exact role of Ca2+o in the 
cardiovascular system and its role in vascular tone. 
 
Importantly, in these studies I used concentrations of Ca2+o within the range of CaSR 
activation, and therefore within the sensitivity range of the CaSR (1.0-5.0mM Ca2+o). The 
purpose of these experiments was to unmask the role of the VSMC-CaSR in this process, 
determining any differences in conductance vs. resistance arteries. My observations show 
that in WT vessels, both Ca2+-dependent contraction (negative values) and Ca2+-
dependent relaxation (positive values) were observed. In KO aortae, it appeared though 
only relaxation occurred, although on some occasions KO aortae contracted very slightly 
(~5%) in the presence of 1.5mM Ca2+o while relaxing at all concentrations thereafter. In 
Figure 51, KO aortic ring responses from the 0% base-line were as follows: 1.5mM Ca2+o: 
-8.33% ± 2.60 WT (N=5) vs. 0.63% ± 5.00 KO (N=5); 2.0mM Ca2+o: -12.87% ± 2.38 
WT (N=5) vs. 5.25% ± 6.94 KO (N=5); 3.0mM Ca2+o: -1.16% ± 9.53 (N=5) vs. 22.9% ± 
9.17 KO (N=5) (P<0.05); 5.0mM Ca2+o: 30.72% ± 2.89 WT (N=5) vs. 36.49% ± 7.59 
KO (N=4) (Figure 51A). These data suggest a biphasic response to Ca2+o in aortae from 
WT mice and a monophasic (relaxation only) response to Ca2+o in aortae from KO mice. 
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Ca2+o induces mild contraction and relaxation in aortic rings from KO mice in the 
presence of L-NAME, but only contraction in aortic rings from WT mice in the 
presence of L-NAME. 
In contrast to the previous observations, treatment with L-NAME had quite opposite 
effects on aortae of both WT and KO mice. In WT aortae, the biphasic response was lost, 
and vessels only contracted in response to all concentrations of Ca2+o (1.5-5.0mM Ca2+o) 
with less contraction in the presence of 5.0mM Ca2+o. In KO aortae, small initial 
contractions were seen at 1.5 and 2.0mM Ca2+o. This was then followed by relaxation in 
all Ca2+o concentrations used thereafter. Therefore in the presence of L-NAME, KO 
aortae exhibited a biphasic response compared with the somewhat monophasic 
(contractile only) responses in WT aortae. For aortic rings in the presence of L-NAME, 
responses were as follows: 1.5mM Ca2+o -14.42% ± 2.15 WT (N=5) vs. -9.92% ± 5.54 
KO (N=5); 2.0mM Ca2+o -19.55% ± 1.52 WT (N=5) vs. -3.69% ± 9.27 KO (N=5); 3.0mM 
Ca2+o -21.17% ± 3.90 WT (N=5) vs. 8.72% ± 13.98 KO (N=5); 5.0mM Ca2+o -8.99% ± 
5.16 WT (N=5) vs. 40.24% ± 14.37 KO (N=4, P<0.001, Figure 51B).  
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Figure 52. Effect of CaSR ablation on tone modulation by cumulative Ca2+o concentrations in aortae 
and mesenteric arteries. Aortic rings (A) and mesenteric arteries (B) were isolated as previously 
described and maintained in 1.0mM Ca2+o Krebs buffer. Experiments were carried out using the same 
concentrations of Ca2+o as in non-cumulative concentration response experiments in Figure 51, however, 
Ca2+o was instead applied cumulatively. Ca2+o was applied for ~3 minutes at each concentration before 
achieving a plateau and then applying the next concentration. (A) Cumulative Ca2+o concentration response 
curve in the aorta. (B) Cumulative Ca2+o concentration response curve in mesenteric arteries. (A) WT N=8 
(EC50= 3.84mM); KO N=5 (EC50= 2.90mM). (B) WT N=8 (EC50= 1.52mM); KO N=5 (EC50= 1.92mM). 
Sigmoidal lines of best fit are applied to data and data are expressed as mean ± SEM. Statistical analysis: 
two-way ANOVA with Bonferroni’s post-test. P<0.001=*** (WT vs. KO Interaction). ns = not significant. 
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CaSR ablation in mouse VSMCs does not affect Ca2+o-induced relaxation 
significantly in mesenteric arteries, but may play a role in aortic vascular tone. 
In a similar manner to aortic rings exposed to non-cumulative Ca2+o application (Figure 
51), cumulative Ca2+o application caused monophasic relaxation only in KO aortic rings 
(Figure 52). This finding was consistently observed at all concentrations tested (1.0-
6.0mM Ca2+o). Thus, both data collected performing non-cumulative (Figure 51) and 
cumulative (Figure 52) Ca2+o concentration response curves were comparable. 
Additionally, consistent with my previous findings, WT aortic rings exhibited a biphasic 
response to Ca2+o. Although these data were not significantly different at each 
concentration, two-way ANOVA reveals that WT and KO responses are significantly 
different from one another across all concentrations (P<0.001). Furthermore, the profiles 
clearly match these that I observed previously in non-cumulative Ca2+o concentration 
response experiments whereby WT vessels initially contract and later relax (Figure 51). 
Genotype-dependent differences are particularly visible at concentrations of 2.0, 3.0 and 
5.0mM Ca2+o with values as follows: 2.0mM Ca2+o: -10.40% ± 7.60 WT (N=8) vs. 7.70% 
± 12.30 KO (N=5); 3.0mM Ca2+o: -15.30% ± 10.10 WT (N=8) vs. 21.60% ± 10.80 KO 
(N=5); 5.0mM Ca2+o: 7.20% ± 12.70 WT (N=8) vs. 38.90% ± 13.80 KO (N=5, Figure 
52A).  
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It has been well-documented that Ca2+ can play opposing roles in conductance and 
resistance vessels, where conductance vessels contract to Ca2+ (Lee et al., 2001, Guedes 
et al., 2004) and resistance vessels relax in response to Ca2+ (Weston, 2005). This is also 
the case in our SM22α x fl CaSR mouse model where cumulative Ca2+o application 
induced relaxation in both WT and KO mesenteric arteries. These data were not 
significantly different. However, due to time constraints, only N=5 experiments were 
performed on KO mouse vessels. Using a power calculation, it is estimated that 
approximately 8-10 repeats will be required to achieve significance at P<0.05. Further 
repeats should be performed to fully assess whether Ca2+o plays a significant role in 
relaxation through the VSMC-CaSR in mesenteric arteries. 
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Figure 53. Selective CaSR ablation from mouse VSMCs increases spermine-induced relaxation in 
the aorta. Aortic rings were incubated in Krebs buffer as previously described and treated with 300nM 
phenylephrine to achieve 70% tone. Once tone had normalised, a measurement was taken at the plateau. 
This value was considered the 0% base-line. After this time, 300µM spermine was applied for 3 minutes. 
Time control experiments were also run to determine natural drift in each aorta. After 3 minutes, data were 
recorded and vessel rings were washed. (A) Spermine responses in WT and KO aortic rings in the absence 
of L-NAME. (B) Spermine responses in WT and KO aortic rings in the presence of 100µM L-NAME. (A) 
N=6 WT; N=7 KO. (B) N=4 WT; N=5 KO. Data are expressed as mean ± SEM. Statistical analysis: two-
way ANOVA with Bonferroni’s post-test. P<0.05=*. P<0.01=**. P<0.001=***. ns= not significant.  
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Spermine induces relaxation in KO and WT aortae in the absence of L-NAME, but 
only relaxes KO aortae in the presence of L-NAME. 
Polyamines such as spermine are known CaSR activators (Quinn et al., 1997, Canaff, 
2000, Kelly et al., 2011). For this reason, it was important to investigate whether 
spermine could affect vascular tone through the VSMC-CaSR. Spermine is positively 
charged at physiological pH, therefore having important implications on membrane 
potential as well as its ability to modulate the CaSR (Quinn et al., 2004). Aortic rings 
were incubated in a physiological Krebs buffer containing 1.0mM Ca2+o; a concentration 
of Ca2+o which should cause minimal activation of CaSR. After phenylephrine pre-
contraction, spermine was administered in a single application of 300µM. Once a plateau 
was reached as a consequence of application of 300nM phenylephrine, this point was 
considered as “0%” tone, and therefore, relaxation was measured as a percentage 
reduction from this value. To normalise for any drift in the tone of vessels over the course 
of spermine application (3 minutes), time controls were run in parallel and plotted (Figure 
53). Upon spermine administration, relaxation was observed in both WT and KO aortae. 
In WT aorta relaxation was: 22.72% ± 4.95 WT (N=6) vs. -2.71% ± 4.74 WT time control 
(N=5, P<0.05). In KO aorta, relaxation was: 28.18% ± 6.30 KO (N=7) vs. 8.24% ± 4.88 
KO time control (N=6, P<0.001, Figure 53). Spermine was significantly effective at 
relaxing both WT and KO aortae with greater relaxation in KO aortae compared to the 
time control. In the presence of L-NAME, relaxation was still observed. Values for WT 
aortae were: -16.02% ± 3.42 WT L-NAME (N=4) vs. -2.71% ± 4.74 WT time control 
(N=5) which was not significant. Values for KO aortae were: -22.97% ± 9.30 KO L-
NAME (N=5) vs. 8.24% ± 4.88 KO time control (N=6, P<0.01). Although relaxation was 
maintained in the presence of L-NAME, it was reduced in both WT and KO aortae. This 
meant that WT aorta relaxation in the presence of L-NAME was no longer significantly 
different from the time control, while KO aorta relaxation in the presence of L-NAME 
was still present with a reduced P value (P<0.01, Figure 53B). 
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Figure 54. CaSR ablation in mouse VSMCs does not significantly affect spermine-induced relaxation 
of aortae and mesenteric arteries. Aortic (A) and mesenteric arteries (B) were incubated in Krebs buffer 
as previously described in the presence of 1.0mM Ca2+o. Vessels were pre-contracted using 300nM 
phenylephrine and tone was allowed to stabilise. A cumulative concentration-response curve for spermine 
was then carried out. Spermine was applied once tone achieved from the previous spermine application 
had stabilised. (A) WT N=6 (EC50= 5.23 x 10-4M); KO N=5 (EC50= 2.13 x 10-4M). (B) WT N=6 (EC50= 
1.76 x 10-4M); KO N=5 (EC50= 1.19 x 10-4M). Sigmoidal lines of best fit are applied to data and data are 
expressed as mean ± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s post-test, ns= not 
significant. 
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Mouse VSMC CaSR ablation does not affect spermine-induced relaxation in WT 
and KO mesenteric arteries. 
In addition to a single application of 300µM spermine (Figure 53), a concentration-
response experiment of spermine on aortic rings and mesenteric arteries was also able to 
relax these vessels. However, results show that concentration-response experiments did 
not yield significant differences between WT and KO blood vessels (Figure 54). In the 
aorta, there were no significant differences in relaxation between WT and KO vessels in 
the presence of spermine (3 x 10-6M - 3 x 10-3M). There were also no significant 
differences in relaxation between WT and KO mesenteric arteries in the presence of 
spermine (3 x 10-6M to 3 x 10-3M).  
 Page 196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. R-568 induces relaxation in WT aortic rings, but not in KO aortic rings. Aortic rings were 
incubated in Krebs buffer containing 1.5mM Ca2+o. Vessels were pre-constricted using 300nM 
phenylephrine and the tone allowed to plateau. After this, the plateau was regarded as 100% base-line tone 
before drug application. R-568 was applied at a concentration of 300nM and vessels were allowed to 
respond for 3 minutes. Negative time controls were also run to detect any natural drift in aortic rings over 
this time. (A) Effects of R-568 on aortic rings from WT and KO mice in the absence of L-NAME. (B) R-
568 responses in WT and KO aortic rings in the presence of 100µM L-NAME. (A) WT N=6; KO N=7. 
(B) WT N=5; KO N=7. Data are expressed as mean ± SEM. Statistical analysis: two-way ANOVA with 
Bonferroni’s post-test. P<0.05=*. P<0.01=**. ns= not significant. 
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R-568 (300nM) is effective at relaxing WT but not KO aortae.  
In order to assess the ability of calcimimetics to modulate vascular tone, the effects of R-
568 were tested in aorta rings. Calcimimetics have been used clinically to treat secondary 
hyperparathyroidism and reports indicate that calcimimetics are modulators of vascular 
tone and blood pressure (Ogata et al., 2003, Rybczyńska et al., 2005, Weston, 2005, 
Smajilovic et al., 2007, Smajilovic and Tfelt-Hansen, 2008, Olgaard et al., 2011). I tested 
the effects of both a single concentration of the calcimimetic R-568 (300nM) in the 
presence of 1.5mM Ca2+o on aortae pre-contracted with 300nM phenylephrine, and a 
concentration response of R-568 in the same conditions. 1.5mM Ca2+o and 300nM 
calcimimetic were selected since this has been shown in previous publications to be 
effective at relaxing blood vessels (Smajilovic et al., 2007). In WT aortae, 300nM R-568 
induced significant relaxation: -2.75% ± 1.88 WT (N=6) vs. 6.01% ± 0.62 WT time 
control (N=5, P<0.05). In KO aortae, 300nM R-568 did not induce affect vascular tone. 
KO values were: 3.68% ± 1.65 KO (N=7) vs. 2.85% ± 1.98 KO time control (N=7) which 
was not significant (Figure 55A). In the presence of 100µM L-NAME, R-568-induced 
relaxation in WT aortae was inhibited. Relaxation values were: 2.86% ± 0.44 WT (N=5) 
vs. 6.01% ± 0.62 WT time control (N=5), not significant. Values for KO relaxation were: 
6.79% ± 2.88 KO (N=7) vs. 2.85% ± 1.98 KO time control (N=7), which was also not 
significant (Figure 55B). 
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Figure 56. CaSR ablation in mouse VSMCs does not affect R-568-induced relaxation of mesenteric 
arteries. Mesenteric arteries were incubated in Krebs buffer as previously described in the presence of 
1.5mM Ca2+o. After application of 300nM phenylephrine, tone was allowed to stabilise. After tone had 
reached a plateau, a cumulative concentration response of R-568 (1 x 10-8 to 1 x 10-5M) was carried out. 
WT N=7 (EC50= 2.57 x 10-7M); KO N=5 (EC50= 3.44 x 10-7M). Sigmoidal lines of best fit are applied to 
data and data are expressed as mean ± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s post-
test, ns= not significant. 
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R-568 is equally effective at relaxing mesenteric arteries from WT and KO SM22α 
x fl CaSR mice.  
R-568 was applied to mesenteric arteries from both WT and KO mice from 
concentrations of 1 x 10-8M to 1 x 10-5M in the presence of Krebs buffer containing 
1.5mM Ca2+o. Concentration response curves for WT and KO mesenteric arteries were 
super-imposable. There were no statistical difference at any concentration in responses 
to R-568, although it was seen in both WT and KO mesenteric vessels that R-568 induced 
relaxation in a concentration-dependent manner (Figure 56).  
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CHAPTER 5: DISCUSSION 
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The VSMC-CaSR mediates vasoconstriction and vasorelaxation in conductive and 
resistance vessels through [Ca2+]o. 
Ca2+ has long been an implicated as an important player in the regulation of blood 
pressure, vascular tone and calcification of vessels (Eddington et al., 2009, Giachelli, 
2009, Rodriguez et al., 2011). The role of Ca2+ in vessel tone, however, remains 
controversial since it has been reported that Ca2+o induces a biphasic response depending 
on vessel type and the concentrations used. In previously conducted studies which look 
at Ca2+o as a modulator of vascular tone, there appears to be little relevance to the role of 
the CaSR since buffers containing already maximally-activating concentrations of 
2.5mM Ca2+o are employed as the baseline. At this concentration (and above), the role of 
CaSR becomes less important and the role of Ca2+o acting through Ca2+-channels in 
vessel tone becomes predominant. Interestingly, the majority of relaxation observed in 
response to Ca2+o in larger vessels such as the aorta are observed beyond this range (>2.0 
- 3.0mM Ca2+o) (Singer and Peach, 1982, Adegunloye and Sofola, 1998, Yildirim et al., 
1998), indicating CaSR-independent mechanisms of tone modulation. Conversely, small 
arteriole Ca2+o-dependent relaxation is observed from CaSR-sensitive levels of >0.5mM 
Ca2+o (Weston, 2005, Rybczynska et al., 2006, Smajilovic et al., 2006). For these reasons 
one can conclude that using a physiologically relevant ex vivo myography setup to 
determine the role of vascular CaSRs in tone modulation remains virtually unexplored. 
Only in recent years have investigators started to show the pivotal and biphasic role of 
Ca2+o in tone modulation at CaSR-sensitive concentrations (Ohanian et al., 2005, 
Weston, 2005, Smajilovic et al., 2007, Weston et al., 2008). 
 
In my study I showed that Ca2+o application in the aorta induced contraction, followed 
by relaxation at supraphysiological concentrations of Ca2+o at the CaSR (>2.0mM Ca2+o). 
This initial contraction was not present in KO aortae (Figure 51). This suggests that 
VSMC-CaSR activation by Ca2+o is responsible for vasoconstriction ex vivo, and 
therefore could relate to increases in blood pressure in vivo. In aortae treated with L-
NAME, WT vessels incubated with 1.0-5.0mM Ca2+o showed no relaxation, only 
contraction. This once again illustrates the significance of the VSMC-CaSR in inducing 
contractions with Ca2+o (Figure 51). In KO vessels incubated with L-NAME, mild 
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contraction was seen which may be due to CaSR-unrelated mechanisms. Relaxation that 
consistently followed in KO aortae is, however, more difficult to define since the nitric 
oxide pathway was blocked by L-NAME (Figure 51B). This would indicate that 
relaxation of vessels can happen by two mechanisms. (i) Additional endothelium-derived 
hyperpolarization produced by factors other than NO may be upregulated in ECs as a 
consequence of VSMC-CaSR ablation; and (ii) VSMCs without a functional CaSR may 
have lower [Ca2+]i or low Ca2+ in stores, leading to vessel dilation or relaxation by myosin 
inactivation. 
 
In order to address the first point, it is important to remember crucial EDRFs involved in 
EC signalling. Although NO is largely considered as the major EDRF contributing to 
dilation and relaxation in vessels, some other hyperpolarizing factors have been 
described. These include ADP, ATP, bradykinin, thrombin, serotonin, histamine, 
acetylcholine, K+, H2O2, epoxyeicosatrienoic acid (EET) and PGI2. (Cherry et al., 1982, 
Vanhoutte et al., 1986, Palmer et al., 1987, Vanhoutte, 1987, Furchgott and Vanhoutte, 
1989, Bukoski et al., 1997, Wang and Bukoski, 1998, Edwards et al., 2008, Luksha et 
al., 2009). It is possible that these factors may be Ca2+-dependent and upregulated by 
endothelial cells in response to VSMC-CaSR ablation. 
 
Already discussed in this thesis has been the in vivo hypercalcaemia resulting from 
VSMC-CaSR knockout. Hypercalcaemia in vivo often results from dysfunctional 
parathyroid gland signalling (Pearce et al., 1995, Frank-Raue et al., 2011). In this 
instance, the PTH/Ca2+ axis is affected and, presumably, hypercalcaemia is brought on 
by hyperparathyroidism which resorbs Ca2+ from bone. During this condition, systemic 
Ca2+o levels are inappropriately elevated (Pearce et al., 1995, Frank-Raue et al., 2011). 
However, in an ex vivo myography setup, the possibility of hormonal messengers such 
as PTH circulating in the blood is not possible, and therefore the effects seen cannot be 
attributed to systemic chances in plasma PTH. It has been shown that CaSR is linked to 
Ca2+o entry into VSMCs (Chow et al., 2011), and it is therefore possible that in the 
absence a VSMC-CaSR, Ca2+o entry is reduced, preventing maximal contraction of KO 
aortae. 
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The potential effects of VSMC-CaSR ablation on Ca2+-channels should also be 
addressed. It is largely known that CaSR activation can signal through the PLC pathway, 
activating IP3Rs and inducing release of Ca2+ from internal stores (Brown et al., 1993, 
Riccardi et al., 1995). Consequently, this elevates [Ca2+]i which in VSMCs would 
ordinarily lead to activation of myosin components and subsequent contraction (Wray et 
al., 2005, House et al., 2008). In physiological [Ca2+]o (~1.05-1.2mM) (Brown, 1991, 
Kovacs and Kronenberg, 1997, Kovacs et al., 1998, Finney et al., 2008), the CaSR is 
activated in the PTGs. Presumably, if the VSMC-CaSR were to be similarly sensitive to 
this level of Ca2+o, one could also speculate that signalling through the VSMC-CaSR 
would occur, leading to elevated [Ca2+]i levels and a more contractile state. This may 
have repercussions on the function of Ca2+-channels expressed in the VSMC, namely, 
the VSMC voltage-gated Ca2+-channel CaV 1.2 (Lipscombe, 2004, Rhee et al., 2009). 
CaV 1.2 has been shown to be expressed in VSMCs, and knockdown of this is associated 
with reduced myogenic tone, reduced depolarisation and reduced VSMC contraction 
(Rhee et al., 2009). On the other hand, hypertension in rodents has been associated with 
upregulation of CaV 1.2 at both the mRNA and protein level at the cell surface, indicating 
an important role in tone modulation (Ohya et al., 1993, Pesic et al., 2004). Whether the 
VSMC-CaSR and VSMC-Ca2+-channels such as CaV 1.2 are functionally linked to one 
another remains to be investigated. 
 
Although these hypotheses help illustrate the potential role of the VSMC-CaSR in the 
aorta, the role of Ca2+o in the aorta and mesenteric artery (Figure 52), and of acetylcholine 
in mesenteric arteries (Figure 49) appears less clear. Although there appear to be a trend 
for Ca2+o to relax these KO arteries less than WT mesenteric arteries, it is not significant. 
It is important to remember that in these mesenteric vessels, endothelial cells play a major 
role in tone modulation, exerting their effects on comparatively fewer adjacent VSMCs 
compared to large conductance vessels. It seems probable that Ca2+o in these two different 
vessel types preferentially acts on either ECs or VSMCs; depending on which cell type 
or response dominates the vessel. For example, in the aorta, rises in [Ca2+]o (within the 
physiological range of 1.0-2.0mM Ca2+o) would presumably impact more on VSMCs 
which far outnumber ECs. In this instance Ca2+o-induced vasoconstriction may dominate 
over vasorelaxation which may be co-ordinated through EC and VSMC CaSRs. In fact, 
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we know these antagonistic responses to both be synergistically active since in the WT 
aorta we have seen that L-NAME incubation allows for contraction only, and no 
relaxation (up to 5.0mM Ca2+o, Figure 51B). In mesenteric vessels this may also be the 
case, however here, Ca2+o may impact the EC-CaSR more than VSMC-CaSR, and so 
relaxation responses through the NO pathway or other EDHs may dominate over 
contractile responses.  
 
Importantly, it should also be remembered that acetylcholine-induced relaxation is 
delayed in KO mesenteric arteries compared to WT mesenteric arteries (Figure 49). Since 
we have also observed that Ca2+o may be less effective at relaxing KO mesenteric arteries 
(Figure 52), it seems likely that the physiological responses of GPCRs to their agonists 
in these arteries is somehow impaired. Again, it may be that the pattern of expression of 
Ca2+-channels present in these vessels is slightly altered, or that alternative Ca2+o-sensing 
mechanisms are at work, I.e. GPRC6A which has been shown to be expressed in rat 
mesenteric arteries (Harno et al., 2008). Due to time constraints NO/EDHF activity, Ca2+-
channel activity/expression and GPRC6A activity/expression were not investigated. 
However, it is likely that looking at these factors in addition to the role of the EC-CaSR 
in the future will shed more light on the role of Ca2+o in arteriolar tone modulation. For 
this reason, it would be extremely beneficial to develop an EC x fl CaSR mouse. Such 
endothelial cell-specific models have been developed using the Tie2 promoter which is 
expressed specifically in ECs (Kisanuki et al., 2001). Using this mouse model alone or 
in combination with the VSMC CaSR-KO mouse, a more intelligible role of Ca2+o and 
CaSR activation in the cardiovascular system could be understood. Furthermore, a 
double-knockout of CaSR in both ECs and VSMCs would provide greater insight into 
Ca2+ signalling in the vessel wall. 
 
Spermine-induced relaxation in the aorta may be mediated by the VSMC-CaSR. 
Spermine, an activator of the CaSR, is a positively charged polyamine and perhaps it is 
not so striking that this is able to activate CaSR, a sensor of cations (Brown, 1991, 
Riccardi et al., 1995). Studies in HEK293 cells overexpressing a human CaSR have 
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shown spermine to be effective in increasing intracellular Ca2+ through IP3 receptor 
activation at the ER/SR (Quinn et al., 1997, Canaff, 2000, Conigrave and Quinn, 2000, 
Conigrave et al., 2002, Kelly et al., 2011). For the characterisation of the SM22α x fl 
CaSR mouse model, I used spermine as a CaSR agonist to determine its effects on 
vascular tone. In the aorta, 300µM (3 x 10-4M) was sufficient to induce relaxation in both 
WT and KO aortic rings. Interestingly, cumulative experiments in the aorta (Figure 54) 
suggest that spermine could be acting through the EC-CaSR to relax VSMCs, or 
somehow hyperpolarize KO VSMCs to a greater degree than WT VSMCs. Spermine 
binds to the CaSR to increase [Ca2+]i which in VSMCs would be expected to  lead to 
contraction (Quinn et al., 1997). Conversely, in ECs, [Ca2+]i increases can induce dilation 
and relaxation through NO (Kerr et al., 2012, Tran et al., 2012). Interestingly, relaxation 
was still seen in L-NAME treated vessels, albeit, significantly reduced. For this reason, 
relaxation here cannot be attributed to NO effects, therefore alternative mechanisms of 
actions need to be tested. Numerous investigators have reported that (i) spermine exists 
as a cation at physiological pH of 7.4, and; (ii) spermine can enter endothelial cells 
through a carrier protein (Bogle et al., 1994, Seiler et al., 1996). Although there are 
currently no studies stating that VSMCs can take up spermine, this also seems possible, 
particularly since almost all cells synthesize their own polyamines (Pajula et al., 1979, 
Heby and Persson, 1990). If indeed the case, uptake of this polyamine cation in VSMCs 
by a its’ respective carrier protein may or may not be mediated by the VSMC CaSR. 
Effects within the cell that lead to vasodilation and vasorelaxation remain unclear. It may 
be possible that elevations in this cationic polyamine inside the cell promote release of 
Ca2+ from internal stores, or hyperpolarization by K+ efflux.  
 
In terms of responses observed in the presence of L-NAME, it seems likely that 
additional EDHs induced by, for example, PGI2 could be responsible for these effects in 
the presence of L-NAME (Triggle et al., 2012). The fact that relaxation was observed in 
the presence of L-NAME suggests that the relaxation observed is at least in some part 
independent of NO. The important role of PGI2 as a hyperpolarising and relaxation factor 
has become more recognised in recent years. Furthermore, it has been reported in a 
double knockout model for eNOS and COX-1 that relaxation still occurs by additional 
(so far unknown) hyperpolarising factors (Scotland et al., 2005). From my data, there 
 Page 206 
 
appear to be some CaSR-dependent and CaSR-independent actions of spermine in WT 
and KO vessels which remain to be clarified (Figure 53).  
 
There were no significant differences in contractile tone when comparing WT and KO 
mesenteric arteries (Figure 54B), indicating that: (i) any visible trends require more 
repeats for clarification, or (ii) selective CaSR ablation in VSMCs does not affect the 
relaxation responses to spermine in mesenteric arteries. 
 
R-568 modulated aortic tone through the VSMC-CaSR. 
R-568 is a calcimimetic currently used to treat secondary hyperparathyroidism in patients 
suffering from CKD (Francis et al., 2008). A number of studies have demonstrated the 
ability of calcimimetics in modulating vascular tone, in addition to reducing vascular 
calcification (Ogata et al., 2003, Rybczyńska et al., 2005, Weston, 2005, Lopez, 2006, 
Smajilovic et al., 2007, Alam et al., 2008, Kawata et al., 2008, Piecha et al., 2008, 
Ivanovski et al., 2009, Koleganova et al., 2009). Conversely, a number of studies have 
shown that calcimimetics have no beneficial effects on cardiovascular outcome (Chertow 
et al., 2012a). For this reason it was important to investigate the effect of calcimimetics 
using the ex vivo myography setup. Calcimimetics require the presence of submaximal 
concentrations of [Ca2+]o and for this reason I used Ca2+o at a concentration which has 
previously been shown to be the EC50 in VSMCs (Smajilovic et al., 2006, Smajilovic et 
al., 2007). R-568 has been shown to left-shift the concentration response curve for Ca2+o 
by increasing the Ca2+o-dependent responses (Nemeth et al., 1998, Hebert, 2006), so this 
concentration was selected for all experiments.  
 
My experiments show that a single application of 300nM R-568 to WT aortic rings 
induced significant relaxation compared to WT time controls (P<0.01) over the course 
of 3 minutes. This was also significantly different to KO aortic rings in which 300nM R-
568 did not relax these vessels (P<0.05, Figure 55A). These observations would suggest 
(as others have shown) that R-568 can play a role in relaxing the vessel. Interestingly, 
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these observations suggest that the effects of R-568 appear to be endothelium-specific 
since addition of L–NAME inhibited this relaxation (Figure 55B). Furthermore, they 
would suggest that R-568 activation of CaSR is somehow linked to NO synthesis. 
Although relaxation in WT aortae in response to 300nM R-568 was small (-2.75% ± 1.88 
WT (N=6) vs. 6.01% ± 0.62 WT time control), these results are in agreement with the 
literature where calcimimetics have been shown to induce a hypotensive effect 
(Rybczyńska et al., 2005, Smajilovic et al., 2007). However, when looking at the 
myography trace the relaxation was small (2.75%). Further experiments with the drug at 
different concentrations in the presence of 1.0-1.5mM Ca2+o may lead to greater 
responses. Also, pre-treatment with the drug could be used to prime the CaSR, which 
might lead to increased responses. In addition, the effects of calcimimetics on isolated 
VSMCs and ECs should be tested in future experiments to determine the sensitivity to 
R-568 in these two cell types. However, since R-568 has been shown to act on Ca2+-
channels at concentrations of >1µM, only concentrations of <1µM should be used. 
 
My observations show that KO vessels did not respond to R-568 (Figure 55). Since KO 
ECs should still contain a functional CaSR, and since R-568 appears to be acting through 
the EC-CaSR, this outcome was slightly unexpected. However, as KO aortae already 
have a reduced contractile tone, perhaps R-568 was not able to evoke further relaxation. 
Determining whether R-568 at different concentrations can induce similar hypotensive 
effects in the aorta remains to be investigated.  
 
Also investigated was a concentration response of R-568 in mesenteric arteries from WT 
and KO animals (Figure 56). It was seen that R-568 induced relaxation in both WT and 
KO arteries at a concentration range of 1 x 10-8 to 1 x 10-5M. Interestingly, mesenteric 
arteries contain far fewer VSMCs (Wagenseil and Mecham, 2009, Wagenseil et al., 2009, 
Wagenseil et al., 2010), therefore any mesenteric artery VSMC-CaSR KO phenotype 
would presumably be different compared to arteries with significantly more CaSR-KO 
VSMCs, I.e. the aorta. At the concentrations of R-568 used for my experiments (up to 
1µM), R-568 acts selectively on the CaSR and induced relaxation in both WT and KO 
mesenteric arteries. My results suggest that relaxation at concentrations of R-568 of 
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<1µM in both WT and KO aortae should be mediated through the EC-CaSR. However, 
above this concentration range, R-568 (a phenylalkylamine) may act non-specifically on 
Ca2+-channels (Tuckwell, 2012). Indeed, high concentrations of calcimimetics (>1µM) 
induce dilation and relaxation by blockage of Ca2+-channels (Thakore and Ho, 2011). 
These data suggest that R-568 may be effective in dilating and relaxing mesenteric 
arteries by the EC-CaSR, but not the VSMC-CaSR. 
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CHAPTER 5: CONCLUSION 
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The VSMC-CaSR is a modulator of vascular tone in both conductance and 
resistance vessels. 
CaSR is expressed in both ECs and VSMCs (Weston, 2005, Smajilovic et al., 2006, 
Smajilovic et al., 2007, Alam et al., 2008). From my data, it is clear that the VSMC-
CaSR plays an important role in tone modulation. In its’ absence, responses from agonists 
such as Ca2+o, spermine and R-568 are significantly altered in the aorta. Ca2+o, spermine 
and R-568 appear to induce greater relaxation, suggesting that the EC-CaSR may 
promote relaxation, while the VSMC-CaSR may promote contraction. This suggests that 
our KO mice would be expected to exhibit a hypotensive phenotype, which is consistent 
from observations seen in Chapter 4, where aortae exhibit reduced contractile tone. To 
test this hypothesis, blood pressure measurements should be taken in both WT and KO 
mice. 
 
The role of R-568 in these studies remains unclear. Although it appears to induce 
relaxation in WT aortae only, it is not fully clear why this was not also observed in KO 
aortae. It seems likely that, in the experimental conditions I have used, R-568 does not 
play a major role in blood vessel tone by acting through the VSMC-CaSR. Any effects 
that are mediated through blood vessel CaSRs seems likely to be due to the EC-CaSR.  
 
 
Chapter Acknowledgments 
Once again I would like to thank Dr. Polina Iarova for her help with dissections and 
myography experiments. 
  
 Page 211 
 
CHAPTER 5: FUTURE WORK 
Future work crucial to this project would include using such pharmacological agents as 
(i) S-568: to determine any stereoselective effects of the R/S-568 compounds, and; (ii) 
calcilytics to determine any effects of CaSR inhibition in WT and KO vessels. 
Furthermore, these responses should be tested in both the aorta and mesenteric arteries 
in the presence and absence of L-NAME. Due to time constraints and limited tissue 
availability, L-NAME was not investigated in mesenteric arteries during these studies. 
 
An additional benefit this project would gain would be to further investigate the role of 
the vascular CaSR in both ECs and VSMCs and consequences of their inactivation. For 
this, it would be crucial to develop a Tie2-driven CaSR knockout which would knock the 
receptor out specifically in the endothelium. Additionally, it would be interesting to 
characterise a SM22α-driven and Tie2-driven double CaSR knockout. Further repeats in 
mesenteric arteries would also be beneficial in determining whether the trends and 
changes observed in response to Ca2+o and spermine are indeed real. Additionally, 
myography may not be sensitive enough to determine levels of [Ca2+]i in whole vessels 
in response to these agonists. Therefore measurements of [Ca2+]i using imaging 
techniques may be required to test the effects of calcimimetics on the VSMC and EC 
CaSR, and the ability of calcilytics to prevent agonist-induced, CaSR-mediated increases 
in [Ca2+]i in these cells. 
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CHAPTER 6:  
IN VITRO CHARACTERISATION OF THE SM22α X fl 
CaSR MOUSE MODEL WITH SELECTIVE ABLATION 
OF CaSR IN VASCULAR SMOOTH MUSCLE CELLS 
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CHAPTER 6: GENERAL INTRODUCTION 
Vascular smooth muscle cells from aortic explants are widely used in investigations of 
vascular calcification (Smajilovic et al., 2006, Kircelli et al., 2012). Chapters 3-5 have 
shown clearly that targeted CaSR ablation from VSMCs leads to altered serum 
biochemistry, increased heart weight, reductions in bone mineral density and impaired 
contractile response. To characterise further the phenotype of the VSMC-CaSR KO, and 
to test the hypothesis that loss of CaSR increases vascular calcification, an in vitro 
approach is required. In this way, the VSMC-CaSR KO phenotype at the cellular level 
can be investigated.   
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Figure 57. Mouse aortic endothelial cells and vascular smooth muscle cells express the CaSR. Mouse 
thoracic aortae were obtained from C57BL/6 WT animals of approximately 3 months of age, washed in 
1X PBS then fixed in 4% PFA for 60 minutes. Organs were washed in 1X PBS, then placed in OCT cryostat 
mounting medium and allowed to freeze at -80ºC. After freezing, aortae were cut into 6µm sections and 
mounted on microscope slides. Sections were stained using antibodies for (Ai) anti-SM22α;green and (Aii) 
anti-CaSR;red (Aiii composite) or (Bi) anti-PECAM-1;green and (Bii) anti-CaSR;red (Biii composite). 
Negative controls for both goat antibodies (SM22α and PECAM-1) are shown in Ci. Rabbit IgG negative 
control is shown in Cii and a composite of negative control auto-fluorescence in Ciii. Nuclear staining 
(blue) was performed using Hoescht. Images are representative of 3 separate aortic isolations with similar 
immunofluorescent results. 
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Mouse endothelial and vascular smooth muscle cells both express a CaSR. 
To confirm the presence of the CaSR protein in the vasculature, WT C57BL/6 aortae of 
3 month old male mice were prepared and stained using antibodies to anti-SM22a, anti-
PECAM-1 and an N-terminal antibody to anti-CaSR. Figure 57Aii shows that VSMCs 
express a CaSR. Figure 57Bii shows intense red staining in the endothelial cell layer 
indicating the presence of CaSR in the tunica intima. Although CaSR immunoreactivity 
is faint in the VSMC layer (Figure 57 Aii), this staining is more prominent than the 
negative rabbit IgG control in Figure 57Cii. In contrast, EC-CaSR immunoreactivity is 
high. 
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Figure 58. WT and KO vascular smooth muscle cells from mouse aortic explant cultures express the 
VSMC marker: SM22α. Mice of 3 months of age were humanely culled by cervical dislocation and 
descending thoracic aortae were isolated. VSMCs were isolated by the explant method as described in 
Methods (2.11 Isolation of mouse primary vascular smooth muscle cells VSMCs). After the first passage 
to passage 1, cells were plated in 24-well plated and allowed to reach confluence. (A) Protein isolated was 
quantified using the BCA method and SM22α expression is confirmed by western blot. Primary antibodies 
for SM22α and β-actin; 1:1,000. Secondary HRP-conjugated antibody; 1:10,000. (B) SM22α levels were 
calculated semi-quantitatively using densitometry (N=3). (C) Genomic DNA isolated from confluent 
VSMCs was used as a template for the amplification of CaSR exon 7. The truncated ∆exon 7 amplicon 
produced in SM22α x fl CaSR KO mice is shown as a 284bp product (absent in all WT VSMC 
preparations). Cell genotyping was repeated for 3 independent WT and KO VSMC isolations with the 
same results. Data expressed as mean ± SEM. Statistical analysis: unpaired two-tailed t-test. ns= not 
significant. 
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WT and KO mouse VSMCs express the marker SM22α. 
In order to determine whether CaSR ablation affected the expression of SM22α, protein 
lysates were isolated from confluent WT and KO VSMCs. Figure 58A shows that SM22α 
protein of the predicted 22kDa size is detected in both WT and KO VSMC preparations. 
SM22α expression was comparable as shown in Figure 58B. 
 
KO mouse genomic DNA in VSMCs has specific deletion of exon 7 in the CaSR 
gene. 
To determine whether mouse genotyping had been performed correctly and that only 
CaSR-KO products could be detected in KO preparations, gDNA was isolated from 
confluent cells and the ∆Exon 7 KO product was amplified from these preparations. 
Figure 58C shows that all WT preparations (3 separate batches tested) showed no 
detectable truncated knocked out CaSR. Conversely, all KO batches (3 separate batches 
tested) all confirmed the absence of exon 7 in the CaSR genomic DNA.  
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Figure 59. WT- and KO-CaSR mouse VSMCs express an N-terminal CaSR protein product. Primary 
mouse VSMCs were isolated from the thoracic aorta of WT and KO mice. Passage 1 VSMCs were cultured 
in the presence of 1.2mM Ca2+o and 10% FBS in DMEM. Cells were seeded at 10,000 cells per coverslip 
in 4-well plates and left in culture medium for 5 days. At this time, medium was removed and cells were 
washed with 1 X PBS and fixed in 4% PFA for 10 minutes. Immunofluorescent staining was then carried 
out as described in methods. Pictures show VSMCs in a typical synthetic, non-contractile proliferative 
phenotype. Row A: WT-CaSR VSMC staining, and Row B: KO-CaSR VSMC staining. (Ai) Composite 
anti-SM22a (green)/anti-CaSR (red). (Aii) anti-SM22a. (Aiii) anti-CaSR. (Bi) Composite anti-SM22a 
(green)/ anti-CaSR (red). (Bii) anti-SM22a. (Biii) anti-CaSR. Anti-CaSR antibody binds to the N-terminal 
CaSR product expressed as a full-length CaSR in WT-CaSR VSMCs, and a truncated protein in KO-CaSR 
VSMCs. Primary antibody dilutions= 1:100. Secondary antibody dilutions= 1:500. Scale bar: 100µm. 
Image kindly provided by Martin Schepelmann. 
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Figure 60. KO mouse VSMCs express less CaSR immunoreactivity compared to WT mouse VSMCs. 
A population of passage 1 explanted WT and KO mouse VSMCs (10,000) were plated onto glass coverslips 
and immunofluorescence was performed using an anti-SM22a antibody (1:250) and an anti-N-terminal 
CaSR antibody (1:100). Cells were fixed after staining and semi-quantitative analysis was carried out using 
Tissue QuestTM software and epi-fluorescent microscopes. The system calculated average intensity values 
within a radius of 8.28µm of VSMC nuclei (blue Hoechst-stained). Intensity values for SM22α-positive 
cells (VSMCs) and CaSR-positive cells were calculated by exposing fixed VSMCs to 488nm (green) filters 
and 594nm (red) filters respectively. Manual calibration was carried out by Martin Schepelmann to confirm 
which cells were to be considered positive or negative for SM22α or CaSR stains. (A) CaSR-positive cells 
within a WT and KO VSMC population. (B) SM22α-positive cells within a WT and KO VSMC population. 
(C) CaSR-positive cells within the SM22α-positive VSMC population. Statistical analysis: two-way 
ANOVA with Bonferroni’s post-test. Data expressed as mean ± SEM. P<0.05=*. P<0.01=**. ns= not 
significant. 
A B 
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WT and KO mouse SM22α x fl CaSR VSMCs express an N-terminal CaSR protein 
product with significantly reduced amounts in KO mouse VSMCs. 
With reliable antibodies which detect the carboxy terminal domain of the CaSR being 
very limited, I was limited to just one amino terminus antibody which worked well in the 
mouse. Unfortunately, this antibody cannot distinguish between WT and KO CaSR 
proteins. The N-terminal domain of CaSR is encoded by exons 2-6. Since only Exon 7 is 
knocked out in our mouse model, KO VSMCs are still able to produce a truncated exon 
2-6 product, which our N-terminal antibody was able to detect. Numerous other 
antibodies were used but showed non-specific nuclear staining in all VSMCs tested. As 
a consequence, immunostaining WT and KO VSMCs both yielded positive results 
(Figure 59). However, automated semi-quantification of CaSR immunofluorescence 
performed by Martin Schepelmann using a TissueFAX system and TissueQuestTM 
software showed firstly that in the whole population of cells on each slide, CaSR 
immunoreactivity was less intense in KO VSMCs compared to WT VSMCs (Figure 
60A). Fluorescent arbitrary values were: 25.84 ± 2.27 WT (N=3/n=6) vs. 16.73 ± 0.66 
KO (N=3/n=6). This difference was significant at P<0.01 using an unpaired two-tailed t-
test, and demonstrated 35.26% less protein in KO VSMCs compared to WT VSMCs. 
Secondly, analysis of SM22α content of the VSMC populations of each genotype was 
carried out (Figure 60B). The results revealed that there was no significant difference in 
SM22α immunostaining intensity, as also shown previously from whole protein isolation, 
between WT and KO VSMCs (Figure 58). Lastly, when CaSR immunostaining was 
normalised relative to VSMC markers within the population (by SM22α staining) in 
VSMCs at passage 1, KO VSMCs expressed significantly less CaSR when compared 
with WT VSMCs (P<0.05; Figure 60C). Data for CaSR/SM22α, in fluorescent units 
were: 0.53 ± 0.05 WT (N=3/n=6) vs. 0.36 ± 0.03 KO (N=3/n=6).  
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Figure 61. Ca2+o does not significantly affect the viability of mouse primary WT and KO VSMCs. 
(A) WT and (B) KO VSMCs were seeded at 2,000 cells per 96-well in DMEM containing 10% FBS and 
1.2mM Ca2+o. After 24h, cells were quiesced for 24h in DMEM containing 1% FBS and 1.2mM Ca2+o and 
1.0mM Pi. After 24h quiescing, medium was changed to contain different Ca2+o concentrations 
(supplemented with CaCl2) which marked day 0. Media were changed every 2-3 days. At the end-point (7 
days), cells were incubated with 0.5mg/mL MTT for 2 hours at 37ºC. MTT crystals (a product of 
mitochondrial reductase activity) were solubilised in DMSO. Solubilised crystals were quantified in an 
Optima plate-reader; absorbance was measured at 570nm wavelength (N=3/n=9 WT; N=2/n=6 KO). Data 
are expressed as average ± SEM. Statistical analysis: one-way ANOVA. 
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Figure 62. The calcimimetic R-568 does not significantly affect the viability of mouse primary WT 
and KO VSMCs. (A) WT and (B) KO VSMCs were seeded at 2,000 cells per 96-well in DMEM 
containing 10% FBS and 1.2mM Ca2+o. After 24h, cells were quiesced for 24h in DMEM containing 1% 
FBS and 1.2mM Ca2+o and 1.0mM Pi. After 24h quiescing, medium was changed to contain different Ca2+o 
concentrations (supplemented with CaCl2) which marked day 0. VSMCs were incubated with calcimimetic 
or vehicle control (0.01% DMSO). Media were changed every 2-3 days. At the end-point (7 days), cells 
were incubated with 0.5mg/mL MTT for 2 hours at 37ºC. MTT crystals (a product of mitochondrial 
reductase activity) were solubilised in DMSO. Solubilised crystals were quantified in an Optima plate-
reader; absorbance was measured at 570nm wavelength (N=3/n=9 WT; N=2/n=6 KO). Data are expressed 
as average ± SEM. Statistical analysis: two-way ANOVA. 
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Ca2+o and the calcimimetic R-568 do not affect the viability of VSMC from WT and 
KO aortae. 
Using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), cell 
viability in the presence of different concentrations of Ca2+o and the calcimimetic R-568 
(1-100nM) was tested. MTT is a substrate for mitochondrial reductase enzymes. In 
healthy metabolising and proliferating cells, these enzymes are active in the 
mitochondria. When cell viability is impeded, enzyme function is reduced. Similarly, 
when cells proliferate actively, mitochondrial reductase activity is increased (Mosmann, 
1983). Figure 61A shows that in the presence of Ca2+o (1.6-5.0mM), there is no 
significant difference in cell viability compared to the 1.2mM Ca2+o control in WT and 
KO VSMCs. Figure 62 also shows that R-568 (1-100nM) in the presence of Ca2+o (1.2-
1.8mM) had no significant effects on WT and KO VSMC viability when compared to 
untreated controls. 
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Figure 63. Proliferation rates of WT- and KO-CaSR VSMCs in vitro. VSMCs were seeded at 10,000 
cells per 12-well plate and allowed to adhere for 24h in DMEM containing 10% FBS and 1.2mM Ca2+o. 
After 24h, medium was changed to contain 1.2mM Ca2+o and 1% FBS. After a further 24h, medium was 
changed to contain 1.2mM Ca2+o and 10% FBS. Cells were left for 10 days with medium changing every 
3 days. At day 10, cells were trypsinised in 0.05% trypsin EDTA and manually counted using a 
haemocytometer. To normalise data, WT VSMC numbers were averaged. Counts for KO VSMCs were 
then normalised to these data to express them as fold changes compared to WT VSMCs. WT N=4/n=8. 
KO N=4/n=8. Data are expressed as average ± SEM. Statistical analysis: unpaired two-tailed t-test. ns= 
not significant.  
  
ns 
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KO-CaSR VSMCs exhibit comparable proliferation rates to WT-CaSR VSMCS at 
physiological Ca2+o in vitro. 
When culturing WT-CaSR and KO-CaSR VSMCs in-vitro it was often seen that KO 
VSMCs proliferated at faster rates than WT VSMCs. Therefore, it was important to 
determine whether this observation was statistically significant under standard conditions 
of culture (DMEM containing 10% FBS and 1.2mM Ca2+o). Cell counts were performed 
after 10 days in culture in these conditions. The previous observation that KO VSMCs 
proliferate faster than WT VSMCs was seen in data presented in Figure 63, however, this 
was not significant. It is therefore likely that more repeats are required to obtain 
significance (P value 0.08, Figure 63). 
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Figure 64. Ca2+o increases VSMC proliferation in a concentration-dependent manner in WT, but not 
in KO VSMCs. (A) WT-CaSR VSMC proliferation. (B) KO-CaSR VSMC proliferation. VSMCs were 
seeded at 10,000 cells per 12-well plate and allowed to adhere for 24h in DMEM containing 10% FBS and 
1.2mM Ca2+o. After 24h, medium was changed to contain 1.2mM Ca2+o and 1% FBS. After a further 24h, 
medium was changed to contain 1.2, 1.8 or 2.5mM Ca2+o in the presence of a 0.001% DMSO vehicle 
control. Cells were left for 10 days with medium changing every 3 days. At day 10, cells were trypsinised 
in 0.05% trypsin EDTA and manually counted using a haemocytometer. Data were normalised to each 
respective batch of cells to the 1.2mM Ca2+o control. This approach was taken to minimise cell batch 
variability. (A) N=4/n=8. (B) N=4/n=8. Data are expressed as average ± SEM. Statistical analysis: one-
way ANOVA. P<0.01=**. P<0.001=***. 
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Figure 65. Calcimimetics reduce Ca2+o-induced proliferation in WT-CaSR VSMCs, but not in KO-
CaSR VSMCs.  (A) WT-CaSR VSMC proliferation. (B) KO-CaSR VSMC proliferation. VSMCs were 
seeded at 10,000 cells per 12-well plate and allowed to adhere for 24h in DMEM containing 10% FBS and 
1.2mM Ca2+o. After 24h, medium was changed to contain 1.2mM Ca2+o and 1% FBS. After a further 24h, 
medium was changed to contain 1.2, 1.8 or 2.5mM Ca2+o in the presence of 10nM R-568 or a 0.001% 
DMSO vehicle control. Cells were left for 10 days with medium changing every 3 days. At day 10, cells 
were trypsinised in 0.05% trypsin EDTA and manually counted using a haemocytometer. Data were 
normalised to each respective batch of cells to the 1.2mM vehicle-treated Ca2+o control. This approach was 
taken to minimise cell batch variability (A) N=4/n=8. (B) N=4/n=8. Data are expressed as average ± SEM. 
Statistical analysis: one-way ANOVA. P<0.01=**. P<0.001=***. 
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Ca2+o increases proliferation in WT-CaSR VSMCs in a concentration dependent 
manner, but not in KO-CaSR VSMCs. 
WT-CaSR VSMCs that were cultured in the presence of >1.2mM Ca2+o had significant 
increases in proliferation. Cell counts were normalised to the baseline 1.2mM Ca2+o 
culture conditions in each batch of cells. Although un-normalised data showed the same 
trend, data became more reliable during normalisation due to cell batch variability. For 
this reason baseline proliferation rates in both WT and KO VSMCs (in the presence of 
1.2mM Ca2+o) averaged 100%. Proliferation values for WT VSMCs were as follows: For 
1.2mM Ca2+o 100% ± 4.31 (N=4/n=8); for 1.8mM Ca2+o 160.78% ± 5.80 (N=4/n=8, 
P<0.01 vs. 1.2mM Ca2+o); for 2.5mM Ca2+o 193.37% ± 21.54 (N=4/n=8, P<0.001 vs. 
1.2mM Ca2+o). Conversely, KO-CaSR VSMCs showed no significant changes in 
proliferation in response to Ca2+o when compared to the KO control VSMCs cultured in 
the presence of 1.2mM Ca2+o. Proliferation values for KO-CaSR VSMCs were as 
follows: For 1.2mM Ca2+o 100% ± 4.59 (N=4/n=8); for 1.8mM Ca2+o 82.33% ± 4.22 
(N=4/n=8); for 2.5mM Ca2+o 97.15% ± 7.49 (N=4/n=8). Comparisons between KO-
CaSR VSMCs across all Ca2+o concentrations showed no significant differences by two-
way ANOVA with Bonferroni’s post-test (Figure 64). 
 
Calcimimetics reduce Ca2+o-dependent proliferation in vitro in WT-CaSR VSMCs, 
but not in KO-CaSR VSMCs. 
The role of R-568 was also investigated in the proliferation of WT- and KO-CaSR 
VSMCs. VSMCs cultured in different Ca2+o concentrations (Figure 64) were also 
cultured in the presence of 10nM R-568 for 10 days (Figure 65). For all experiments, 
N=4; n=8. It was shown that in WT-CaSR VSMCs, R-568 reduced Ca2+o-dependent 
proliferation in the presence of 1.8mM Ca2+o and 2.5mM Ca2+o. Proliferation values for 
WT VSMCs in the presence of 10nM R-568 vs. vehicle control were as follows: For 
1.2mM Ca2+o 101.95% ± 8.38 vs. 100% ± 4.31- not significant. For 1.8mM Ca2+o 
105.88% ± 7.24 vs. 160.78% ± 5.80 (P<0.01). For 2.5mM Ca2+o 120.96% ± 10.83 vs. 
193.37% ± 21.54 (P<0.001). Effects of R-568 on Ca2+o-dependent proliferation were not 
seen in KO-CaSR VSMCs. Proliferation values for KO VSMCs in the presence of 10nM 
R-568 vs. vehicle control were as follows: For 1.2mM Ca2+o 85.38% ± 3.51 vs. 100% ± 
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4.59- not significant. For 1.8mM Ca2+o 87.21% ± 5.41 vs. 82.33% ± 4.22- not significant. 
For 2.5mM Ca2+o 114.82% ± 10.83 vs. 97.15% ± 7.49- not significant.  
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Figure 66. CaSR ablation from VSMCs significantly reduces Ca2+o-induced apoptosis. WT or KO 
VSMCs were seeded at 25,000 cells per 24-well plate onto glass coverslips. VSMCs were left for 24h to 
adhere in DMEM containing 10% FBS, 0.001% DMSO and 1.2mM Ca2+o. After this time, medium was 
changed to contain just 1% FBS for 24h. After 24h, medium was switched to contain 1.0 or 3mM Pi in the 
presence of 1.2, 1.8 or 2.5mM Ca2+o. VSMCs were left in this medium for 48h before fixing in 4% PFA 
for 10 minutes. Cells were then stained for TUNEL as described in methods. TUNEL-positive nuclei were 
then counted using a TissueFAX system by Martin Schepelmann. (A) WT (N=3/n=6) vs. KO (N=4/n=8) 
VSMCs in the presence of 1mM Pi. (B) WT vs. KO VSMCs in the presence of 3mM Pi. Data are expressed 
as mean ± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s post-test. P<0.05=*. P<0.01=**. 
P<0.001=***.  
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Figure 67. R-568 does not affect apoptosis either in CaSR-WT or in CaSR-KO VSMCs. WT or KO 
VSMCs were seeded at 25,000 cells per 24-well plate onto glass coverslips. VSMCs were left for 24h to 
adhere in DMEM containing 10% FBS, 0.001% DMSO and 1.2mM Ca2+o. After this time, medium was 
changed to contain 1% FBS for 24h. After 24h, medium was switched to contain 1.0 or 3mM Pi in the 
presence of 1.2, 1.8 or 2.5mM Ca2+o. Cells were also treated with 10nM R-568 or a 0.001% DMSO vehicle. 
VSMCs were left in this medium for 48h before fixing in 4% PFA for 10 minutes. Cells were then stained 
for TUNEL as described in methods. TUNEL-positive nuclei were then counted using a TissueFAX system 
by Martin Schepelmann. (A) WT (N=3/n=6) vs. KO (N=4/n=8) VSMCs in the presence of 1mM Pi. (B) 
WT vs. KO VSMCs in the presence of 3mM Pi. Data are expressed as mean ± SEM. Statistical analysis: 
two-way ANOVA with Bonferroni’s post-test.  
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CaSR ablation in VSMCs reduces Ca2+o-induced apoptosis in vitro. 
To assess the role of the VSMC-CaSR in VSMC apoptosis, TUNEL analysis was carried 
out to determine DNA fragmentation in response to different culture conditions. Figure 
66 shows that there was a significant decrease in the rate of Ca2+o-induced apoptosis in 
KO-CaSR VSMCs compared to WT-CaSR VSMCs in the presence of 2.5mM Ca2+o and 
1mM Pi. Data values were: 5.90% ± 1.59 WT (N=3/n=6) vs. 0.94% ± 0.06 KO (N=4/n=8; 
P<0.05). There was also a very significant decrease in the rates of apoptosis in KO 
VSMCs compared to WT VSMCs at all Ca2+o concentrations tested overall (Figure 66A, 
P<0.001). In experiments using mineralising conditions (I.e. 3mM Pi) DNA 
fragmentation was reduced at all Ca2+o concentrations tested in WT VSMCs compared 
to that seen in the presence of 1mM Pi. Values for WT VSMCs were: 4.53% ± 1.34 
(1.2mM Ca2+o/1mM) vs. 3.13% ± 0.54 (1.2 Ca2+o/3mM Pi); 4.54% ± 1.11 (1.8 
Ca2+o/1mM Pi) vs. 3.22% ± 0.74 (1.8 Ca2+o/3mM Pi); 5.90% ± 1.59 (2.5 Ca2+o/1mM Pi) 
vs. 3.44 ± 0.76 (2.5 Ca2+o/3mM Pi).  
 
R-568 (10nM) does not significantly affect apoptosis in WT-CaSR or KO-CaSR 
VSMCs. 
To assess the role of calcimimetics in VSMC apoptosis, 10nM R-568 was used to treat 
both WT and KO VSMCs in the presence of medium containing either 1mM or 3mM Pi 
and different concentrations of Ca2+o (1.2-2.5mM). Although it was observed that R-568 
reduced apoptosis in KO VSMCs in the presence of 3mM Pi and either 1.8 or 2.5mM 
Ca2+o, this was not significant. There were also no significant effects of R-568 on 
apoptosis in WT VSMCs. 
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Figure 68. Mineralisation cultures of 3 month old mouse primary WT VSMCs at passage 6 
exposed to medium containing different [Ca2+]o in the presence of 1.4mM Pi ± R-568. Cells were 
plated in 24-well plates at a density of 40,000 cells per well and left for approximately 1 week until 
confluent in standard DMEM with 1.2mM Ca2+o and 10% FBS. Confluency was achieved at 
approximately 1 week and media were switched to mineralising medium which contained DMEM with 
10% FBS, supplemented with CaCl2 with or without the calcimimetic R-568 at 10nM (or 0.001% 
DMSO control). These media were also supplemented with 0.4mM Pi giving a total Pi of 1.4mM. Cells 
were cultured for 10 days with media changing every 2-3 days. At day 10, cells were washed in 1X 
PBS and fixed in 4% PFA and stained with Alizarin Red S for 5 minutes. Cells were washed in dH2O 
and photographed at 4 magnification (Scale bar=1,000µm). Experiments were performed in 
quadruplicate for each condition yielding consistent results (n=4), with 3 separate batches of cells 
(N=3).
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Figure 69. Mineralisation cultures of 3 month old mouse primary WT VSMCs at passage 6 exposed 
to medium containing different [Ca2+]o in the presence of 3.0mM Pi ± R-568. Cells were plated in 24-
well plates at a density of 40,000 cells per well and left for approximately 1 week until confluent in standard 
DMEM with 1.2mM Ca2+o and 10% FBS. Confluency was achieved at approximately 1 week and media 
were switched to mineralising medium which contained DMEM with 10% FBS, supplemented with CaCl2 
with or without the calcimimetic R-568 at 10nM (or 0.001% DMSO control). These media were also 
supplemented with 2.0mM Pi giving a total Pi of 3.0mM. Cells were cultured for 10 days with media 
changing every 2-3 days. At day 10, cells were washed in 1X PBS and fixed in 4% PFA and stained with 
Alizarin Red S for 5 minutes. Cells were washed in dH2O and photographed at 4 magnification (Scale 
bar=1,000µm). Experiments were performed in quadruplicate for each condition yielding consistent results 
(n=4), with 6 separate batches of cells (N=6). 
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Figure 70. Mineralisation cultures of 3 month old mouse primary KO VSMCs at passage 6 exposed 
to medium containing different [Ca2+]o in the presence of 1.4mM Pi ± R-568. Cells were plated in 24-
well plates at a density of 40,000 cells per well and left for approximately 1 week until confluent in standard 
DMEM with 1.2mM Ca2+o and 10% FBS. Confluency was achieved at approximately 1 week and media 
were switched to mineralising medium which contained DMEM with 10% FBS, supplemented with CaCl2 
with or without the calcimimetic R-568 at 10nM (or 0.001% DMSO control). These media were also 
supplemented with 0.4mM Pi giving a total Pi of 1.4mM. Cells were cultured for 10 days with media 
changing every 2-3 days. At day 10, cells were washed in 1X PBS and fixed in 4% PFA and stained with 
Alizarin Red S for 5 minutes. Cells were washed in dH2O and photographed at 4 magnification (Scale 
bar=1,000µm). Experiments were performed in quadruplicate for each condition yielding consistent results 
(n=4), with 3 separate batches of cells (N=3). 
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Figure 71. Mineralisation cultures of 3 month old mouse primary KO VSMCs at passage 6 exposed 
to medium containing different [Ca2+]o in the presence of 3.0mM Pi ± R-568. Cells were plated in 24-
well plates at a density of 40,000 cells per well and left for approximately 1 week until confluent in standard 
DMEM with 1.2mM Ca2+o and 10% FBS. Confluency was achieved at approximately 1 week and media 
were switched to mineralising medium which contained DMEM with 10% FBS, supplemented with CaCl2 
with or without the calcimimetic R-568 at 10nM (or 0.001% DMSO control). These media were also 
supplemented with 2.0mM Pi giving a total Pi of 3.0mM. Cells were cultured for 10 days with media 
changing every 2-3 days. At day 10, cells were washed in 1X PBS and fixed in 4% PFA and stained with 
Alizarin Red S for 5 minutes. Cells were washed in dH2O and photographed at 4 magnification (Scale 
bar=1,000µm). Experiments were performed in quadruplicate for each condition yielding consistent results 
(n=4), with 5 separate batches of cells (N=5). 
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Figure 72. Ca2+ incorporation in mineralised cultures of 3 month old mouse primary WT VSMCs 
cells. WT VSMCs were plated and mineralised as described in Figures 68 and 69 in medium containing 
different [Ca2+]o in the presence of either 1.4 or 3.0mM Pi. At day 10, cells were washed in 1X PBS and 
Ca2+ was eluted and quantified as described in the methods using the O-cresolphthalein complexone 
method. Protein was also quantified using the BCA assay as described. Units are in µg Ca2+/mg protein, 
and expressed as fold-changes compared to Ca2+ incorporation within each batch of VSMCs in the presence 
of the 1.2mM Ca2+o for each Pi concentration. (A) VSMCs mineralised in 1.4mM Pi (N=3/n=12). (B) 
VSMCs mineralised in 3.0mM Pi (N=5/n=20). Data are expressed as mean ± SEM. Statistical analysis: 
one-way ANOVA. P<0.05=*. 
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Figure 73. Ca2+ incorporation in mineralised cultures of 3 month old mouse primary KO VSMCs 
cells. KO VSMCs were plated and mineralised as described in Figures 70 and 71 in medium containing 
different [Ca2+]o in the presence of either 1.4 or 3.0mM Pi. At day 10, cells were washed in 1X PBS and 
Ca2+ was eluted and quantified as described in the methods using the O-cresolphthalein complexone 
method. Protein was also quantified using the BCA assay as described. Units are in µg Ca2+/mg protein, 
and expressed as fold-changes compared to Ca2+ incorporation within each batch of VSMCs in the presence 
of the 1.2mM Ca2+o for each Pi concentration. (A) VSMCs mineralised in 1.4mM Pi (N=2/n=8). (B) 
VSMCs mineralised in 3.0mM Pi (N=5/n=20). Data are expressed as mean ± SEM. Statistical analysis: 
one-way ANOVA. P<0.05=*. P<0.01=**. P<0.001=***. 
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Figure 74. CaSR-KO VSMCs incorporate more Ca2+ mineral than CaSR-WT VSMCs in both 
mineralising and non-mineralising conditions. WT and KO VSMCs were mineralised as described in 
Figures 72 and 73). Data from Figures 73 and 74 are compiled here for statistical analyses against one 
another to demonstrate differences in mineralisation of these WT and KO VSMCs. (A) WT vs. KO VSMCs 
cultured in the presence of 1.4mM Pi. (B) WT vs. KO VSMCs cultures in the presence of 3.0mM Pi. Data 
are expressed as mean ± SEM. Statistical analysis: two-way ANOVA with Bonferroni’s post-test. 
P<0.05=*. P<0.001=***. 
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KO VSMCs mineralise more readily in the presence of high phosphate (Pi) than 
WT VSMCs. 
In the presence of 1.4mM Pi, Ca2+o at all concentrations tested (1.2-2.5mM) did not 
increase calcification in WT VSMCs (Figure 72A). However, in KO VSMCs, 2.5mM 
Ca2+o was sufficient to increase Ca2+ incorporation significantly from the 1.2mM Ca2+o 
control (Figure 73A). Values in the presence of 2.5mM Ca2+o were: 1.44 ± 0.15 
(N=3/n=12) vs. 1.00 ± 0.04 (N=3/n=12) in the 1.2mM Ca2+o control (P<0.05). In the 
presence of 3.0mM Pi (mineralising conditions), calcification was only significantly 
increased in WT VSMC mineralised cultures in the presence of 2.5mM Ca2+o (Figure 
72B). Values were: 1.85 ± 0.27 (N=5/n=20) vs. 1.00 ± 0.07 (N=5/n=20) in the 1.2mM 
Ca2+o control (P<0.05). Conversely, in KO VSMCs cultured in the presence of 3.0mM 
Pi, calcification was significantly increased in the presence of both 1.8 and 2.5mM Ca2+o 
(Figure 73B). Values for 1.8mM Ca2+o were 2.42 ± 0.24 (N=5/n=20) vs. 1.00 ± 0.11 
(N=5/n=20, P<0.01). Values for 2.5mM Ca2+o were 3.88 ± 0.44 (N=5/n=20) vs. 1.00 ± 
0.11 (N=5/n=20, P<0.001). 
 
In Figures 72 and 73 it was shown that within each genotype in the presence of 3.0mM 
Pi, Ca2+o induced significantly more calcification than 1.2mM Ca2+o in a concentration 
dependent manner. Figure 74 demonstrates that KO VSMCs mineralise more than WT 
VSMCs relative to their 1.2mM Ca2+o controls in both the presence of 1.4mM Pi and 
3.0mM Pi. In the presence of 1.4mM Pi and 2.5mM Ca2+o, KO VSMCs had significantly 
more Ca2+ incorporation compared to WT VSMCs. Fold changes at 2.5mM Ca2+o were 
as follows: 0.86 ± 0.07 (N=3/n=12) WT vs. 1.44 ± 0.15 (N=3/n=12, P<0.001). Increases 
in Ca2+ incorporation were more observable in the presence of 3.0mM Pi. There were no 
significant differences at 1.2mM Ca2+o since these were the normalised values however, 
Ca2+o incorporation values at 1.8mM Ca2+o were as follows: 1.41 ± 0.18 (N=5/n=20) WT 
vs. 2.32 ± 0.25 (N=5/n=20, KO, P<0.05). Ca2+o incorporation values at 2.5mM Ca2+o 
were 1.85 ± 0.27 (N=5/n=20, WT) vs. 3.88 ± 0.44 (N=5/n=20, KO, P<0.001). 
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Figure 75. Selective ablation of CaSR in VSMCs promotes osteogenic transdifferentiation by 
upregulating Runx2. WT and KO VSMCs were plated and mineralised as described in Figures 68 and 71 
in medium containing different [Ca2+]o in the presence of 3.0mM Pi. At day 5, cells were washed in 1X 
PBS and TRIzol® reagent was added to cell monolayers. RNA was obtained and converted to cDNA as 
described in methods. 50ng of cDNA was used in each qPCR reaction with GAPDH and Runx2 primer 
sets as described in methods. Plasmid clones containing either GAPDH or Runx2 amplicons were also run 
alongside experimental cDNA to confirm efficient amplification. Runx2 Ct values were normalised to 
GAPDH Ct levels present in each sample. All data were then normalised to Runx2 ∆Ct values from cDNA 
of WT VSMCs cultures in the presence of 1.8mM Ca2+o and 3.0mM Pi sample averages. This was 
considered the baseline level of Runx2 expression. WT: N=2/n=4, KO: N=4/n=8. Data are expressed as 
mean ± SEM. Statistical analysis: one-way ANOVA. P<0.05=*. 
  
 Page 243 
 
Selective ablation of CaSR in VSMCs promotes osteogenic transdifferentiation by 
upregulation of Runx2. 
To investigate whether mineralising conditions of culture (3.0mM Pi and 1.8mM or 
2.5mM Ca2+o) were sufficient to promote osteogenic transdifferentiation in mouse 
VSMCs, qPCR was performed to amplify Runx2 mRNA. Runx2 is considered as an early 
master osteoblastic transcription factor upregulated in VSMCs in pro-mineralising 
conditions (Sun et al., 2010). Demer et al first described the process of calcification as a 
cell-mediated process associated with abnormal upregulation of osteogenic markers in 
calcified arteries (Demer and Watson, 1994). To test whether mineral deposition in 
mouse VSMCs cultured in vitro involved upregulation of osteoblast gene expression, the 
expression of Runx2 mRNA, not normally expressed in non-mineralising conditions, was 
analysed. WT and KO cells were mineralised in the presence of 3.0mM Pi and 1.8mM 
Ca2+o ± R-568, or 2.5mM Ca2+o in the absence of R-568. Runx2 primer sets were used in 
qPCR reactions with cDNA from mineralised WT and KO VSMCs. GAPDH primer sets 
were also used for normalisation to a house-keeping gene. Data show that, when cells 
were cultured in the presence of 1.8mM and 2.5mM Ca2+o, Runx2 mRNA expression was 
not significantly different in WT mineralised VSMCs compared to KO mineralised 
VSMCs. Additionally, there was no significant difference in levels of Runx2 mRNA cells 
cultured in the presence of 1.8mM Ca2+o added with 10nM R-568. However, there was 
an overall significant increase in Runx2 expression in mineralised KO VSMCs compared 
to mineralised WT VSMCs at all concentrations tested (P<0.05, Figure 75).  
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Figure 76. R-568 reduces Ca2+o-dependent mineralisation of 3 month old mouse primary WT 
VSMCs. WT VSMCs were prepared and mineralised in the same way as Figure 68 and 69 in medium 
containing either 1.4 or 3.0mM Pi in the presence of 1.2mM or 1.8mM Ca2+o, with either 10nM R-568 or 
a 0.001% DMSO vehicle. Mineralisation was performed using the same method. (A) VSMC mineralisation 
in the presence of 1.4mM Pi (N=3/n=12). (B) VSMC mineralisation in the presence of 3.0mM Pi. 
(N=5/n=20). Data are expressed as mean ± SEM. Statistical analysis: one-way ANOVA. P<0.05=*. 
P<0.01=**.  P<0.001=***. 
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Figure 77. R-568 did not effect Ca2+o-dependent mineralisation of 3 month old mouse primary KO 
VSMCs. KO VSMCs were prepared and mineralised in the same way as Figure 70 and 71 in medium 
containing either 1.4 or 3.0mM Pi in the presence of 1.2mM or 1.8mM Ca2+o, with either 10nM R-568 or 
a 0.001% DMSO vehicle. Mineralisation was performed using the same method. (A) VSMC mineralisation 
in the presence of 1.4mM Pi (N=3/n=12). (B) VSMC mineralisation in the presence of 3.0mM Pi. 
(N=5/n=20). Data are expressed as mean ± SEM. Statistical analysis: one-way ANOVA. P<0.05=*. 
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The calcimimetic R-568 reduces Ca2+ incorporation and mineralisation in WT 
mouse VSMCs but not in KO mouse VSMCs. 
As described previously, cells were mineralised in the presence of 1.4mM and 3.0mM Pi 
with different Ca2+o concentrations. 10nM R-568 was also used in the presence of either 
1.2mM Ca2+o or 1.8mM Ca2+o to determine any effect through the VSMC-CaSR. WT and 
KO VSMCs were mineralised as described in the presence of 10nM R-568 or a vehicle 
of 0.001% DMSO for 10 days. At day 10, WT VSMCs cultured in medium containing 
1.4mM Pi exhibited significantly reduced Ca2+ incorporation. Ca2+ incorporation in the 
presence of 1.2mM Ca2+o was: 0.58 ± 0.03 treated vs. 1.00 ± 0.04 untreated (N=3/n=12, 
P<0.001, Figure 76A). Although differences in the presence of 1.8mM Ca2+o were not 
significant, it was shown that the overall relationship between treated and untreated WT 
VSMCs was significant (P<0.001; Figure 76A). In the presence of 3.0mM Pi, R-568 also 
reduced calcification in the presence of 1.8mM Ca2+o. R-568 decreased calcification from 
1.41 ± 0.18 (vehicle) to 0.98 ± 0.09 (treated) (N=5/n=20, P<0.05). Although R-568 
treatment in the presence of 1.2mM Ca2+o was not significant, there was a significant 
effect of R-568 treatment vs. no treatment overall (P<0.01; Figure 76B). R-568 did not 
reduce mineralisation in KO VSMC cultures in the presence of 1.4mM Pi and either 1.2 
or 1.8mM Ca2+o (Figure 77A). Interestingly, in the presence of 3.0mM Pi and 1.8mM 
Ca2+o, R-568 actually increased calcification from 2.32 ± 0.25 (vehicle) to 3.28 ± 0.40 
(treated, N=5/n=20, P<0.05, Figure 77B). 
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CHAPTER 6: DISCUSSION 
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CaSR is expressed in mouse vascular smooth muscle cells and mouse endothelial 
cells. 
It has previously been demonstrated that, endothelial cells express the CaSR where the 
receptor plays a crucial role in blood vessel tone modulation (Weston, 2005). My findings 
show that mouse aortae also express very intense CaSR immunoreactivity in the 
endothelium. Whether this CaSR protein is localised to the plasma membrane or not has 
not yet been determined, although it is likely since CaSR is functionally active in 
endothelial cells. Comparatively, CaSR immunostaining in VSMCs in the tunica media 
appears to be less intense and more diffuse throughout the cytosol as shown by 
immunofluorescent imaging. Albeit fainter than in ECs, VSMC CaSR staining is above 
that seen in the negative controls. Whether VSMC-CaSR protein is at the plasma 
membrane or not has also yet to be determined. 
 
Ablation of CaSR in VSMCs reduces total CaSR protein as determined by semi-
quantitative immunofluorescent imaging. 
Studies from several laboratories indicate that CaSR is a poorly expressed protein, 
particularly outside of the parathyroid glands. Indeed, many groups have failed to detect 
it at the mRNA level and/or the protein level. For this reason it has been difficult to 
amplify CaSR transcripts by qPCR which are lowly expressed. Semi-quantitative 
immunofluorescent imaging offers some benefits here in determining the expression 
levels of the protein by using an N-terminal antibody to CaSR. As one of the few 
antibodies that shows specificity and cross-reactivity in mouse tissue and cells, this N-
terminal antibody (AnaSpec) has been used for my protein expression studies. By using 
the Tissue QuestTM software on slides stained at the same time using the same protocol, 
we were able to quantify the relative brightness of the CaSR signal in these 
immunofluorescently-labelled VSMCs. Data showed a 35.26% reduction in the intensity 
of CaSR-positive cells, when comparing WT to KO VSMCs under cultured under 
physiological conditions (Figure 60). Although only semi-quantitative, these data suggest 
that the CaSR expression is downregulated in KO VSMCs. Importantly, it should also be 
noted that although CaSR protein remains in KO VSMCs (~35.26%), this is a truncated 
form that encodes the N-terminus of the CaSR unable to bind agonists as shown by the 
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Chang group (Chang et al., 2008). The development of novel antibody directed against 
the carboxy terminus of the CaSR, to distinguish between WT and KO CaSR proteins, 
will provide a significant advantage for studies which use the exon 7 CaSR deletion 
mouse model. 
 
Ca2+o (1.2-1.8mM) and R-568 (1-100nM) do not affect cell viability in WT and KO 
VSMCs. 
In order to determine whether Ca2+o and R-568 effected cell viability in the exon 7 CaSR 
deletion mouse model, an MTT assay was performed. This study was important since a 
variety of in vitro conditions were to be tested in both WT and KO-CaSR VSMCs. My 
studies revealed that at 7 days in culture in the conditions tested (1.2-5.0mM Ca2+o and 
1.2-1.6mM Ca2+o ± 1-100nM R-568) there was no significant effect of Ca2+o or R-568 on 
cell viability of WT and KO VSMCs compared to the 1.2mM Ca2+o/1mM Pi control 
culture conditions. In the case of R-568, there was no difference in all treatments (1-
100nM) vs. untreated VSMCs in the presence of 1.2-1.6mM Ca2+o. Due to time 
constraints the role of Pi in VSMC cell viability was not investigated. However, it would 
be beneficial to investigate the role of Pi in VSMC viability since hyperphosphataemia 
is correlated with calcification an apoptosis. One might presume that VSMC viability 
would be affected in mineralising conditions, particularly in the presence of R-568. 
 
KO-VSMC and WT-VSMC proliferation rates are not different in standard 
conditions of VSMC culture. 
During my experiments, I observed that KO-VSMCs appear to proliferate faster than WT 
VSMCs and therefore I tested this possibility in vitro. My data reflect that this is indeed 
the case, however, this was not significant using a two-tailed t-test with a P value of 0.08. 
It is therefore likely that more repeats (n=8 as determined using the power calculation) 
will need to be carried out to obtain significance. It has been reported previously that 
activation of CaSR by calcimimetics suppress parathyroid cell proliferation both in vivo 
and in vitro (Wada et al., 1997a, Wada et al., 2000, Roussanne et al., 2001, Colloton et 
al., 2005). In our KO VSMCs where there is no functional CaSR, this would suggest that 
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under normal conditions of 1.2mM Ca2+o and 1.0mM Pi in culture, activation of CaSR is 
not possible and therefore, CaSR-dependent inhibition of proliferation could not occur 
resulting in faster proliferation rates.  
 
Ca2+o induces proliferation in a concentration-dependent manner in WT VSMCs, 
but not in KO VSMCs. 
The role of Ca2+o in proliferation of VSMCs was investigated (Figure 64). My results 
show that WT VSMC proliferation rates greatly increased in response to increasing 
[Ca2+]o. We have previously shown in bovine VSMCs that culturing cells in the presence 
of Ca2+o higher than 1.2mM leads to downregulation of CaSR protein by, so far, unknown 
mechanisms (Alam et al., 2008). Therefore, this increase in proliferation may be a 
consequence of downregulation of CaSR in the presence of 1.8 and 2.5mM Ca2+o. 
Furthermore, activation of CaSR by agonists such as calcimimetics has been shown to 
suppress proliferation both in vivo and in vitro (Wada et al., 1997a, Wada et al., 2000, 
Roussanne et al., 2001, Colloton et al., 2005), possibly by upregulating membrane CaSR 
(Mizobuchi et al., 2004). If this is true, then the anti-proliferative properties of CaSR 
diminish in the presence of increasing concentrations of Ca2+o. This may perhaps be the 
reason why Ca2+o induces proliferation in a concentration dependent manner in WT 
VSMCs only.  
 
My observations also show that KO VSMC proliferation rates in the presence of 1.2, 1.8 
and 2.5mM Ca2+o were not different from one another. This would illustrate that KO-
CaSR VSMCs are unable to ‘sense’ Ca2+o through the CaSR and respond accordingly to 
alterations in VSMC proliferation as WT-CaSR VSMCs have. What remains unclear is 
a reason for WT VSMC proliferation in the presence of 1.8 and 2.5mM Ca2+o to be higher 
than KO VSMC proliferation under these same conditions. Since the CaSR has 
previously been linked to regulation of the cell cycle protein Ki 67 in parathyroid glands 
(Roussanne et al., 2001), I hypothesize that CaSR ablation in VSMCs has phenotypically 
altered these cells and so limited their maximal proliferation rates. 
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R-568 (10nM) reduces Ca2+o-induced proliferation in WT VSMCs, but not in KO 
VSMCs. 
It was also shown that R-568 reduced Ca2+o-induced proliferation in WT VSMCs but not 
in KO VSMCs. R-568 did not significantly affect KO VSMC proliferation. This is in 
agreement with previous observations that calcimimetics reduce proliferation in 
parathyroid cells (Wada et al., 1997a, Wada et al., 2000, Roussanne et al., 2001, Colloton 
et al., 2005). This suggests that both the PTG-CaSR and VSMC-CaSR share some similar 
function, particularly in their reduced proliferation rates in response to calcimimetics. 
Calcimimetics have been shown to increase [Ca2+]i in cells, and it can therefore be 
speculated that increases in [Ca2+]i through this pathway are associated with reductions 
in proliferation. If this is the case, this would suggest that KO VSMCs have reduced 
[Ca2+]i as suggested in previous chapters where CaSR ablation in VSMCs is associated 
with reductions in contractile tone. However, this remains to be investigated using, for 
example, calcium imaging experiments.  
 
KO VSMCs have reduced apoptosis compared to WT VSMCs. 
Increased apoptosis is correlated with increased vascular calcification in vivo and in vitro 
(Proudfoot et al., 2000, Clarke et al., 2008). For this reason it was important to investigate 
apoptosis rates of both WT and KO VSMCs in physiological and pathophysiological 
conditions. Figures 66 and 67 show that there was no significant effect of a range of 
[Ca2+]o on apoptosis. Interestingly, I have consistently shown that KO VSMCs had 
decreased levels of apoptosis at all concentrations compared to WT VSMCs overall in 
the presence of both 1mM and 3mM Pi (P<0.001 and P<0.01 respectively). These results 
were surprising since this suggests that CaSR expression and activation promotes 
apoptosis, which is in stark contrast to what previous investigators have shown. One 
study by Molostov and colleagues showed that CaSR activation by neomycin can reduce 
apoptosis in VSMCs, and that disrupting neomycin signalling through ERK inhibition 
increases apoptotic rates (Molostvov et al., 2008). It has also been shown that activation 
of CaSR by Mg2+ and La3+ significantly reduces apoptosis and calcification (Shi et al., 
2009, Kircelli et al., 2012). Additionally, in a mouse model of selective ablation of CaSR 
in osteoblasts, developed by Dr. Chang, the group report that apoptosis is increased 
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(Chang et al., 2008). This further supports the idea that CaSR protects against apoptosis. 
It is therefore possible that during apoptosis experiments of KO VSMCs, cells detach 
from coverslips. In this way, only apoptotic cells which still remain adhered to coverslips 
are detectable by immunostaining. To test this hypothesis, supernatants from cells in 
mineralising medium should be taken in the future to test for the presence of apoptotic 
or dead cells. The role of R-568 was also investigated to determine whether 
pharmacological allosteric activation of the VSMC CaSR had an effect on apoptosis. My 
observations show that there are no significant effects of Ca2+o (1.2-2.5mM), Pi (1.0 and 
3.0mM) and R-568 (10nM) at all concentrations tested. Furthermore, when group 
comparisons were made to compare all conditions within each Pi group or within each 
genotype, there was also no significant effect. This was not so surprising since apoptosis 
is considered quite a rare event with rates normally at <5%. It is likely that by using 
different conditions, I.e. concentrations of 100nM R-568, the role of R-568, if any, on 
the VSMC CaSR may become clear. 
 
CaSR protects against calcification in vitro in mouse VSMCs. 
The rate of mineralisation was significantly augmented by selective ablation of CaSR 
from VSMCs. As previously demonstrated in bovine VSMCs, loss of expression of CaSR 
is associated with increased mineralisation of VSMCs (Alam et al., 2008). Here, I 
provide conclusive evidence that this is indeed the case using the SM22α x fl CaSR 
mouse model.  
 
We have seen in previous chapters that VSMC-KO of the CaSR induces (i) 
hypercalcaemia, (ii) heavier hearts, (iii) reduced contractile tone, and (iv) monophasic 
vasorelaxation of the aorta/aortic VSMCs. In particular, the lack of contractile tone 
suggests that VSMCs cannot regulate Ca2+o levels effectively through activation of the 
CaSR. This could either be by preventing Ca2+o release from internal stores or by 
preventing Ca2+o uptake from extracellular environments. CaSR is linked to the 
expression of Ca2+o-binding proteins such as MGP (Mendoza et al., 2010) and there is 
evidence for an upregulation of MGP mRNA during R-568 treatment and 
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hypercalcaemia. Given this evidence, it is difficult to determine expression levels of 
MGP in KO VSMCs without yet performing qPCR experiments. On one hand, WT 
VSMCs containing a functional CaSR may upregulate MGP expression. Conversely, KO 
VSMCs that are associated with a hypercalcaemic environment in vivo are also likely to 
upregulate MGP expression in a compensatory manner. It is therefore difficult to 
speculate whether MGP levels will be up- or downregulated in KO VSMCs, or whether 
there will be no difference compared to WT MGP levels.  
 
Selective ablation of CaSR in VSMCs promotes osteogenic transdifferentiation. 
Runx2 is a master regulator of osteoblastic differentiation (Sun et al., 2010). My 
observations show that there is an increase in Runx2 mRNA expression in KO VSMCs 
compared to WT VSMCs in the presence of mineralising conditions (Figure 75). 
Although the individual inter-sample comparisons were not statistically different, the fact 
that there are only 2 WT VSMC isolations run in duplicate (n=4) is likely to account for 
the lack of inter-sample significance. However, these preliminary observations support 
the well-established fact that increased calcification is associated with Runx2 
upregulation. Although the mechanisms by which CaSR achieves this effect are 
unknown, previous studies have suggested the possibility that it is likely due to a lack of 
expression of protective factors such as MGP, which have also been shown to be linked 
to CaSR expression and activation (Mendoza et al., 2010). Due to time constraints, I was 
unable to perform qPCRs for other important genes involved in the calcification process 
such as SM22α, BMPs and MGP. This remains an important area for future investigation. 
 
R-568 significantly reduces mineralisation in mouse WT VSMCs but not in KO 
VSMCs in vitro. 
Our group has previously reported that R-568 attenuates calcification in vitro at 
concentrations as low as 1nM (Alam et al., 2008). For this study we assessed the ability 
of R-568 to activate the VSMC CaSR. In this study I showed that R-568 in the presence 
of mineralising conditions (3.0mM Pi) significantly reduced calcification in WT-CaSR 
mouse VSMCs in vitro. It has been shown that when R-568 binds to the CaSR, this leads 
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to an increase in the phosphorylation of ERK, as well as increases in [Ca2+]i mediated by 
IP3Rs (Brown et al., 1993). This may possibly be a pathway activated to reduce 
calcification and will be tested in the future. 
 
There is now also growing evidence that calcimimetics can up-regulate CaSR mRNA 
and CaSR protein at the plasma membrane by a pharmacochaperone mechanism 
(Mizobuchi et al., 2004, Mendoza et al., 2009). In these studies, uremic rats were treated 
with a vehicle or calcimimetics (R-568/AMG 641). Rats exhibited significantly elevated 
CaSR mRNA expression and CaSR protein in response to R-568 treatment. In this regard, 
our initial hypothesis of the CaSR being protective against vascular calcification appears 
very relevant, particularly since we have demonstrated that R-568 treatment decreases 
calcification. If CaSR mRNA and protein are indeed upregulated in response to R-568, 
then the anti-calcifying effects of CaSR may be accentuated in such a scenario. 
Interestingly, I have shown that R-568 had no significant effect on KO VSMCs in the 
presence of 1.4mM Pi, however, in the presence of 3.0mM Pi, there was an unexpectedly 
significant effect of R-568 increasing calcification (P<0.05). Whether R-568 enhances 
calcification through alternative mechanisms in the absence of a CaSR remains to be 
investigated. It is possible that these effects are modulated through an additional GPCR 
with similar sequence homology. One such candidate is GPRC6A which has been shown 
to be expressed in rat mesenteric arteries (Harno et al., 2008). Since GPRC6A is also a 
Ca2+o sensor (Pi et al., 2008), it may be possible that this is upregulated in response to 
the loss of CaSR expression. GPRC6A can respond to Ca2+o at a much greater range of 
concentrations compared to CaSR (1-60mM). It is also upregulated in response to the 
Ca2+o-binding protein osteocalcin, and for this reason GPRC6A is often termed a bone 
Ca2+o-sensor (Pi et al., 2005). GPRC6A has been shown to be upregulated in areas where 
Pi handling is common such as bone and the kidney (Pi et al., 2005, Pi et al., 2008). The 
role of R-568 in GPRC6A activation remains controversial since the only evidence that 
it does so comes from experiments by Pi et al where concentrations between 500nM and 
5µM have been used on HEK293 cells over expressing GPRC6A (Pi et al., 2005). It is 
speculated that at 500nM, R-568 may act specifically through CaSR (Nemeth et al., 
1998) or GPRC6A, however, whether the is enhanced calcification observed in 
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mineralised KO VSMCs is due to GPRC6A activation seems unlikely since only 10nM 
R-568 was been used . 
 
Although the role of GPRC6A has not been investigated in these studies, it seems likely 
that GPRC6A may be upregulated in KO CaSR VSMCs as an alternative Ca2+o-sensing 
mechanism. If so, Pi and Ca2+ may be handled in a similar manner to bone, promoting 
mineralisation and a less contractile SMC-like phenotype. To investigate this hypothesis 
further, gene expression studies and immunohistochemical analysis of isolated arteries 
should be performed.  
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CHAPTER 6: CONCLUSION 
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CaSR is protective against vascular calcification in vitro. 
Taken together, my data confirm that CaSR plays a significant role in proliferation, 
apoptosis and mineralisation in vitro. The previously hypothesized protective role of 
CaSR in bovine VSMC mineralisation has now been confirmed in our model of targeted 
deletion of CaSR in VSMCs. Furthermore, R-568 appears to be specific to the VSMC 
CaSR by significantly reducing both proliferation and mineralisation in vitro. In the 
context of cardiovascular disease and calcification, the existence of proliferation and 
apoptosis in vivo in VSMCs are key features of vessel damage or calcification. For these 
reasons, there is now strong evidence that calcimimetics such as R-568 may be effective 
at reducing vascular calcification in vivo. 
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CHAPTER 6: FUTURE WORK 
From these studies it is clear that calcimimetics, at the concentrations tested (1-100nM), 
act on the CaSR, and appear to be specific to this receptor in physiological conditions. 
However, in light of mineralisation data in VSMCs from KO mice, it appears as though 
R-568 is having additional effects in mineralising conditions. For this reason, it is likely 
that under these pathophysiological conditions, R-568 may be carrying out additional 
roles by so far unknown mechanisms. This is crucially important from a clinical 
perspective since patients with calcified vessels may have diminished CaSR expression. 
In vitro data suggest that R-568 treatment in such pathological conditions may enhance 
calcification. It is therefore important to perform additional experiments to determine the 
mechanism of action of R-568 in KO VSMCs in these mineralising conditions. It would 
be interesting to investigate the role of calcilytics in proliferation, apoptosis and 
mineralisation in vitro in both WT and KO VSMC. 
 
To determine whether unexpected responses in mineralisation experiments are the result 
of expression of the GPRC6A receptor, the presence of GPRC6A in both normal and 
mineralising culture conditions should firstly be investigated. It would be interesting to 
analyse mRNA expression patterns in these conditions in addition to 
immunohistochemical analysis. Furthermore, however unlikely it may be that R-568 is 
producing these unexpected effects through Ca2+-channels, this should still be 
investigated by using S-568, a stereoisomer of R-568. 
 
Due to time constraints, extensive gene expression analyses were not yet carried out to 
determine the role of protective factors against vascular calcification in WT and KO 
VSMCs. It was shown that Runx2 was significantly upregulated in KO VSMC 
mineralisation cultures, however the exact mechanism of action of this remains unclear. 
Future studies should include a more extensive analysis of the expression of vascular 
smooth muscle cell markers, osteoblast markers and protective factors such as MGP to 
draw more complete conclusions to the exact actions of R-568 in VSMCs. Furthermore, 
the role of apoptosis on mineralisation should also be investigated by analysing the 
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medium supernatants of mineralising VSMC cultures. Here, apoptotic cells and markers 
of cell death such as caspases could be investigated. 
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CHAPTER 7:  
THESIS DISCUSSION & FINAL CONCLUSIONS 
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The aims of my investigation were to characterise the cardiovascular role of the CaSR in 
physiology, in the control of vessel tone, and in vascular calcification. This task was to 
be performed using a new transgenic mouse model with selective ablation of CaSR in 
VSMCs; the SM22α x fl CaSR mouse model. Summarised overleaf are the key findings 
discovered within each experimental chapter of this thesis: 
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Chapter 3 (in vivo) Key findings 
 VSMC-CaSR KO mice exhibit hypercalcaemia throughout adulthood 
 VSMC-CaSR KO mice exhibit mild hyperkalaemia at 3 months of age 
 VSMC-CaSR KO mice exhibit reduced bone integrity 
 VSMC-CaSR KO mice exhibit increased FGF23 levels throughout adulthood 
 VSMC-CaSR KO mice exhibit increased heart weights at 18 months of age 
 
Chapter 4 (ex vivo) Key findings 
 
VSMC-CaSR KO mice exhibit reduced luminal diameters of the aorta and mesenteric 
arteries 
 VSMC-CaSR KO mice exhibit reduced contractile tone of the aorta 
 
VSMC-CaSR KO mice exhibit reduced acetylcholine-dependent contraction in the 
presence of L-NAME 
 
VSMC-CaSR KO mice exhibit reduced acetylcholine-dependent relaxation in 
mesenteric arteries 
 
Chapter 5 (ex vivo) Key findings 
 VSMC-CaSR KO mice exhibit loss of Ca2+o-dependent contraction in the aorta 
 
VSMC-CaSR KO mice exhibit Ca2+o-dependent relaxation in the aorta in the presence 
of L-NAME 
 VSMC-CaSR KO mice exhibit greater relaxation in response to spermine in the aorta 
 VSMC-CaSR KO mice exhibit loss of R-568-induced relaxation in the aorta 
 
 
Chapter 6 (in vitro) Key findings 
 KO-CaSR VSMC cultures show that the CaSR gene is knocked down 
 KO-CaSR VSMC cultures show reduced CaSR protein 
 WT-CaSR VSMCs proliferate in response to Ca2+o, KO-CaSR VSMCs do not 
 KO-CaSR VSMCs have reduced apoptosis compared to WT-CaSR VSMCs 
 KO-CaSR VSMCs mineralise more and faster than WT-CaSR VSMCs. 
 
R-568 reduces proliferation and mineralisation in WT-CaSR VSMCs but not in KO-
CaSR VSMCs 
 
Table 7. Holistic characterisation of the SM22a x fl CaSR mouse model. In vivo, ex vivo and in vitro 
phenotypes demonstrated experimentally in each chapter are described in these tables. (A) Chapter 3 in 
vivo. (B) Chapter 4 ex vivo. (C) Chapter 5 ex vivo. (D) Chapter 6 in vitro. 
A 
B 
C 
D 
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The SM22α fl CaSR Mouse Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
Figure 78. Key features of the SM22a x fl CaSR mouse model. (i) KO Mice exhibit elevated serum Ca2+ 
and K+. Elevated serum Ca2+ most likely comes from increases in circulating PTH (not yet tested). 
Increases in PTH secretion also occur in response to elevated Pi (not yet tested). PTH could act on 
intestines, kidney and bone to increase overall [Ca2+]o. (ii) Elevated K+ suggests renal insufficiency, 
specifically inhibition of aldosterone and a reduction in K+ excretion. Inactivation of the RAAS would 
result in a hypotensive phenotype which has been observed. 1,25-(OH)2D3 activity may also be increased 
in the kidney in response to PTH secretion to increase Ca2+ retention. (iii) Possible elevations in Pi are 
implicated by increases in FGF23 levels which promote Pi excretion. Elevations in Pi could come from 
bone which appears less dense. 
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When investigating the role of CaSR in any tissue or cell type, particularly through 
transgenic mouse models, one has to consider the more widespread implications of 
overexpression or in this case, tissue-specific gene knockout. This is particularly the case 
in my studies, where CaSR ablation in VSMCs could affect many organs. At the initial 
outlook, one might presume that any gene knockout in one cell type may produce a very 
localised and specific phenotype. However this is seldom the case, particularly in the 
case of CaSR which is a crucial regulator of Ca2+o homeostasis in the parathyroid glands, 
bone, kidney and intestines. In the last 20 years, we have learned that CaSR is expressed 
widely (Riccardi et al., 1995, Kifor et al., 1997, Kovacs and Kronenberg, 1997, Cheng 
et al., 1999, Shozo et al., 2004, Busque et al., 2005, Dufner et al., 2005, Weston, 2005, 
Levin et al., 2006, Smajilovic et al., 2006, Smajilovic et al., 2007, Alam et al., 2008, 
Finney et al., 2008, Vizard et al., 2008, Weston et al., 2008, Caudrillier et al., 2010, 
Christian et al., 2010) and that it plays a major role in the Ca2+o/Pi/Vitamin 
D/PTH/FGF23 axis (Shanahan et al., 2011). For this reason, knockout of CaSR in 
VSMCs has expectedly demonstrated more systemic effects on organs typically 
associated with Ca2+o homeostasis such as the kidneys, bone and parathyroid. The in vivo 
data presented in this thesis have confirmed that this is indeed the case with elevated 
FGF23 levels, reduced bone content, hypercalcaemia and mild hyperkalaemia in younger 
mice. The challenging part of these concluding remarks comes when attempting to 
determine the sequence in which such events would occur, and ultimately, which is the 
main driver of each of these deviations from normal physiology. Presented overleaf is 
my interpretation of the data currently available and how the observed phenotype in 
VSMC-CaSR KO mice may arise. 
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Figure 79. Physiology of the SM22α x fl CaSR KO mouse model. The phenotype observed appears to 
come from VSMC-KO of CaSR. (i) CaSR-KO in VSMCs results in a systemic hypotensive phenotype. (ii) 
Glomerular filtration rate (GFR) could be compromised and a reduction in vascular pressure within the 
kidney reduces excretion of Pi through the glomerulus. (iii) Sustained elevated serum Pi induces FGF23 
formation and secretion by osteocytes of bone. (iv) FGF23 also inhibits 1α-hydroxylase activity in the 
kidney, reducing the uptake of Ca2+ from the intestines. (v) Elevations in serum Pi are sufficient to drive 
PTH secretion from the PTGs. (vi) PTH can act on kidney to reabsorb Ca2+, bone to reabsorb Ca2+ and Pi 
(vi), and may play a role in the rescue of downregulated kidney 1α-hydroxylase (vii). (viii) 1α-hydroxylase 
may cause increases in 1,25(OH)2D3, thereby increasing Ca2+ and Pi absorption in the intestine. (vi) 
Hypercalcaemia can also inhibit renin secretion and reduce the RAAS system, inducing hyperkalaemia by 
inhibiting downstream the actions of angiotensin II. (ix) Finally, chronic and sustained hypercalcaemia is 
sufficient to downregulate the parathyroid CaSR to the PTH-inhibiting effects of Ca2+o. This results in 
tertiary hyperparathyroidism as seen in patients with CKD. To combat hypotension, hearts of ageing mice 
are remodelled and may become heavier (hypertrophic). Abbreviations= CKD: Chronic kidney disease; 
PTH: Parathyroid hormone; PTG: Parathyroid glands; RAAS: Renin-angiotensin-aldosterone system.  
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Figure 79 illustrates the proposed pathway in which VSMC-CaSR KO leads to the 
hypotensive and hypercalcaemic phenotype present in our mice. Through a so far 
unknown mechanism, we know that VSMC-CaSR KO reduces contractile tone 
generating a hypotensive phenotype. Principles of renal physiology dictate that blood 
pressure in the kidney is crucially important for glomerular filtration rate (GFR) (Seifter 
et al., 2005, Rhoades and Bell, 2012). When blood pressure in the afferent arteriole is 
low, this reduces the GFR. Consequently, solutes and small molecules are retained. GFR 
can be calculated using the Starling-Landis equation: 
 
   = Kf x (PG – PB – IIG + IIB) 
 
    = Glomerular filtration rate (GFR) 
Kf  = Filtration constant 
PG  = Hydrostatic pressure within the glomerular capillaries 
PB  = Hydrostatic pressure within the Bowman’s capsule 
IIG  = Colloid osmotic pressure within the glomerular capillaries 
IIB  = Colloid osmotic pressure within the Bowman’s capsule 
 
 
Using the Starling-Landis equation for the calculation of GFR, one can see the effects of 
arterial pressure on GFR (Seifter et al., 2005, Rhoades and Bell, 2012). PG and PB 
represent the arterial blood pressure and Bowman’s capsule respectively. Normally, PG 
is greater than PB, increasing the glomerular hydrostatic pressure, therefore increasing 
the GFR. During poor blood flow, often a consequence of atherosclerosis or hypotension, 
PG is decreased. PG can be restored by an increase in efferent arteriolar pressure brought 
about by increases in angiotensin II; a vasoconstrictor (Seifter et al., 2005). In our SM22α 
x fl CaSR KO mouse model we have evidence to suggest that RAAS is impaired since 
mice exhibit hyperkalaemia. This would also suggest that overall kidney function is also 
impaired. Consequently, the rescue of renal hypotension and low GFR may not occur by 
the actions of angiotensin II, or this pathway is at least significantly reduced. 
From my data and the hypothesis described in Figure 79, it appears that the hypotensive 
phenotype of CaSR-KO VSMCs is the cause of the systemic phenotype observed in 
dQ 
dT 
dQ 
dT 
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SM22α x fl CaSR KO mice. Figure 79 describes how impaired renal function, resulting 
in Pi retention (yet to be measured) could lead to FGF23 elevation and likely 
hyperparathyroidism (since serum [Ca2+] is significantly elevated in KO mice) in a 
sustained manner. Furthermore, it has been shown that Ca2+o, PTH and the CaSR are 
negative regulators of renin secretion (Atchison et al., 2011). Increased [Ca2+]o has been 
shown to activate the CaSR on juxtaglomerular cells in the kidney. This is associated 
with downstream activation of the ryanodine receptor which releases Ca2+ from internal 
stores. These increases in [Ca2+]i, in combination with decreases in cAMP inhibit renin 
secretion (Ortiz-Capisano et al., 2013). When components of RAAS such as renin are 
impaired, this can have knock-down effects on vasoconstrictors such as aldosterone. In 
addition to reductions in blood pressure, consequences of RAAS impairment are an 
increase in K+ retention- which we have observed in our KO mice (Atchison et al., 2011). 
Although serum Pi and PTH remain to be tested, we have observed the consequences 
resulting from elevated levels of these which have been incorporated into the hypothetical 
pathway in Figure 79. To more fully understand the role of Pi and PTH in the SM22α x 
fl CaSR KO phenotype, serum Pi and PTH will require measurement in both WT and 
KO mice in the future. 
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A possible mechanism for CaSR-KO VSMC hypotension 
Despite the emerging evidence of the CaSR-KO VSMC exhibiting a hypotensive 
phenotype, the mechanism of this hypotension remains to be elucidated. It is likely that 
future Ca2+-imaging experiments and patch clamp electrophysiology are required to 
confidently describe Ca2+ handling mechanisms within the CaSR-KO VSMC. Figure 80 
below describes the in vitro phenotype observed at the cellular level and how this may 
contribute to the hypotensive and hypercalcaemic phenotype we have measured.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80. Possible consequences of VSMC-CaSR knockout. SM22α x fl CaSR demonstrate decreased 
VSMC apoptosis, increased hypotension, increased luminal narrowing, increased VSMC mineralisation 
and possibly increased proliferation in vitro. Activation of the CaSR increases [Ca2+]i from internal stores 
and knockout of CaSR in VSMCs may prevents uptake of extracellular Ca2+o. Increased Ca2+ resorption 
from bone may also liberate Pi, resulting in increased FGF23 (observed in vivo) and reduced mineral 
density (observed in vivo). 
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SM22α x fl CaSR KO mouse model validation 
Importantly, with the demonstrated phenotype affecting bone, kidneys and presumably 
the parathyroid gland from hyperparathyroidism, one should consider whether there is 
any knockout of CaSR in these tissues associated with Ca2+o homeostasis. Since blood 
vessels permeate all organs and are extremely widespread, this makes isolating tissues in 
the absence of blood vessels almost impossible. However, we do know from transgenic 
studies that knockout of CaSR in both the parathyroid and in bone results in severe 
skeletal retardation (Chang et al., 2008), and from a group investigating the role of the 
CaSR in the kidney by a similar knockout strategy only a hypercalciuric phenotype was 
observed (Toka et al., 2012). Since impaired growth and severe skeletal retardation are 
not observed in our mouse, we can presume that CaSR is not knocked out in the 
parathyroid, bone or kidney. Additionally, when considering the specificity of the 
∆SM22α promoter, the tool by which we have driven VSMC-specific knockout, we know 
this to be localised specifically to VSMCs in all arteries through embryogenesis up to at 
least 1 month post-natally (Li et al., 1996a, Li et al., 1996b). Of course, we cannot rule 
out a partial leakage of the cre recombinase promoter. 
 
Collectively, the evidence supports that we have a VSMC-CaSR knockout which is 
responsible for the phenotype observed. However, the question still remains as to how 
VSMC-CaSR KO leads to this hypotensive phenotype. Figure 80 sheds some light on 
processes involving the VSMC-CaSR, and the SM22α x fl CaSR phenotype at the 
cellular level: (i) KO VSMCs exhibit a hypotensive phenotype and CaSR agonist binding 
causes increases in [Ca2+]i (Ward, 2004). In the absence of a CaSR, increases in [Ca2+]i 
are not possible through CaSR. Indeed, it has also been shown that CaSR activation is 
linked to Ca2+o uptake through Ca2+-channels, particularly in VSMCs (McGehee et al., 
1997, Chow et al., 2011). If KO VSMCs also have reduced uptake of Ca2+o, this Ca2+o 
may be available to act on endothelial cells to promote NO release, reducing the Ca2+o-
dependent contraction of VSMCs, potentiating hypotensive effects. (ii) KO VSMCs may 
have increased proliferation. It has been shown that increased VSMC proliferation is 
associated with downregulation of both RyR and SERCA (Lompré, 1999, Vallot et al., 
2000). Again, in the absence of a CaSR, CaSR agonists are not able activate the receptor 
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and increase [Ca2+]i. (iii) KO VSMCS exhibit reduced apoptosis compared to WT 
VSMCs. Though in stark contrast to what has been previously published, it is likely 
apoptotic cells are detached from the coverslip. Whether this is true remains to be 
investigated in future studies. (iv) KO VSMCs exhibit increased calcification. Once 
again, it is likely that in the absence of the CaSR, Ca2+o uptake is reduced. It is likely that 
this may then be available for mineralisation in extracellular environments. Of course, it 
is also likely that, since CaSR has been shown to be linked to upregulation of MGP, 
protective Ca2+o-binding proteins also play a prominent role in this process. 
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Validation of R-568 specificity on the VSMC-CaSR 
At a concentration of <1µM, R-568 has been shown to act specifically at the CaSR 
(Nemeth et al., 1998). Despite this, it has been reported that R-568 at concentrations of 
>500nM and in the presence of physiological Ca2+o (2-3mM) can also activate GPRC6A 
(Pi et al., 2005). ERK phosphorylation in response to 500nM R-568 was observed in 
HEK293 cells overexpressing GPRC6A, however, the group did also use concentrations 
>1µM which may activate Ca2+-channels (Nemeth et al., 1998). Furthermore, it has been 
shown that GPRC6A is functionally expressed in rat mesenteric arteries and can respond 
to calcimimetics (Harno et al., 2008). This activity is now widely believed to be because 
GPRC6A and CaSR share identical calcimimetics binding sites at the protein level (Faure 
et al., 2009). However, the role of R-568 in GPRC6A signalling has not been investigated 
in-depth. Although the literature does support that R-568 is a CaSR-specific allosteric 
modulator, the possibility that R-568 may also be activating an additional Ca2+o-sensor, 
GPRC6A, also requires investigation. Data from R-568 experiments are summarised 
overleaf: 
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Ex vivo myography:  
(i) 300nM R-568 relax aortae from WT mice, but not aortae from KO mice. 
(ii) 300nM R-568 does not relax aortae from WT and KO mice in the 
presence of L-NAME. 
(iii) R-568 (10-8-10-5M) relaxes mesenteric arteries from both WT and KO 
mice. 
In vitro cell studies: 
(i) 10nM R-568 reduces proliferation in WT VSMCs but not KO VSMCs. 
(ii) 10nM R-568 reduces calcification in WT VSMCs, but not in KO 
VSMCs. 
(iii) 10nM R-568 enhances calcification in KO VSMCs in the presence of 
2.5mM Ca2+o and 3mM Pi. 
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Given the specificity of R-568 for CaSR, the results obtained from KO VSMC 
mineralisation experiments are somewhat surprising, especially since the only effect I 
have observed in these experiments is increased calcification in response to R-568. Until 
this study, the role of R-568 has not been investigated in mouse VSMCs. The fact that 
this agonist gives unexpected results raises the possibility that GPRC6A may be 
expressed or upregulated in KO VSMCs. The possibility that R-568 may act on this 
receptor should be tested in future experiments. 
 
R-568 Conclusions 
Although it is highly likely that R-568 is acting through the CaSR (which is supported 
by a plethora of studies in the literature) R-568 may also be acting through GPRC6A. It 
would be interesting to see whether these effects would still be present in CaSR-KO 
VSMCs which also have GPRC6A-KO in these cells. Furthermore, the possibility of 
GPCR heterodimerisation between, for example, CaSR and GPRC6A should be 
investigated. 
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FUTURE WORK 
From the data obtained within this thesis, I can only speculate on the highly suggestive 
roles of hormones, proteins and enzymes that we have not yet quantified. Future work to 
further confirm the roles of the VSMC-CaSR would firstly involve characterising these 
from mouse serum. For this reason, future work will entail characterising the role of the 
following components: 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Speculative roles of components so far not measured in SM22α x fl CaSR KO mice. Tests 
that have not yet been performed are required in the future to determine whether the hypotheses suggested 
are correct.  
 
COMPONENT/TEST 
HYPOTHESIZED 
OBSERVATION? 
Blood pressure Decreased 
Nitric Oxide Increased 
Renin Decreased 
Aldosterone Decreased 
Angiotensin-converting enzyme Decreased 
1,25(OH2)D3 Increased/Decreased 
Serum Pi Increased 
Serum MGP Decreased 
PTH Increased 
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